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ABBREVIATIONS AND ACRONYMS 
Throughout this manuscript, abbreviations and acronyms recommended by 
the American Chemical Society in the Organic Chemistry and Medicinal Chemistry 
areas have been employed (revised in the Journal of Organic Chemistry and 
Journal of Medicinal Chemistry on June 2014; 
http://pubs.acs.org/page/joceah/submission/authors.html and 
http://pubs.acs.org/paragonplus/submission/jmcmar/jmcmar abbreviations.pdf). In 
addition, those indicated below have also been used. 
ATX Autotaxin 
DAPI 4',6-Diamidino-2-phenylindole 
DMEM Dulbecco’s modified Eagle medium 
EGFP Enhanced green fluorescent protein 
Emax Maximal receptor activation 
ESI Electrospray ionization 
FACS Fluorescence-activated cell sorting 
FAF BSA Fatty acid free bovine serum albumin 
FBS Fetal bovine serum 
GPCR G protein-coupled receptor 
IRES Internal ribosomal entry site 
IUPHAR International Union of Basic and Clinical Pharmacology 
LP Lysophospholipid 
LPA Lysophosphatidic acid 
LPAAT Lysophosphatidic acid acyltransferase  
Lpar LPA receptor mouse gene 
LPAR LPA receptor mammalian gene 
LPC Lysophosphatidylcholine 
LPP1 Lipid phosphate phosphohydrolase 1 
N.E. No effect 
   
NAEPA N-acyl ethanolamide phosphoric acid or (2-[(9Z)-octadec-9-
enoylamino]ethyl dihydrogen phosphate 
NPC Neural progenitor cell 
OMPT  1-Oleoyl-2-O-methyl-rac-glycerophosphothionate or (2S)-2-
methoxy-3-(thiophosphonooxy)propyl (9Z)-octadec-9-enoate 
PA Phosphatidic acid 
PG Protecting group 
PS Polystyrene supported  
RA Rheumatoid arthritis 
s.e.m. Standard error of the mean 
S1P Sphingosine 1-phosphate 
SF Synovial fibroblasts 
TBAI Tetrabutylammonium iodide 
UCM Universidad Complutense de Madrid 
VEC Vascular endothelial cell 
VSMC Vascular smooth muscle cell 
VZ Ventricular zone 
vzg-1 Ventricular zone gene 1 
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 INTRODUCTION AND OBJECTIVES 
Lysophospholipids are lipid molecules that are receiving growing attention 
because, in addition to their structural function in the cell membrane, they are now 
regarded as important regulators for diverse biological functions through activation 
of specific receptors. These receptors have been characterized during the last two 
decades as G protein-coupled receptors (GPCRs) and, among them, two families 
stand out: lysophosphatidic acid (LPA1-6) and sphingosine 1-phoshate (S1P1-5) 
receptors. Despite their interest, the high structural similarity between them has 
restrained the development of selective and high affinity ligands and therefore the 
elucidation of the role of these receptors in the central nervous system (CNS). 
This work will focus on the LPA receptors and, in particular, on the LPA1 
subtype, considering its prominent expression in the CNS and the lack of potent 
and selective agonists and antagonists that allow for the elucidation of its 
(patho)physiological roles.  
1.1 Phospholipids as signalling molecules 
The phospholipid superfamily has been traditionally linked to structural roles, 
as key constituents of biological membranes. Nevertheless, research from the last 
decades has associated some phospholipids with diverse signalling functions, 
reporting their action as extracellular signals and, moreover, their involvement in 
many physiological and pathological processes.1,2 
Phospholipids are usually divided into two broad families: (i) 
glycerophospholipids,3 which are structurally based on the glycerol scaffold (Figure 
1A) and (ii) sphingophospholipids, which are derivatives of the amino alcohol 
sphingosine (Figure 1B). They present a polar head bearing a phosphate group    
(-OPO3Y-, Y = H, choline, ethanolamine…, Figure 1A, B) and two hydrophobic 
chains (R, X, Figure 1A, B). When one of the fatty acid chains is missing (X = H, 
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Figure 1A, B), the resulting derivatives are denominated lysophospholipids. These 
molecules are quantitatively minor lipid species compared to their parent 
compounds, the phospholipids -which have a major presence in cell membranes- 
but despite their low concentration they are important because of their ability to 
signal through GPCRs. Lysophosphatidic acid (LPA, 1-acyl-sn-glycerol-3-
phosphate, Figure 1C) and sphingosine 1-phosphate3 (S1P, Figure 1D), are the 
two most prominent molecules of this family, which are being extensively studied 
and whose biological activities have been shown to be extremely relevant.4  
Although they belong to distinct signalling systems, similarities between these 
two lipids extend to their tissue distribution and concentration, homology and 
effector pathways of their cognate receptors, and the broad range of their biological 
roles. In contrast, the actions of other lysophospholipids have not been elucidated 
to such a high degree and very little is known about their endogenous receptors. 
However, recent in vitro studies suggest that they can induce various and unique 
cellular responses.5  
 
Figure 1. General structure of common glycerophospholipids (A) and 
sphingophospholipids (B). Structures of LPA (C) and S1P (D). 
Among the bioactive phospholipids, LPA stands out as a molecule that elicits 
a plethora of biological effects, both in the CNS and in the periphery, by acting on 
at least six different receptors. Nonetheless, its therapeutic potential is still far from 
being established given the complexity of the system and the lack of specific 
ligands, agonists and antagonists, that enable the elucidation of the 
(patho)physiological roles played by a particular LPA subtype.  
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1.2 Lysophosphatidic acid receptors 
LPA has a well-known structural function as precursor and metabolite in the 
biosynthesis of membrane phospholipids. However, it was not until the 1960s that 
several groups started to report biological actions mediated by LPA, such as 
smooth muscle contraction and platelet aggregation.6 Nevertheless, the specific 
function of this intriguing molecule was still unknown.  
During the mid-1980s, proliferative LPA-dependent effects in fibroblasts were 
described. These responses were completely inhibited with pertussis toxin pre-
treatment, which specifically inactivates Gαi/o-type G proteins.7 This was followed by 
the description in the early 1990s of several morphological cell changes attributed 
to LPA, such as cell growth, cell rounding/neurite retraction8,9 and actin stress fiber 
formation.10 At the same time, S1P was reported to evoke cellular responses 
similar to those induced by LPA, suggesting they might even share the same 
GPCRs.11 
Growing evidence was making clear that LPA was acting through a GPCR, as 
it was finally demonstrated by van Blitterswijkin12 through photoaffinity labeling 
experiments, which revealed [32P]LPA-binding membrane proteins of 38–40 kDa 
present in various LPA-responsive cell types and in brain. This binding protein met 
all the pharmacological criteria for a specific, high-affinity LPA receptor since its 
labelling was competitively and specifically inhibited by unlabelled LPA with an IC50 
as low as 10 nM. In addition to the LPA responses, LPA binding was not detectable 
in LPA-unresponsive cells such as human neutrophils, and was blocked by 
suramin, a known inhibitor of LPA actions. Although similar evidences were shown 
independently by Clark,13 the biophysical properties of LPA or the possibility of 
second messenger activities were also proposed as alternative mechanisms for 
LPA actions, and this ambiguity persisted in the absence of molecularly identified 
receptors.  
Finally, in 1996, Chun and coworkers reported the discovery of the first 
lysophospholipid receptor gene, ventricular zone gene 1 (vzg-1),14 during their 
studies on mammalian neurogenesis. Vzg-1 encoded a GPCR that had the 
properties of a high-affinity LPA receptor. Identification of this gene as encoding a 
LPA receptor was independently demonstrated by Goetzl15 and Kiefer.16 Definitive 
confirmation about the identity of this receptor was achieved by heterologous 
expression in mammalian cells17 and genetic deletion of the receptor.18  
Similar approaches allowed the identification of new receptors, like the first 
receptor for S1P, which was independently reported by two groups in 1998.19,20 
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Since then, several members of the orphan GPCR receptor family called 
“endothelial differentiation genes” (Edg) were identified as GPCRs for both LPA 
and S1P, including Edg4 (LPA2),21,22 Edg7 (LPA3),23 Edg5 (S1P2), Edg3 (S1P3), 
Edg6 (S1P4)24 and Edg8 (S1P5).25 Regarding the LPA receptors, another group of 
less similar GPCR genes have also been identified, which are GPR23 (LPA4),26,27 
GPR92 (LPA5),28,29 and P2Y5 (LPA6).30,31 This latter group is more closely related 
to the family of P2Y purinergic receptor genes, indicating that LPA receptors have 
evolved via two distinct lineages in the rhodopsin GPCR family. Up to date, a total 
of eleven receptors have been described, six for LPA (LPA1-6) and five for S1P 
(S1P1-5). The current nomenclature includes the cognate ligand and the 
chronological order of identification. All LPA receptors are type I, rhodopsin-like 
GPCRs that differ in their tissue distribution and downstream signalling pathways32 
(see Table 1, page 9, for a summary of some relevant features).  
 
Figure 2. Schematic representation of the signalling pathways activated by the LPA1-5 
receptors (Source: Annu. Rev. Pharmacol. Toxicol. 2010, 50, 157–186). 
1.2.1 LPA1 receptor 
The mammalian LPAR1 gene encodes an approximately 41 kDa protein 
consisting of 364 amino acids with seven putative transmembrane domains.  
Human LPAR1 is widely expressed in heart, brain, placenta, skeletal muscle, 
kidney, pancreas, spleen, prostate, testis, ovary, small intestine and colon.33 
Similar distribution is observed for the Lpar1 mouse gene, although it is more 
spatially restricted during embryogenesis, where it is mainly found in the ventricular 
zone (VZ), a major site for neuroprogenitor cell proliferation during prenatal 
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developmental stages. VZ disappears prior to birth, reappearing during postnatal 
life within oligodendrocytes and Schwann cells that may influence myelination in 
central and peripheral nervous system, indicating roles for LPA signalling in cortical 
development.34 
Signalling through LPA1 receptor induces a range of cellular responses: cell 
proliferation and survival, cell migration and cytoskeletal changes. At the molecular 
level, LPA1 receptor activation can be transduced through three types of G 
proteins: Gαi/o, Gαq/11, and Gα12/13, that are responsible of Ca2+ mobilization, adenylyl 
cyclase inhibition and activation of phospholipase C, Akt, Rho and mitogen-
activated protein kinase pathways. 
The targeted disruption of Lpar1 in mice revealed unanticipated in vivo 
functions of this receptor. Lpar1−/− mice show 50% perinatal lethality and survivors 
have a reduced body size, craniofacial dysmorphism, and increased apoptosis in 
sciatic nerve Schwann cells.18  
1.2.2 LPA2 receptor 
Lpar2 was identified in 1998 from GenBank searches of orphan GPCR genes 
because of its ∼60% amino acid similarity to Lpar1. In humans, LPAR2 encodes a 
protein that has a predicted amino acid sequence of 348 residues, with a 
calculated molecular mass of ∼39 kDa.21 The expression pattern of LPA2 receptor 
is more spatiotemporally restricted compared to LPA1 receptor. Lpar2 is found in 
the embryonic brain, but its expression strongly attenuates one week after birth. In 
humans, LPAR2 is found in testis, leukocytes, prostate, spleen, thymus and 
pancreas.32 LPA2 couples to three G proteins, Gαi/o, Gαq/11, and Gα12/13. 
LPA2 null mice were born normally and showed no obvious behavioural, 
anatomical or histological abnormalities, in contrast with LPA1 null mice.35 When 
LPA1/LPA2 double-null mice were generated, an aggravation of the phenotypic 
abnormalities was expected, as LPA2 is coexpressed with LPA1 in several organs 
and cells and thus a major loss of LPA signalling would be achieved. However, no 
qualitative differences in phenotypes, compared to LPA1 null mice, were observed. 
Thus, LPA1 and LPA2 receptors may have redundant functions in LPA signalling. 
1.2.3 LPA3 receptor 
LPAR3 encodes a ∼40-kDa GPCR that is ∼50% identical to mouse LPA1 and 
LPA2 in amino acid sequence. Expression of LPAR3 is broad and has been 
observed in human heart, testis, prostate, pancreas, lung, ovary, and brain. Like 
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LPA1 and LPA2 receptors, LPA3 can couple with Gαi/o and Gαq/11 to mediate LPA-
induced Ca2+ mobilization, adenylyl cyclase inhibition, and phospholipase C and 
mitogen activated protein kinase activation. Additionally, LPA3 has a strong 
preference for unsaturated chains and has a relatively high affinity for 2-acyl-LPA 
containing unsaturated fatty acids.  
Despite the fact that LPA3 is expressed in the frontal cortex, hippocampus, 
and amygdala, no phenotypes related to LPA3 loss in the nervous system have 
been reported to date. 
1.2.4 LPA4 receptor 
LPA4 receptor was cloned as an orphan GPCR and was found to be a specific 
receptor for LPA through ligand screening. LPA4 is structurally distinct from 
classical LPA1-3 and S1P receptors that share significant homology, and is more 
closely related to P2Y purinergic receptors. It does not, however, respond to any 
nucleotide or nucleoside tested. In humans, the LPAR4 gene encodes 370 amino 
acids with a calculated molecular mass of ∼42 kDa. LPA4 is ubiquitously expressed 
in both humans and mice and it is specifically abundant in the ovary. Its activation 
induces intracellular cAMP accumulation via Gαs, and Ca2+ mobilization through 
Gαq/11 and Gαi/o.  
1.2.5 LPA5 receptor 
LPA5 (GPR92) was identified by two independent groups in 2005 from the 
receptor gene data bank. This receptor is structurally different to LPA1-3, but shares 
35% homology with LPA4. Lpar5 is relatively broadly expressed in murine tissues. 
In humans, gene expression for LPA5 is observed in spleen, heart, small intestine, 
placenta, liver and colon. LPA5 couples to Gα12/13 and to Gαq/11.  
1.2.6 LPA6 receptor 
The orphan receptor P2Y5, closely related to the purinergic family and sharing 
high homology with LPA4 receptor, has been recently classified as the LPA6 
receptor.31 This receptor has been found to be essential for the maintenance of 
hair growth.36  
1.2.7 Other proposed receptors 
GPR87 and P2Y10 are orphan GPCRs that have been described to be 
responsive either to LPA or to both LPA and S1P, respectively. They belong to the 
P2Y family and are similar to LPA4 and LPA5 receptors.37 
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Table 1. Summary of the most relevant LPA receptor features 
IUPHAR 
nomenclaturea 
Gene 
symbol 
(human) 
Chromosomal 
location 
(human) 
Number of 
aminoacids 
(human) 
Calc. 
mass 
(kDa) 
Similarity 
to LPA1 
(%) 
LPA1 LPAR1 9q31.3 364 41  
LPA2 LPAR2 19p12 348 39 60 
LPA3 LPAR3 1p22.3 p31.1 353 40 50 
LPA4 LPAR4 Xq13–q21.1 370 42 10 
LPA5 LPAR5 12p 13.31 372 41 12 
LPA6 LPAR6 13q14 344 39 13 
aIUPHAR: International Union of Basic and Clinical Pharmacology 
 
From all LPA actions, the ones elicited through LPA1-3 receptors have been 
the most studied up to date, revealing crucial roles in the nervous, vascular, 
immune and reproductive systems. Focusing on the CNS, LPA1 is described as the 
receptor with a major expression and, even though the information is very scarce, 
there is evidence enough to suggest that it can contribute to the pathogenesis of 
several diseases and, accordingly, could be endowed with therapeutic relevance 
for the treatment of CNS disorders. 
1.2.8 Lysophosphatidic acid receptor structure 
Currently, no crystal structures have been resolved for any native LPA 
receptor. The only phospholipid GPCR crystal structure available is the structure of 
S1P1,38 which has provided valuable information about the receptor-ligand 
interaction of this type of receptors.39 This is especially useful for molecular 
modelling of LPA receptors, because they share much higher sequence homology 
with this receptor than with any of the other currently available GPCR crystal 
structures, fact that will enable the construction of homology models of LPA1-3 
receptors using the structure of S1P1 receptor as template.40 
Mutagenesis studies combined with computational analysis identified several 
important residues in LPA1–3 receptors, most of them located in transmembrane 
domains.41,42 In this regard, Arg3.28 is important for efficacy and potency for all 
three receptors, as it forms a salt bridge with the phosphate group while Gln3.29 
interacts with the hydroxy group of LPA. Thus, this latter position is responsible of 
LPA/S1P selectivity, as S1P receptors bear a glutamic acid instead. These two 
residues are conserved over the LPA1–3 receptors, together with Trp4.64, which, in 
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contrast, is only implicated in LPA3 activation. Other aminoacids important for 
ligand recognition and selectivity among the LPA1–3 and S1P receptors are found in 
positions 5.38 (Asp in LPA1) and 7.36 (Lys in LPA1), though their function is still not 
clear. LPA4 and LPA5 share less amino acid identity with LPA1–3, and detailed 
models of their interaction with LPA are not available. Most of the residues 
described above are not present in LPA4 and LPA5, suggesting that these 
receptors have different ligand binding characteristics. Further research is needed 
to identify the critical residues for these receptors, and this information will need to 
be re-evaluated once crystal structure data become available.43  
1.3 Biosynthesis and degradation of LPA 
LPA is generally known as a mixture of various lysophospholipids with both 
saturated (16:0, 18:0) and unsaturated (16:1, 18:1, 18:2, 20:4) fatty acid chains. It 
must be noted that in the context of LPA as a signalling molecule, and thus 
throughout this work, LPA refers to 1-oleoyl-sn-glycerol-3-phosphate. 
LPA is found in almost all eukaryotic tissues and biological fluids, including 
blood.32 Among them, serum is the best characterized source of LPA, where it is 
bound to albumin and other proteins, probably preventing the molecule from rapid 
degradation.44 
Autotaxin (ATX),45,46 a secreted glycoprotein with lysophospholipase D 
activity, is the primary enzyme responsible for LPA production in blood. In fact, 
ATX heterozygote knocknout mice have a 50% reduction of circulating LPA 
compared to wild type mice47 and negligible levels of LPA are detected after 
treatment with ATX inhibitors.48 Outside the cell, the enzyme ATX converts 
lysophosphatidylcholine (LPC), produced from different membrane phospholipids, 
into LPA (Figure 3). 
 
 
Figure 3. Pathway for LPA production. 
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Degradation of LPA can occur through two main routes. In the first one, LPA is 
irreversibly dephosphorylated to monacylglycerol by lipid phosphate 
phosphohydrolases, presumably LPP1. In the second route, LPA is reversibly 
esterified to phosphatidic acid (PA) by the enzyme LPA-acyltransferase (LPAAT).49 
 
Figure 4. LPA degradation pathways. 
1.4 Physiological roles of LPA1 receptor and therapeutic potential 
LPA displays a wide range of cellular effects through its receptors. Among the 
most important actions of LPA, those mediated by the LPA1 receptor in the CNS 
stand out, fact that immediately suggests a potential for the treatment of related 
diseases.  
1.4.1 Nervous system  
As highlighted before, the nervous system is one of the major locations for 
LPA receptors,34 as they are expressed in most of its cell types in physiological and 
pathological conditions. In addition, LPA can be found in the brain in high 
concentrations, influencing many developmental processes and neurological 
disorders.  
Among the different LPA receptors, the LPA1 subtype is the most abundant 
one in brain,32 where it plays a major role in the development of the embryonic 
brain and thus in neurogenesis, due to its main expression in the VZ of the 
embryonic brain. Neural progenitor cells (NPCs) -the differentiable cells 
responsible for neurogenesis- express LPA1-3 receptors and are found in this area, 
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where they proliferate and sequentially differentiate into various cell types, such as 
neurons, astrocytes or oligodendrocytes.  
Several in vitro and in vivo studies have demonstrated that LPA controls 
proliferation and differentiation of NPCs via LPA1. Furthermore, LPA1 null NPCs do 
not present the ability to achieve LPA-dependent neurogenesis-related changes, 
confirming LPA1 as a modulator of neurogenesis. In adult neurons, LPA is known 
to influence neuronal survival/death processes. Moreover, it has been described 
that LPA1 is related with neuroprotection, as apoptotic cell death is described in 
LPA1 null mouse brains.34  
Neuropsychiatric disorders, like schizophrenia, anxiety, memory impairment or 
Alzheimer’s disease, have been recently linked to LPA signalling. LPA1 null 
mutants share schizophrenia-type defects, such as pre-pulse inhibition, serotonin 
synthesis alteration or cranial dysmorphism. In addition, LPA signalling through 
LPA1 in the hippocampus modulates neurogenesis, which is related with learning 
and emotional behaviour; and memory impairments have been reported in LPA1 
deficient mice.34  
Two important developmental disorders are linked to LPA1 receptor: fetal 
hypoxia and fetal hydrocephalus. It was shown that mouse brains exposed to LPA 
develop fetal hydrocephalus, and that treatment with a LPA1 antagonist blocked 
this response, demonstrating the implication of the receptor.50 Regarding fetal 
hypoxia, it has been described that the absence of the adequate supply of oxigen 
causes cortical disorganization throughout NPCs via overactivation of LPA1 
receptor.51 Since both diseases are associated with latter development of CNS 
disorders, such as epilepsy, schizophrenia or autism, it is clear that LPA1 signalling 
needs to be tightly regulated to ensure unaltered brain functions. 
LPA1 has also been associated with myelination because its expression in 
oligodendrocytes (CNS myelinating cells) correlates spatiotemporally with their 
maturation and myelination, and it has been shown that LPA influences several of 
its cellular responses. Moreover, in the peripheral nervous system (PNS) a recent 
study has shown that LPA, acting through LPA1 receptor, promotes Schwann cell 
migration, which precedes myelination and remyelination in the PNS.52  
It has been suggested that LPA plays a key role in the initiation of neuropathic 
pain, a form of chronic pain which accounts for almost the 20% of its diagnosed 
cases in the U.S. Neuropathic pain is the result of a combination of multiple factors, 
but a direct link with fiber demyelination has been reported.53 LPA produces nerve 
injury via LPA1-mediated demyelination with subsequent loss of the structural and 
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functional integrity of neurons. In further support of this, LPA1 deficient mice do not 
show neuropathic pain behaviour or demyelination in response to intrathecal LPA 
injection or nerve injury. LPA5 null mice are also protected from developing 
neurophatic pain, although the mechanisms involved are different to those 
mediated by LPA1.54 
1.4.2 Peripheral roles for LPA1 receptor 
The main peripheral roles of LPA characterized so far are related with the 
ability of this molecule to influence cellular proliferation and differentiation in 
several tissues and systems. In this regard, LPA performs an important role in the 
vascular system, where it modulates different effects in vascular smooth muscle 
cells (VSMCs) and vascular endothelial cells (VECs), which are involved in 
processes like angiogenesis (the formation of new capillary networks from pre-
existing vasculature by sprouting and/or splitting of capillaries) or vascular 
maturation. Angiogenesis involves coordinated proliferation, migration, adhesion, 
differentiation, and assembly of both VECs and their surrounding VSMCs, and its 
dysregulation can lead to diverse pathological conditions, such as 
atherosclerosis,55 cardiovascular diseases, or development of tumours.  
Similarly, and related with the ability of LPA to promote cell proliferation, the 
LPA1 receptor is gaining attention as a druggable target for fibrosis.56,57 This 
disease consists in the formation of excessive connective tissue, and it has been 
found to be strongly influenced by receptor-mediated LPA signalling in lung, kidney 
and skin. Hence, increased epithelial cell apoptosis, migration and proliferation of 
lung fibroblasts, together with enhanced fibroblast resistance to apoptosis are 
LPA1-mediated processes directly linked with the development of pulmonary, 
dermal and kidney fibrosis. In addition, results obtained with a dual LPA1/LPA3 
antagonist suggests a possible implication of LPA3 receptor. Supporting these 
data, one LPA1 antagonist is currently in phase II clinical trials for idiopathic 
pulmonary fibrosis58 and another one is still in preclinical stages, indicated for the 
treatment of liver, lung and kidney fibrosis.59  
Recent research has also associated LPA1 receptor with the initiation and 
development of rheumatoid arthritis (RA). It is known that synovial fibroblasts 
(SFs), implicated in the beginning and perpetuation of RA, express all LPA 
receptors and that LPA stimulates proliferation, adhesion and migration of SFs. 
Accordingly, LPA1 receptor has been suggested as a possible therapeutic target in 
the treatment of this disease.60,61 
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LPA1 is also the most widely expressed lysophospholipid receptor in adipose 
tissue, fact that makes it an interesting pharmacological target for the treatment of 
obesity-associated metabolic diseases. Obesity, one of the key factors leading to 
type II diabetes, is accompanied by an increased ATX-mediated synthesis of LPA 
by adipocytes, where LPA exerts different biological actions through the activation 
of LPA1 receptor.62  
Finally, it is well known that LPA signalling influences cancer-related 
processes,63 especially via LPA2. Nevertheless, there is also evidence of LPA1 
implication in cancer progression, specifically in ovarian, breast and 
gastrointestinal ones.  
1.5 LPA1 receptor ligands 
Given the importance of LPA1 receptor in a variety of pathologies, the need of 
potent and selective ligands is crucial to unravel its potential as a therapeutic 
target, but up to this moment there are no drugs in the market targeting any of the 
LPA receptors. The only commercialized drug targeting a lysophospholipid 
receptor is Fingolimod, (1, Gilenya®), a non-selective S1P antagonist approved for 
the treatment of multiple sclerosis.64 
 
Although much research is ongoing in this field, the lack of potent and 
selective ligands is still an issue. Lipid-ressembling molecules encounter solubility 
problems and show very high protein binding with only a small percentage within 
plasma available to interact with receptors. Moreover, the abundant cell surface 
lipid phosphate phosphohydrolases may rapidly degrade them. Regarding non-lipid 
structures, some advances have been done in the field of antagonists, as two of 
them have currently reached clinical trials.58,65,66 Still, small molecule agonists 
structurally different from LPA have not been described yet.  
1.5.1 Agonists of LPA1 receptor 
Detailed studies have been carried out on the search for the essential patterns 
required to obtain selective agonism at the LPA1 receptor.40 The information 
available so far comes from LPA analogues, as no structurally different synthetic 
agonists have been described yet.  
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The first LPA-based agonist was N-acyl ethanolamide phosphoric acid (2-
[(9Z)-octadec-9-enoylamino]ethyl dihydrogen phosphate or NAEPA, 2) described 
by Sugiura in 199467 as a LPA mimetic and later confirmed as a dual LPA1/LPA2 
agonist.68 Several changes in its structure have led to ligands with improved 
activity and, in some cases, selectivity over LPA1 receptor. Initial modifications 
included the introduction of different substituents in the β-carbon atom (Figure 5, 
left panel) and revealed a strong enantiomer preference, as well as a decrease in 
agonist potency when bulky substituents were introduced. Among all the 
synthesized compounds, 3, 4 and 5 stand out as potent dual LPA1/LPA3 agonists, 
with stronger preference for LPA1 and activity values similar to LPA [EC50 (LPA1) = 
7.9, 4.9 and 3.4 nM; EC50 (LPA3) = 321.8, 683.7 and 112.6 nM, respectively].69 
Further replacements of the phosphate group by its mimetics thiophosphate 
(Y = S, Z = O, Figure 5), and the metabolically stabilized phosphorothioate (Y = O, 
Z = S, Figure 5) and phosphonate groups (Y = C, Z = O, Figure 5) were carried out. 
These groups, especially phosphonates, had higher pKa values than LPA, so α-
substituted phosphonate groups with electronegative groups at the α- carbon were 
also prepared in order to maintain acidity (Figure 5, right panel). Amid them, 
selective compounds 7 [EC50 (LPA1) = 318 nM] and 8 [EC50 (LPA1) = 221 nM] kept 
an activity similar to NAEPA at the LPA1 receptor (EC50 = 197 nM), and compound 
6 [EC50 (LPA1) = 40 nM; EC50 (LPA2) = 108 nM] improved it. It must be noted that 
analogue 9, bearing a α-fluorophosphonate moiety, more acid than compound 6, 
was inactive at LPA1 receptor, indicating that acidity is not the only requirement for 
receptor activation when modifying the phosphate moiety.70 In fact, also LPA-
derived phosphonates and analogues bearing fluoro or difluoro moieties in the α-
carbon have led to good LPA2 or LPA3 agonists, but are inactive at LPA1.71  
 
Figure 5. Structure of NAEPA and derivatives. 
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The LPA analogue (2S)-2-methoxy-3-(thiophosphonooxy)propyl (9Z)-octadec-
9-enoate or OMPT (10), was one of the first LPA3 selective agonists with an EC50 
value of 276 nM.72 Its modification led to diverse structures, such as the 
enantiomers 11 [EC50 (LPA1) = 790 nM; EC50 (LPA3) = 62 nM] and 12 [EC50 (LPA1) 
= 571 nM; EC50 (LPA3) = 80 nM], which turned out to be good LPA3 agonists but 
also present modest activity at LPA1.73 In order to prevent acyl chain migration, 
other metabolically stabilizing modifications were carried out, leading to 
phosphorothioate analogues of sn-2 LPA (compounds 13-15). These three 
compounds displayed weak LPA1 agonism, but they stand out as potent LPA3, 
LPA5 and LPA6 agonists.74  
 
Figure 6. OMPT and derivatives. 
The influence of the position of the acyl chain has been also studied. For 
example, sn-2 LPA derivatives resistant to acyl migration such as 1,1-difluorinated 
phosphates,75 difluoromethyl phosphates76 or α-fluorinated phosphonates77 were 
synthesized. Unfortunately, none of these compounds was active at the LPA1 
receptor,71 though LPA1 and LPA2 receptors were reported to show no 
regioisomeric preference between sn-1 and sn-2 positions.  
Cyclic phosphate analogues have also been described as LPA1 agonists. The 
cyclic difluorophosphate 16 was reported as a weak LPA1-3 agonist [EC50 (LPA1) > 
1940 nM; EC50 (LPA2) > 9460 nM; EC50 (LPA3) > 7030 nM].78 In addition, some 
acetal phosphatidates, also known as Darmstoff analogues, have been reported as 
LPA mimetics. Some of these compounds are LPA pan-agonists (17-20), though 
with activity in the low micromolar range at LPA1 receptor.79 Again, small structural 
modifications turn the compounds into antagonists.  
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Figure 7. Structure of cyclic phosphate agonists. 
In summary, around 20 years after the discovery of the first LPA1 ligands, 
there is still a lack of potent and selective agonists. Nowadays, the knowledge 
about the features needed for activity has been somehow disclosed, but even 
though, the complete puzzle of the structural requirements for activating this 
receptor is not yet fully understood. 
1.5.2 Antagonists of LPA1 receptor 
The LPA1 antagonist field is a current focus of pharmaceutical companies. 
Structurally, LPA1 antagonists can be classified into two broad classes: a family 
closely related with LPA and a second group formed by compounds whose 
structures widely differ from LPA.  
Starting with LPA analogues, modification of the agonist NAEPA (2, page 15) 
with a bulky substituent in the β-carbon atom led to compound 21, which turned out 
to be a dual LPA1/3 antagonist [IC50 (LPA1) = 5210 nM; IC50 (LPA3) = 6450 nM],69 
and has been used in vivo in a model of lung fibrosis.80 An exhaustive SAR of this 
structure yielded compounds 22, a selective LPA1 ligand with moderate activity 
[IC50 (LPA1) = 2490 nM] and 23, which showed increased potency [IC50 (LPA1) = 
109 nM; IC50 (LPA3) = 175 nM] and which is five times more active than its (S)-
enantiomer.81 Further optimizations led to 24, a dual LPA1/3 antagonist with 
nanomolar potency [IC50 (LPA1) = 84 nM; IC50 (LPA3) = 48 nM].82 
 
Figure 8. Structure of NAEPA-derived antagonists.  
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Another important LPA analogue is the bromophosphonate 25, also known as 
BrP-LPA, a LPA pan-antagonist [IC50 (LPA1) = 1500 nM; IC50 (LPA2) = 1420 nM; 
IC50 (LPA3) = 1160 nM; IC50 (LPA4) = 266 nM] and ATX inhibitor with in vivo 
activity.83 This molecule has contributed to elucidate the involvement of LPA 
receptors in the inhibition of tumour growth84 and in the attenuation of arthritis in 
animal models.85 
 
Figure 9. Structure of the pan-antagonist bromophosphonate BrP-LPA (25). 
Cyclic LPA derivatives have also been described as LPA1 antagonists. 
Compound 26 and cyclic phosphorothioates 27 and 28 show activity as partial 
LPA1/LPA3 antagonists with moderate potencies [IC50 (LPA1) = 106-941 nM; IC50 
(LPA3) = 1270-7720 nM].78  
 
Figure 10. Structure of cyclic phosphate antagonists. 
Overall, these series of compounds show the difficulty of discovering the 
requirements needed to regulate the pharmacology of LPA-derived ligands, as 
subtle changes in their structures convert agonists into antagonists and cause 
drastic changes in activity. In addition, the coexistence of a polar head and a long 
hydrophobic tail becomes a problem in order to obtain orally active compounds. 
Thus, high-throughput screening was used to discover novel hits, structurally 
different from LPA, followed by hit to lead processes to improve their 
pharmacology.  
The first reported non-lipid dual LPA1/3 antagonist was compound 29 
(Ki16425)86 [IC50 (LPA1) = 130 nM; IC50 (LPA3) = 2300 nM] which has been widely 
used as a tool compound as it displays in vivo activity.50,61 Several modifications of 
its structure by different academic groups and pharmaceutical companies have led 
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to more potent and selective compounds, some of them even achieving clinical 
trials. 
 
Based on this scaffold, Amira Pharmaceuticals (currently Bristol-Myers 
Squibb) developed a series of isoxazole derivatives. Among them, compounds 30 
(AM966),87 [IC50 (LPA1) = 17 nM; IC50 (LPA2) = 1700 nM; IC50 (LPA3) = 1600 nM] 
and 31 (AM095)88,89 [IC50 (LPA1) = 25 nM; IC50 (LPA2-5) > 8000 nM] stand out as 
potent LPA1 antagonists with good oral bioavailability and antifibrotic in vivo 
activity. Moreover, a compound coming from this series, BMS-986020, whose 
structure has not been disclosed yet, is currently facing phase II trials for the 
treatment of idiopathic pulmonary fibrosis.58 
 
Figure 11. Isoxazole LPA1 receptor antagonists developed by Amira Pharmaceuticals. 
Hoffman-La Roche’s modifications of Ki16425 involved changes in the 
carboxylic acid and the heterocyclic core, replacing the isoxazole moiety with 
pyrazole and triazole rings. The best compounds were 32, with low nanomolar 
activity and good selectivity values [IC50 (LPA1) = 25 nM; IC50 (LPA3) > 30000 nM], 
and 33, a dual LPA1/LPA3 antagonist [IC50 (LPA1) = 24 nM; IC50 (LPA3) = 65 nM].90  
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Figure 12. Triazole LPA1 receptor antagonists developed by Hoffman-La Roche. 
Further exploration of the central heterocycle ring by other pharmaceutical 
companies has led to potent antagonists of the LPA1 receptor, with IC50 values in 
the low nanomolar range, such as compound 34, which is a selective LPA1 
receptor antagonist [IC50 (LPA1) < 50 nM; IC50 (LPA3) > 500 nM).91 Introduction of 
different sulfonamide groups led to LPA1 antagonists with activities in the low 
nanomolar scale.92,93 For example, compound 35 is a LPA1 antagonist with an IC50 
value of 6.6 nM.  
 
Figure 13. Thiazole LPA1 receptor antagonists. 
Initially inspired by Ki16425, Sanofi-Aventis synthesized a series of non-
natural aminoacids, such as compound 36, with IC50 values lower than 100 nM. It 
must be highlighted that SAR100842 (structure not yet disclosed), is a LPA1/LPA3 
antagonist from this set of compounds which is currently undergoing phase II 
clinical trials for systemic sclerosis.66  
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Figure 14. Sanofi-Aventis antagonist. 
In conclusion, it is clear that LPA1 receptor has an outstanding but yet 
intriguing role in physiological and pathological conditions. Thus, the discovery of 
potent and selective agonists and antagonists is nowadays a crucial need to 
achieve the validation of this receptor as a therapeutic target, which is the main 
goal of the present work.  
This overall objective involves the following steps:  
1. Design and synthesis of new ligands for the LPA1 receptor  
2. Determination of the capacity of the compounds to activate the LPA1 
receptor  
3. Evaluation of LPA1 receptor antagonism 
4. Study of the selectivity of the synthesized compounds in the LPA receptor 
family 
5. Biological evaluation of selected compound(s) 
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 RESULTS AND DISCUSSION 
2.1 Design and synthesis of new ligands for the LPA1 receptor 
LPA receptors were discovered less than two decades ago. Thus, at the 
moment of starting this project, little information about this novel signalling system 
was available. No receptor 3D structures had been elucidated and, although 
several structure-activity relationship (SAR) studies had been carried out, no potent 
ligands for the LPA1 receptor had been described, especially in the agonist field. In 
this context, we focused our efforts on finding molecular entities with activity at this 
receptor, using as starting point the structure of the endogenous ligand, LPA. 
Initially, two series of compounds were designed: series I, which comprised 
changes in the acid group, and series II, which included modifications in the 
hydrophobic unit (Figure 15).  
 
Figure 15. Design of new LPA1 ligands. 
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2.1.1 Design and synthesis of series I  
Several SAR studies40 suggest that changes in the polar head of LPA are 
poorly tolerated. In particular, it has been shown that an important requirement for 
activity is the presence of free acid groups that retain their negative charge under 
physiological conditions.94 In fact, when the phosphate group has been modified in 
LPA-like structures, it has usually led to a decrease in LPA1 activity of agonists. 
This is confirmed by the few potent agonists described for this receptor despite the 
variety of phosphate modifications tried (see Introduction).  
Accordingly, phosphorous-free isosters, specifically carboxylic and boronic 
acids (Figure 16) were chosen as acidic subunits, as they have been described as 
carboxy-based phosphoryl replacements, specially malonic acid.95,96 Furthermore, 
they maintain pKa values similar to the phosphate group, which has been shown to 
be important for activity.  
 
Figure 16. Acid groups proposed for series I. 
The synthesis of compounds of series I implied the preparation of the 
corresponding glycerol derivatives for their subsequent regioselective coupling with 
the oleate moiety (Figure 16). It must be noted that in all cases the stereochemistry 
was conserved identical to LPA.  
The preparation of the glycerol derivatives started by choosing the adequate 
and compatible protecting groups (PGs) for the diol and the carboxylic acid 
moieties present in these derivatives (Figure 17). The two groups had to be 
orthogonal, this is, it was required that the deprotection of the diol (PG) did not 
affect the protecting group of the carboxylic acid (PG1). Additionally, the final 
deprotection of PG1 had to be compatible with the presence of the oleate ester 
group. 
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Figure 17. Retrosynthetic analysis for the glycerol moieties. 
Therefore, the tert-butyl (tBu) ester was chosen as PG1 due to its easy 
cleavage in acid media which should not affect the base-labile oleate ester. 
Regarding the glycerol, the acetal was first considered as starting material, as it is 
a cheap and commercially available reagent that can be deprotected under mild 
conditions. However, the conditions tested (catalytic amounts of iodine in methanol 
at room temperature, Table 2) showed that the acetal cleavage occurred with 
simultaneous hydrolysis of the tert-butyl ester. In view of these results, the benzyl 
group (Bn) was finally chosen as the glycerol protecting group since its removal by 
hydrogenation would not affect the ester function. 
Table 2. Tested conditions for acetal cleavage 
Substrate Cat. I2 (%) Time Product 
 
0.5 18h Starting material 
1 4h Starting material 
1.5 4h Starting material 
2.5 4h 
 
 2.5 4h  
 
2.5 4h 
 
 
Regarding the compound bearing a boronic acid, the need of two orthogonal 
protecting groups (PG and PG1) was solved by protecting the diol as an acetal 
(PG), whereas the boronic acid was introduced as a pinacol ester (PG1) whose 
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deprotection conditions should be compatible with the presence of the oleate 
moiety (Figure 18).  
 
Figure 18. Retrosynthetic analysis for the boronic moiety. 
Hence, for carboxylic acid derivatives, alkylation of commercially available (S)-
(-)-2,3-bis(benzyloxy)propan-1-ol with tert-butyl bromoacetate in the presence of 
sodium hydride and tetrabutylammonium iodide (TBAI) led to the intermediate 37, 
which was deprotected by catalytic hydrogenation to afford the glycerol 
intermediate 38 (Scheme 1).  
 
 
Scheme 1 
Next, glycerol derivatives functionalized with malonic and α-fluoromalonic acid 
were prepared, where the fluorine atom was introduced in order to increase the 
acidity of the carboxylic acids. Thus, (S)-(-)-2,3-bis(benzyloxy)propan-1-ol was 
transformed into the corresponding mesylate 39, which was then alkylated with di-
tert-butyl malonate using sodium hydride as base to yield intermediate 40. For the 
preparation of the α-fluoromalonic derivative, intermediate 40 was treated with 
Selectfluor® under basic conditions. Catalytic hydrogenation of intermediates 40 
and 42 afforded the glycerol derivatives 41 and 43 (Scheme 2). 
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Scheme 2 
For the glycerol derivative bearing a boronic acid moiety (46), the synthesis 
started with the tosylation of commercially available (S)-(+)-1,2-
isopropylydeneglycerol to obtain intermediate 44, which was further reacted with 
commercial 4-hydroxyphenylboronic acid pinacol ester to yield derivative 45. Diol 
46 was obtained by deprotection of the acetal using polystyrene-supported p-
toluensulfonic acid (PS-pTsOH) (Scheme 3). In a first attempt, 45 was treated with 
HCl, but this conditions led to the cleavage of the boronate moiety.  
 
Scheme 3 
Once the functionalized glycerol derivatives 38, 41, 43 and 46 were 
synthesized, their regioselective condensation with oleic acid was carried out. 
Following conditions previously employed by our group,97 a two-fold stoichiometric 
excess of 38 was reacted with oleic acid using N,N-dicyclohexylcarbodiimide 
(DCC) as coupling reagent and catalytic amounts of 4-dimethylaminopyridine 
(DMAP). However, the corresponding ester 47 was obtained in very low yield 
(Scheme 4). 
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Scheme 4 
In order to improve the yield of this reaction, 38 was coupled with the more 
reactive oleoyl chloride in the presence of 2,4,6-collidine at low temperature, which 
afforded ester 47 with better yield. The reaction was also completely regioselective, 
and only the acylation at sn-3 position of the glycerol moiety was observed. The 
tert-butyl group of intermediate 47 was removed by treatment with trifluoroacetic 
acid (TFA), yielding the final compound 1a without detection of the hydrolysis of the 
oleate ester (Scheme 5). 
 
Scheme 5 
The esterification conditions were then applied to the reaction of the oleoyl 
chloride with the malonate derivatives 41 and 43 to yield the intermediate esters 48 
and 49 which were then subjected to acid conditions to remove the tert-butyl group. 
However, treatment of derivatives 48 and 49 with TFA led to the formation of 
lactones 1b and 1c instead of the expected malonic acids (Scheme 6). These 
products, obtained as a mixture of diastereoisomers in 1:1 proportion, are the 
consequence of an intramolecular cyclization of the carboxylic acid with the 
hydroxy group in γ position.  
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Scheme 6 
The optimized conditions were also used to carry out the esterification 
reaction of glycerol 46 with oleoyl chloride. The pinacolyl boronate ester 50 was 
transformed into the corresponding trifluoroborate salt 51, following hydrolysis with 
trimethylsilyl chloride (TMSCl) to yield final compound 1d (Scheme 7). Pinacolyl 
boronate ester 50 had been previously subjected to other deprotection conditions 
such as transesterification reaction with phenylboronic acid or displacement with 
diethanolamine followed by hydrolysis, but no reaction occurred or it was 
incomplete. 
 
Scheme 7 
Once the compounds 1a-d were synthesized, they were tested in a LPA1-
overexpressing cell line, in order to determine if any of the phosphate 
replacements carried out had allowed to obtain compounds with activity at this 
receptor. 
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2.1.2 Determination of the agonist activity at LPA1 receptor 
In order to test the synthesized compounds as LPA1 receptor agonists, the 
corresponding biological assay was set up in our laboratory. The ability of the 
compounds to activate the receptor was determined by the measurement of 
calcium mobilization in RH7777 cells stably transfected with the receptor, as the 
binding of an LPA1 agonist causes an increase in intracellular calcium levels,98 
which can be quantified using a fluorescence-based assay.  
After some experimental optimizations, Fluo 4-NW (no-wash) was chosen as 
the most appropriate calcium sensor. To determine the agonist activity of the 
compounds, cells were preloaded with Fluo 4-NW and then incubated in the 
presence of the compounds under study. Fluorescence intensity was measured 
(excitation wavelength of 494 nm and emission wavelength of 516 nm) in a 96-well 
microplate reader. Ionomycin 10 µM was employed as positive control, with 10 µM 
LPA response being 30% of ionomycin response.99 In order to rule out non-LPA1 
receptor mediated calcium mobilization, parallel experiments using non-transfected 
RH7777 cells were carried out.  
The compounds were initially tested at a fixed dose of 10 µM and the maximal 
receptor activation (Emax) for each of them was expressed as a percentage, 
referring their response to the response induced by 10 µM LPA. The complete 
dose-response curve, at six or seven different concentrations of the ligand, was 
determined for those compounds that presented Emax over 30%. Data are 
expressed as the average and standard error (s.e.m.) obtained from two to four 
independent experiments carried out in triplicate. 
The obtained results for compounds 1a-d are shown in Table 3.  
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Table 3. Agonist activities of compounds 1a-d at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b pKac 
1a 
 
N.E.d - 3.4 ± 0.1 
1b 
 
N.E. - 2.7 ± 0.4 
1c 
 
33 ± 5 1.7 ± 0.2 0.5 ± 0.4 
1d 
 
N.E. - 8.7 ± 0.2 
LPA 
 
100 0.83 ± 0.02 1.8 ± 0.1 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor 
Emax > 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two independent 
experiments, performed in triplicate. cValues estimated with ACDLabs program. dNo effect was 
observed at the highest concentration of compound tested (10 µM). 
 
In this initial set of compounds, the influence of pKa seems to be important for 
activity, as only compound 1c, with a pKa value lower than LPA, activates the 
receptor (Table 3). Accordingly, it was necessary to confirm if the non-cyclic 
malonic derivatives originally proposed, with two free carboxylic acids, would 
exhibit better activities at LPA1 receptor. In order to avoid cyclization, the most 
straightforward structural modifications were either the removal of the hydroxy 
group (compounds 1e, f) or its masking with a methyl group, as in derivative 1g 
(Figure 19). 
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Figure 19 
Hence, the commercially available 3-(benzyloxy)propan-1-ol was transformed 
into the corresponding mesylate 52, which was further alkylated with di-tert-butyl 
malonate to obtain intermediate 53. This compound was treated with Selectfluor® 
to yield the fluorinated derivative 55. The obtention of the desired diols 54 and 56 
involved catalytic hydrogenation to remove the benzyl group of their precursors 53 
and 55 (Scheme 8). 
 
Scheme 8 
Once the glycerol moieties were synthesized, acylation with oleoyl chloride 
followed by hydrolysis with TFA of the resulting intermediates 57 and 58 allowed to 
obtain final compounds 1e and 1f in good yields (Scheme 9). 
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Scheme 9 
Synthesis of final compound 1g started from derivative 49, which by reaction 
with trimethylsilyldiazomethane followed by hydrolysis of the tert-butyl ester groups 
led to the desired compound (Scheme 10).  
 
Scheme 10 
The capacity of compounds 1e-g to activate LPA1 receptor was determined 
and the results are shown in Table 4. Taking together all the data obtained for 
series I, the necessity of an acidic polar group seems clear. However, it is not the 
only requirement, as 1f, with a pKa value similar to compound 1g, is completely 
inactive. This suggests the importance of the oxygen atom of the hydroxy group in 
the spacer that separates the fatty acid chain and the polar head group.  
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Table 4. Agonist activities of compounds 1e-g at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b pKac 
1e 
 
N.E.d - 3.2 ± 0.2 
1f 
 
N.E. - 1.1 ± 0.4 
1g 
 
74 ± 14 6 ± 1 0.9 ± 0.4 
LPA 
 
100 0.83 ± 0.02 1.8 ± 0.1 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor 
Emax > 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two independent 
experiments, performed in triplicate. cValues estimated with ACDLabs program. dNo effect was 
observed at the highest concentration of compound tested (10 µM). 
 
In conclusion, this initial series of compounds allowed to identify two LPA1 
receptor agonists, 1c (Emax = 33%; EC50 = 1.7 µM) and 1g (Emax = 74%; EC50 = 6 
µM), which confirms that it is possible to mimic the phosphate group of LPA with 
other polar moieties. However, these two agonists are still less potent than LPA 
so, in order to optimize the structure, the study of the influence of the hydrophobic 
chain of LPA was addressed.  
2.1.3 Design and synthesis of series II 
During the last years, several studies have been carried out trying to establish 
the structural requirements needed for the hydrophobic moiety. Although no 
definitive conclusions have been reached yet, it seems clear that modifications on 
this part of the molecule are less critical for activity at LPA1 receptor, probably 
because its flexible disposition facilitates its fitting into the receptor pocket. In fact, 
it must be noted that LPA1 receptor admits the presence of either saturated or 
insaturated moieties, even though most of the agonist compounds reported (see 
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Introduction) bear an oleic acid chain in their structure, and show preference for 
this length when compared to the shorter palmitoleic acid chain.  
Thus, for series II, a comprehensive study of the influence of the hydrophobic 
moeity was carried out, including modifications on the overall length of the fatty 
acid chain as well as the incorporation of aromatic rings (Figure 20).  
 
Figure 20. Design of compounds of series II. 
 Derivatives of series II containing aliphatic chains  
Modifications of the length of the fatty acid chain implied the synthesis of the 
corresponding alkynylcarboxylic acids, followed by their partial hydrogenation to 
obtain the Z-alkenes. Regarding the phosphorylated glycerol protecting groups, the 
compatibility between the deprotection conditions of the phosphate group (PG1) 
and the existence of double bonds in the molecule had to be considered, and so, 
tert-butyl group was chosen, as its hydrolysis takes place in acid media, which 
should not affect the double bond. Furthermore, the deprotection conditions of the 
diol PG should be orthogonal with PG1, so benzyl group was selected as the most 
appropriate option (Figure 21).  
 
Figure 21. Retrosynthetic analysis for aliphatic derivatives of series II. 
Alkynyl derivatives 61-63 were achieved by a Sonogashira coupling of methyl 
8-bromooctanoate (60) and the corresponding commercially available alkynes 
using a carbene ligand suitable for unactivated alkyl bromides100 (Scheme 11). The 
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subsequent hydrogenation of the alkynes 61-63 turned out to be extremely 
challenging. A variety of conditions was tried, including hydrogenation in the H-
Cube continuous flow hydrogenation reactor using different catalysts, conventional 
hydrogenation in a Parr instrument with Lindlar catalyst (Pd/CaCO3/Pb)/quinoline 
system, and also a transfer hydrogenation reaction with Pd(OAc)2 as catalyst and 
DMF/KOH as hydrogen source. Time, solvent, and temperature were modified 
(Tables 5-7) searching for a complete conversion of the starting material to the 
alkene, as mixtures of saturated and insaturated products cannot be separated by 
chromatography.  
In our hands, all the conditions tested in the H-Cube flow reactor (Table 5) gave a 
mixture of products. In the case of the Parr apparatus (Table 6), conditions for the 
obtention of the Z-alkene were found by using but-2-yne-1,4-diol as model 
substrate. However, when these conditions (2.5% w Lindlar catalyst, 3% mol 
quinoline, 5:1 toluene:methanol, 20 psi, rt, 2 h) were used with the 
alkynylcarboxylic acids, only starting material was recovered. A possible 
explanation could be the poisoning of the Lindlar catalyst with remaining traces of 
the catalyst from the previous Sonogashira reaction. Transfer hydrogenation with 
Pd(OAc)2 was also tried (Table 7), but a mixture of alkyne and alkene was 
obtained.  
Table 5. Hydrogenation conditions with H-Cube reactor 
Substrate Catalyst Conditions Result 
 
Pd/CaCO3/Pb 10 bar, rt, ethanol Alkyne+alkene 
 
Pd/CaCO3/Pb 20 bar, rt, ethanol Alkyne+alkene 
 
Pd/C 1% 30 bar, rt, ethanol Alkyne+alkene+alkane 
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Table 6. Hydrogenation conditions with Parr instrument 
Substrate Catalyst Conditions Result 
 
Lindlar cat. (5% w) 
Quinoline (3% mol) 
Toluene:methanol 
5:1, 20 psi, rt 
1 h Alkene+alkane 
2 h Alkene+alkane 
Lindlar cat. (2.5% w) 
Quinoline (3% mol) 
Toluene:methanol 
5:1, 20 psi, rt 
15 
min 
Alkyne 
30 
min 
Alkyne+alkene 
1 h Alkyne+alkene 
2 h Alkene 
3 h Alkene+alkane 
 
Lindlar cat. (2.5% w) 
Quinoline (3% mol) 
Toluene:methanol 
5:1, 20 psi, rt 
1 h Alkyne 
2 h Alkyne 
 
Lindlar cat. (5% w) 
Quinoline (3% mol) 
Toluene: 
methanol 
5:1, rt 
20 psi 
1 h Alkyne 
2 h Alkyne 
40 psi 2 h Alkyne 
Lindlar cat. (10% w) 
Quinoline (3% mol) 
Toluene:methanol 
5:1, 40 psi, 6 h, rt 
 
Alkyne 
Lindlar cat. (10% w) 
Toluene, 40 psi,        
6 h, rt 
 
Alkyne 
Ethyl acetate, 40 psi, 
4 h, rt 
 
Alkyne 
Lindlar cat. (20% w) 
Ethyl acetate, 40 psi, 
overnight, rt 
 
Alkyne 
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Table 7. Other conditions 
Substrate Reaction conditions Result 
 
Pd(OAc)2, KOH, DMF, H2O, 145ºC,  
overnight 
 Alkyne+alkene 
 
Ni(OAc)2·4H2O, NaBH4, 
ethylenediamine, H2 (balloon), ethanol, 
rt  
30 min Alkyne+alkene  
1 h Alkyne+alkene  
2 h Alkene 
 
Finally, Brown hydrogenation reaction101 (optimization of the reaction in   
Table 7) allowed to obtain the desired alkenes 64-66 with total conversion 
employing nickel acetate tetrahydrate and sodium borohydride as the catalytic 
system, in the presence of ethylendiamine and under hydrogen atmosphere. Then, 
the alkenes were hydrolyzed to their corresponding carboxylic acids 67-69 
(Scheme 11).  
 
Scheme 11 
Next, phosphate moieties were prepared following a synthetic methodology 
previously set up in the laboratory consisting on a phosphoramidite reaction and 
oxidation of the intermediate phosphite formed.102 Thus, one-pot reaction of (S)-(-)-
2,3-bis(bencyloxy)propan-1-ol with di-tert-butyl N,N-diisopropylphosphoramidite, 
followed by oxidation with m-chloroperbenzoic acid (mCPBA) led to derivative 70. 
Removal of the benzyl groups by catalytic hydrogenation yielded diol 71    
(Scheme 12).  
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Scheme 12 
Finally, the esterification reaction between myristoleic or palmitoleic acid or 
the non-commercial carboxylic acids 67-69 and the phosphorylated diol 71 led to 
intermediates 72-76, which were then deprotected to obtain the final products 2a-e 
with good yields (Scheme 13).  
 
Scheme 13 
Synthesized compounds 2a-e were tested for their activity at the LPA1 
receptor (Table 8). The most remarkable conclusion that can be drawn from the 
data obtained is the great influence on activity exerted by the length of the 
hydrophobic chain. As shown in Table 8, variations in just one methylene unit can 
turn a compound inactive (for example derivative 2d shows an activity 
comparable to LPA whereas 2e is inactive) or increase its activity almost two-fold, 
as shown by compounds 2d (Emax = 88%; EC50 = 3.6 µM) and 2c (Emax = 202%; 
EC50 = 2.1 µM). These data suggest that the optimal chain is the corresponding to 
(9Z)-hexadec-9-enoic acid, present in compound 2b (Emax = 205%; EC50 = 0.45 
µM), the most potent derivative within the series and better than the endogenous 
ligand LPA (Emax = 100%; EC50 = 0.83 µM).  
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Table 8. Agonist activities of compounds 2a-e at LPA1 receptor 
 
 Derivatives of series II containing aromatic rings 
Previous results from our group indicate that phenyl and biphenyl groups can 
mimic unsaturated fatty acid chains.103 Accordingly, the possibility of replacing the 
hydrophobic chain with other hydrophobic units containing aromatic rings was 
studied. In addition, and considering the importance of the length of the chain for 
activity, the influence of the distance between the aromatic rings and the ester 
group of the molecule (n) was screened in detail (Figure 22).  
In this case, the synthesis involved the preparation of the non-commercial    
ω-phenylalkanoic carboxylic acids as well as the conveniently protected 
phosphorylated glycerol (Figure 22). Regarding the glycerol moiety and searching 
for synthetic simplicity and high yields, the phosphate group was protected with an 
 
Compound 
 
Emax (%)a EC50 (µM)b 
2a 
 
127± 1 2.8 ± 0.1 
2b 
 
205 ± 9 0.45 ± 0.01 
2c 
 
202 ± 1 2.1 ± 0.3 
2d 
 
88 ± 2 3.6 ± 0.2 
2e 
 
N.E.c - 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 
bFor Emax > 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two 
independent experiments, performed in triplicated. cNo effect was observed at the highest 
concentration tested (10 µM). 
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ethyl moiety (PG1), whose removal should not interfere with the presence of an 
ester. As for the diol protecting group, the commercially available acetal was 
initially selected. 
 
Figure 22. Retrosynthetic analysis for aromatic ring derivatives of series II. 
Non-commercially available carboxylic acids (X = H, n = 7-9) were 
synthesized as depicted in Scheme 14, either by oxidation of the corresponding 
alcohol, in the case of acid 77, or by Wittig reaction between the appropriate 
bromoacid and benzaldehyde, followed by catalytic hydrogenation, in the case of 
acids 80 and 81.  
 
Scheme 14 
The protected glycerol was reacted with diethyl chlorophosphate in the 
presence of a base to yield intermediate 82, which after cleavage of the acetal 
group afforded the phosphorylated glycerol 83 (Scheme 15).  
 
Scheme 15 
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Once the phosphorylated glycerol 83 and the carboxylic acids 77, 80 and 81 
were prepared, the coupling reaction between 83 and 77 was carried out and the 
resulting ester 84 was treated with TMSBr as generally described104 to remove the 
ethyl groups from the phosphate. However, instead of the expected product, the 
brominated derivative 3a was obtained (Scheme 16). The formation of this product 
could be explained by migration of the acyl chain to the secondary hydroxy group, 
and substitution of the primary hydroxy group by the bromide present in the 
reaction media. This sn-1/sn-2 migration has been observed in other LPA 
derivatives.105 
 
Scheme 16 
Although different deprotection conditions were assayed for compound 84, it 
was not possible to isolate the desired product. Starting material was used 
thoroughly dried, N,O-bis(trimethylsilyl)trifluoroacetamide was employed as 
additive, and the reaction times were reduced, but it was observed that the 
migration occurred prior to the deprotection of the phosphate group, and a mixture 
of starting material, desired product and brominated product was obtained in all 
cases.  
Hence, to obtain the phosphorylated diol, the phosphate group was introduced 
using the methodology previously used based on the employment of a 
phosphoramidite reagent. In this case, the protecting group selected for the 
phosphate was the benzyl group (Scheme 17). 
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Scheme 17 
The regioselective esterification reaction between diol 86 and the 
corresponding ω-phenylalkanoic acids (n = 6-9, 14) allowed to obtain the esters 
87-91, which after elimination of the benzyl groups by catalytic hydrogenation 
afforded the desired final compounds 2f-j (Scheme 18). 
 
Scheme 18 
All the synthesized compounds 2f-j were tested for activity at LPA1 receptor 
and the results are shown in Table 9. Although compound 3a bears a different 
phosphate scaffold, it was also tested, as a lack of regioselectivity between sn-1 
and sn-2 positions has been reported for LPA1 receptor. Furthermore, compounds 
containing a bromine in the polar head have been described as good agonists or 
antagonists for LPA receptors.83 
Again, the obtained data (Table 9) point out the importance of the length of the 
hydrophobic chain of the compound in the activity at LPA1 receptor, as small 
changes within the number of methylene units dramatically affects Emax and EC50 
values. For example, compound 2g, with n = 7, is inactive, whereas derivative 2h, 
with n = 8, is almost as active as LPA. In addition, it must be highlighted that 
compound 3a, with a different polar head group, exhibits a very good activity at 
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LPA1 receptor. Among these derivatives, compounds 2i and 3a, with Emax > 100% 
and EC50 values of 0.5 and 0.24 µM, respectively, stand out.  
Table 9. Agonist activities of compounds 2f-j and 3a at LPA1 receptor 
 
Compound  
 
Emax (%)a EC50 (µM)b 
2f 
 
N. E.c - 
2g 
 
N. E. - 
2h 
 
74 ± 4 2.1 ± 0.3 
2i 
 
112 ± 3 0.5 ± 0.1 
2j 
 
N. E. - 
3a 
 
118 ± 24 0.24 ± 0.09 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 
bFor Emax > 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two 
independent experiments, performed in triplicate. cNo effect was observed at the highest 
concentration of compound tested (10 µM). 
 
Regarding the fragments bearing a biphenyl ring (X = Ph, n = 6, 9, 12), the 
synthetic strategy employed was the same as for the phenyl ring derivatives, using 
a Wittig reaction to obtain the desired ω-biphenylalkanoic acids, and intermediate 
86 to incorporate the phosphoglycerol moiety.  
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Thus, 9-bromononanoic acid 94 and 12-bromododecanoic acid 98 were first 
prepared by oxidation of 9-bromononan-1-ol and 12-bromododecan-1-ol 97, 
respectively, with fuming nitric acid. Previously, alcohol 97 had been obtained from 
commercially available 1,12-dodecanodiol by selective bromination. The ω-
bromoalkanoic acids reacted with triphenylphosphine in refluxing toluene to yield 
the corresponding phosphonium salts, which, by Wittig reaction with biphenyl-4-
carbaldehyde, led to alkenes 92, 95 and 99. These intermediates were transformed 
into the desired carboxylic acids 93, 96 and 100 by catalytic hydrogenation of the 
double bond (Scheme 19).  
 
Scheme 19 
Then, the carboxylic acids 93, 96 and 100 were coupled with diol 86 to obtain 
the esters 101-103. Final hydrogenation of these intermediates gave compounds 
2k-m in good yields (Scheme 20). 
 
Scheme 20 
Compounds 2k-m were tested for LPA1 activity, and the results are shown in 
Table 10. Once more, the exquisite influence of the length of the chain was 
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confirmed, with the compound bearing a nine carbon atom chain (2l) showing the 
highest activity (Emax = 127 %, EC50 = 3.3 µM).  
Table 10. Agonist activities of compounds 2k-m at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b 
2k 
 
N. E.c - 
2l 
 
127 ± 9 3.3 ± 0.6 
2m 
 
37 ± 1 19 ± 2 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor 
Emax > 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two independent 
experiments, performed in triplicate. cNo effect was observed at the highest concentration of 
compound tested (10 µM).  
 
 Analogues of 3a 
Considering the excellent activity of compound 3a, which turned out to be the 
best LPA1 receptor agonist among all the synthesized compounds so far (Emax = 
118%, EC50 = 0.24 µM), additional structural exploration was extended around this 
scaffold. In particular, it was analysed whether changes in the length of the 
methylenic chain would affect its activity in the same degree observed for other 
compounds of series I and II (compounds 3b, c). In addition, the replacement of 
the hydrophobic unit by the oleic acid chain was studied, in order to see if it would 
involve an increase in activity. Hence, compounds 3b-d (Figure 23) were 
synthesized.  
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Figure 23. Designed derivatives of 3a. 
Phenyl-containing derivatives 3b and 3c were obtained from (S)-oxiran-2-
ylmethanol, which was phosphorylated following the usual conditions. Then, 
opening of the oxirane ring of intermediate 104 with tetrabutylammonium bromide 
(TBABr) in the presence of TFA yielded derivative 105, which was coupled with the 
corresponding ω-phenylalkanoic acids. Subsequent catalytic hydrogenation of the 
benzyl groups gave the desired final compounds 3b, c (Scheme 21). 
 
Scheme 21 
A similar synthetic route, but employing tert-butyl instead of benzyl as 
protecting group for the phosphate, due to the presence of the double bond in the 
oleate moiety, allowed to obtain compound 3d (Scheme 22).  
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Scheme 22 
Activity of these new compounds at the LPA1 receptor was determined (Table 
11). The obtained results showed that only the oleic acid chain derivative (3d) was 
able to activate the receptor, although it did not reach neither LPA nor 3a values.  
Table 11. Agonist activities of compounds 3a-d at LPA1 receptor 
 
Compound 
 
Emax (%)a EC50 (µM)b 
3a 
 
118 ± 24 0.24 ± 0.09  
3b 
 
N. E.c  - 
3c 
 
N. E.  - 
3d 
 
39 ± 3 3.2 ± 0.4 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor Emax 
> 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two independent 
experiments, performed in triplicate. cNo effect was observed at the highest concentration of 
compound tested (10 µM). 
 
Results and discussion 
- 51 - 
2.2 Combination of the acid and hydrophobic subunits 
Among all the synthesized compounds, derivatives 1c, 1g, 2b, 2i, 2l, 3a and 
3d have shown the best activities at the LPA1 receptor (Figure 24). They present 
EC50 values between 0.24 and 6 µM, comparable or even better than the 
endogenous ligand LPA (EC50 = 0.83 µM). This suggests that the phosphate 
glycerol of LPA can be mimicked by other acid moieties such as (5S)-3-fluoro-5-
(hydroxymethyl)-2-oxotetrahydrofuran-3-carboxylic acid (present in 1c), fluoro[(2S)-
3-hydroxy-2-methoxypropyl]malonic acid (present in 1g) and (2S)-3-bromo-2-
hydroxypropyl dihydrogen phosphate (present in 3a and 3d). In addition to the oleic 
acid chain of LPA, the LPA1 receptor recognizes shorter chains such as (9Z)-
hexadec-9-enoic acid (present in 2b), 10-phenyldecanoic acid (present in 2i and 
3a) and 10-biphenyl-4-yldecanoic acid (present in 2l) (Figure 24).  
 
Figure 24. Compounds with activity at the LPA1 receptor 
With these results in hand, we combined some of the hydrophobic moieties 
present in these compounds with the polar heads that seem to be able to mimic the 
LPA phosphate group. Hence, the fluorinated lactone and the fluorinated malonic 
acid present in derivatives 1c and 1g were selected as polar heads. Regarding the 
hydrophobic moiety, palmitoleic acid chain present in 2b and 10-phenyldecanoic 
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acid chain present in 2i and 3a were chosen. The combination of these moieties 
led to products 4a-c which were synthesized and tested as agonists of the LPA1 
receptor (Figure 25).  
 
 
Figure 25. Combination of the acid and hydrophobic subunits. 
The synthesis of lactone 4a started with the benzylation of (R)-oxiran-2-
ylmethanol, followed by oxirane opening with di-tert-butyl malonate in basic media 
and intramolecular cyclization to give lactone 112. Fluorination in the usual 
conditions led to derivative 113, whose catalytic hydrogenation yielded alcohol 114. 
The esterification between 114 and 10-phenyldecanoic acid allowed to obtain ester 
115, which was treated with TFA to give final product 4a as a mixture of 
diastereoisomers (Scheme 23).  
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Scheme 23 
Malonic acid derivatives 4b, c were prepared by regioselective coupling of the 
corresponding carboxylic acid and diol 43. Methylation of the hydroxy group 
present in the resulting esters 116 and 118 with trimethylsilyldiazomethane 
followed by removal of the tert-butyl groups yielded the desired compounds 4b, c 
(Schemes 24 and 25).  
 
Scheme 24 
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Scheme 25 
Compounds 4a-c (Table 12) were tested for their activity at LPA1 receptor. 
Unfortunately, the results obtained for compounds 4a, b showed that replacement 
of the oleic acid chain by 10-phenyldecanoic acid is detrimental for activity. 
Instead, derivative 4c, bearing a palmitoleic acid chain and malonic acid as polar 
head was able to activate LPA1 receptor (Emax = 43%, EC50 = 1.4 µM).  
 
Table 12. Agonist activities of compounds 4a-c at LPA1 receptor 
Compound Structure Emax (%)a EC50 (µM)b 
4a 
 
N. E.c  - 
4b 
 
N. E. - 
4c 
 
43 ± 6 1.4 ± 0.4 
LPA 
 
100 0.83 ± 0.02 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 
bFor Emax > 30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two 
independent experiments, performed in triplicate. cNo effect was observed at the highest 
concentration of compound tested (10 µM). 
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In summary, up to this moment we have successfully identified novel agonists 
with activity at LPA1 receptor. The two series proposed for mimicking the 
hydrophobic chain and the polar head of the endogenous ligand LPA have yielded 
new scaffolds capable to activate the receptor. Regarding the combination 
process, the identification of compound 4c, with good activity values, paves the 
way for further optimization processes.  
From all the compounds synthesized so far, derivative 3a stands out as the 
first agonist structurally different from the endogenous ligand LPA, with excellent 
activity values, which was selected for further biological characterization.  
 
 
Figure 26 
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2.3 Determination of the antagonist activity at LPA1 receptor 
The involvement of LPA1 receptor in diverse biological and pathological 
processes highlights the need of potent and selective antagonists as useful tools 
for evaluating these roles. Taking into account the fact that the structural 
requirements for agonism and antagonism at LPA1 receptor have not been 
rationalized yet and that small changes in structure can turn agonists into 
antagonists and viceversa, all the synthesized compounds which were inactive as 
agonists at the LPA1 receptor were screened for their antagonist capacity.  
Hence, to determine the antagonist activity of the compounds, RH7777 cells 
stably transfected with the receptor were preloaded with Fluo 4-NW and then 
incubated with the compound under study at a fixed dose of 10 µM, followed by the 
addition of 10 µM LPA. The antagonism was measured as the capacity of the 
compound to decrease the intensity of LPA response. None of the compounds 
tested presented antagonist activity over 30% so their dose-response curves were 
not performed. Positive and negative controls were identical to those employed in 
previous experiments. 
2.4 Selectivity over other LPA receptors 
The high sequence homology among the LPA receptors, especially LPA1-3, 
has hampered the development of high affinity and selective ligands for LPA1 
receptor, also slowing down the elucidation of its biological roles. Therefore, the 
characterization of the synthesized agonists in this work at each of the LPA 
receptors is crucial to define their role as tools to be used for the validation of LPA1 
receptor as a therapeutic target.  
Towards this aim, cell lines stably overexpressing each of the five LPA 
receptor subtypes were generated. A B103 neuroblastoma cell line, which does not 
express LPA receptors intrinsically,17 was chosen for its transfection with the 
corresponding plasmid containing LPA1-5 receptors fused with the enhanced green 
fluorescent protein (EGFP). B103 cells expressing high levels of EGFP, and thus of 
the desired receptor, were isolated by fluorescence-activated cell sorting (FACS). 
The generation of these cell lines was carried out during a predoctoral stay at Prof. 
Jerold Chun Lab, at The Scripps Research Institute (La Jolla, California). 
Up to this moment, the screening of all the synthesized compounds at the 
LPA2 receptor has been completed, being the characterization at the rest of the 
receptors currently under way in our laboratory. Table 13 shows the compounds 
active at any of the LPA receptors analysed.  
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Table 13. Agonist activities of compounds at LPA1 and LPA2 receptor  
  LPA1 receptor LPA2 receptor 
Compound Emax (%)a EC50 (µM)b Emax (%) EC50 (µM) 
1c 
 
33 ± 5 1.7 ± 0.2 N. E. c  - 
1g 
 
74 ± 14 6 ± 1 N. E. - 
2a 
 
127 ± 1 2.8 ± 0.1 42 ± 5 8.1 ± 0.8 
2b 
 
205 ± 9 0.45 ± 0.01 N. E. - 
2c 
 
202 ± 1 2.1 ± 0.3 N. E. - 
2d 
 
88 ± 2 3.6 ± 0.2 N. E. - 
2h 
 
74 ± 4 2.1 ± 0.3 59 ± 2 12 ± 2 
2i 
 
112 ± 3 0.5 ± 0.1 74 ± 6 5.3 ± 0.6 
2l 
 
127 ± 9 3.3 ± 0.6 N. E. - 
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Table 13 (cont.). Agonist activities of compounds at LPA1 and LPA2 receptor  
 LPA1 receptor LPA2 receptor 
Compound Emax (%)
a EC50 (µM)b Emax (%)a EC50 (µM)b 
2m 
 
37 ± 1 19 ± 2 N. E. - 
3a 
 
118 ± 24 0.24 ± 0.09 N. E.  - 
3c 
 
N. E.  - 57 ± 7 5 ± 1 
3d 
 
39 ± 3 3.2 ± 0.4 67 ± 8 4.9 ± 0.2 
4b 
 
N. E.  - 55 ± 10  4.8 ± 0.1 
4c 
 
43 ± 6  1.4 ± 0.4 81 ± 1 10.8 ± 0.8 
aEmax = maximal efficacy of the drug/maximal efficacy of LPA, expressed as the percentage.
 bFor Emax > 
30%, EC50 values are expressed as mean ± s.e.m, from a minimum of two independent experiments, 
performed in triplicate. cNo effect was observed at the highest concentration of compound tested (10 µM). 
 
Among the tested compounds, seven derivatives were able to activate LPA2 
receptor. Compounds 2a, 2h, 2i, 3d, and 4c are dual agonists at LPA1-2 receptors, 
and compounds 3c and 4b show no activity at LPA1 receptor. It must be remarked 
that compounds 1c, 1g, 2b-d, 2l, 2m, and especially 3a, are inactive at LPA2 
receptor.  
These results indicate that slight differences in structure can render important 
changes in activity, also between receptors, fact that highlights the difficulty to 
obtain selective ligands for a particular LPA receptor subtype.   
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2.5 Biological characterization of compound 3a 
In order to verify whether compound 3a, which has been identified as a good 
LPA1 agonist by calcium mobilization assay, and which is selective over LPA2 
receptor, is really acting at the LPA1 receptor, a set of additional cellular 
experiments was performed. Compound 1c, with moderate activity at LPA1 and 
selective over LPA2, was also tested for comparison. The existence of a correlation 
between the in vitro agonism and the cellular effects is the first and necessary step 
towards a complete biological characterization that would continue with diverse in 
vivo studies in the target validation process.  
LPA1 activation induces a range of well known cellular responses, from which 
cell migration106 or cytoskeletal changes17 stand out as they are implicated in 
diverse processes such as cancer, angiogenesis, fibrosis or neurodegenerative 
disorders. In B103 neuroblastoma cells, LPA induces neurite retraction with cells 
acquiring a rounded shape. Receptor internalization after stimulation with an 
agonist, characteristic of GPCRs, was also measured.107  
2.5.1 Neurite retraction 
B103 neuroblastoma cells overexpressing LPA1 receptor and tagged with 
EGFP were exposed to different concentrations of compounds 1c and 3a. Then, 
they were fixed and stained with phalloydin and DAPI (4',6-diamidino-2-
phenylindole) for cell morphology and the number of cells with retracted neurites 
and the number of total cells were counted. 1 µM LPA was employed as positive 
control, and 0.1% fatty acid free bovine serum albumin (FAF BSA) as negative 
control (Figure 27).  
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Figure 27. Neurite retraction induced by 3a and 1c. Percentage of retracted neurites at 10, 
5 or 1 µM for compound 3a (A) and 1c (B). Visualization of neurite retraction: control 0.1% 
FAF BSA (C), 1 µM LPA (D), 10 µM 3a (E), 1 µM 3a (F), 10 µM 1c (G), 1 µM 1c (H). 
Representative images of neurite retraction: 0.1% FAF BSA (I), 10 µM 3a (J). Samples were 
imaged under the same conditions by using a Zeiss fluorescence microscope (C-H, bars 
100 µm) or Zeiss fluorescence confocal microscope (I-J, bars 10 µm).  
Figures 27 A and 27 B show the percentage of retracted neurites for each of 
the compounds tested, with derivative 3a exhibiting similar response to LPA at a 10 
µM concentration, and also a dose-dependent response at the different 
concentrations assayed. As expected from its lower agonist activity, derivative 1c 
does not reach LPA effects even at the highest dose tested (10 µM).  
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2.5.2 Cell migration 
B103 neuroblastoma cells overexpressing LPA1 receptor were seeded into the 
upper chamber of a permeable membrane, and compounds 1c and 3a and 
controls were placed in the lower chamber. After 5 h of incubation, migrated cells 
were stained and quantified under a microscope (Figures 28 and 29).  
 
 
Figure 28. Migration experiment for compounds 3a and 1c at 10 µM. Number of migrated 
cells (A). Visualization of migrated cells (B-E): 0.1% FAF BSA (B), 1 µM LPA (C), 10 µM 3a 
(D), 10 µM 1c (E). Samples were imaged under the same conditions by using a Zeiss 
microscope (bars 50 µm). Cells were stained with 0.1% crystal violet solution. 
 
 
Figure 29. Migration experiment for compound 3a at 1 µM. Number of migrated cells (A). 
Visualization of migrated cells (B-D): 0.1% FAF BSA (B), 1 µM LPA (C), 1 µM 3a (D). 
Samples were imaged under the same conditions by using a Zeiss microscope (bars 50 
µm). Cells were stained with 0.1% crystal violet solution. 
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Again, it was verified that, at the highest concentration tested, compound 3a 
response is similar to LPA whereas derivative 1c does not reach the same levels, 
according to their EC50 values. 3a was also tested at 1 µM, and a decrease in the 
response was observed, in accordance with a dose-dependent behaviour.  
2.5.3 Receptor internalization 
B103 neuroblastoma cells overexpressing LPA1 receptor were exposed to 
compounds 3a or 1c at concentrations ranging from 0.1 µM to 10 µM. LPA (1 µM) 
was employed as positive control and 0.1% FAF BSA as negative control. After 
fixing and staining the cells, their images were acquired with a confocal 
microscope. Both derivatives were able to induce internalization of the receptor at 
all the concentrations assayed. Figure 30 shows representative examples.  
 
 
Figure 30. Visualization of receptor internalization. Compound 3a, 1 µM (A). LPA, 1 µM (B). 
Cells were stained with DAPI and phalloydin for cell morphology. Samples were imaged 
under the same conditions by using a Zeiss fluorescence confocal microscope (bars 10 µm).  
 
All in sum, these assays have helped to confirm the action of derivative 3a at 
the LPA1 receptor, not only in vitro but also at the cellular level, underscoring its 
significance as a promising hit with good activity and selectivity values.  
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 CONCLUSIONS 
1. In this work we have carried out the design and synthesis of new ligands for 
the LPA1 receptor using as starting point the endogenous ligand, LPA. Both the 
polar head and the hydrophobic chain of LPA have been successfully mimicked by 
other moieties, thus paving the way for the development of structurally novel LPA1 
receptor ligands. 
2. Five cell lines overexpressing the different LPA receptor subtypes LPA1-5 
have been generated to enable the study of the complete selectivity profile within 
the LPA receptor family. 
3. All the synthesized compounds have been evaluated for their functional 
activity at the LPA1 receptor as well as for their selectivity at the LPA receptor 
family. Among all of them, compound 3a stands out as a LPA1 receptor agonist 
more potent than LPA. In addition, 3a is selective against other LPA receptor 
subtypes such as LPA2, and it is active in cellular assays, where it induces similar 
effects to LPA. 
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 EXPERIMENTAL SECTION 
4.1 Synthesis 
Unless otherwise stated, the starting materials, reagents, and solvents used 
were high-grade commercial products from Sigma-Aldrich, ABCR, Acros, Biotage, 
Fluka, Lancaster, Scharlab, or Panreac. Dichloromethane, diethyl ether and 
tetrahydrofuran (THF), were dried using a Pure SolvTM Micro 100 Liter solvent 
purification system. Triethylamine and pyridine were dried over CaH2 and distilled 
prior to its use. Alcohol-free chloroform was obtained by washing with water, drying 
over MgSO4, filtration and distillation over P2O5. Ethylenediamine was dried over 
4Å molecular sieves, distilled and used immediately. All non-aqueous reactions 
were performed under an argon atmosphere in oven-dried glassware.  
Analytical thin-layer chromatography (TLC) was run on Merck silica gel plates 
(Kieselgel 60 F-254), with detection by UV light ( = 254 nm), ninhydrin solution, or 
10% phosphomolybdic acid solution in ethanol. Flash chromatography was 
performed on glass column using Merck silica gel type 60 (particle size 230-400 
mesh), or on a Varian 971-FP flash purification system, using silica gel cartridges 
(Varian, particle size 50 µm).  
All compounds were obtained as oils, except for those whose melting points 
(m.p.) are indicated, which were solids. M.p. were determined on a Stuart Scientific 
electrothermal apparatus. Infrared (IR) spectra were measured on a Bruker Tensor 
27 instrument equipped with a Specac ATR accessory of 5200-650 cm-1 
transmission range; frequencies () are expressed in cm-1. Optical rotation [was 
measured on a Perkin Elmer 241 polarimeter using a sodium lamp ( = 589 nm) 
with a 1 dm path length; concentrations are given as g/100 mL. 1H, 13C and 31P 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker Avance III 
700MHz (1H, 700 MHz; 13C, 175 MHz), Bruker Avance 500MHz (1H, 500 MHz; 13C, 
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125 MHz, 31P, 202 MHz) or Bruker DPX 300MHz (1H, 300 MHz; 13C, 75 MHz, 31P, 
121 MHz) instrument at room temperature at the UCM’s NMR core facility. 
Chemical shifts () are expressed in parts per million relative to internal 
tetramethylsilane; coupling constants (J) are in hertz (Hz). The following 
abbreviations are used to describe peak patterns when appropriate: s (singlet), d 
(doublet), t (triplet), q (quartet), qt (quintuplet), m (multiplet), dd (double doublet), dt 
(double triplet), td (triple doublet), app (apparent) and br (broad). 2D NMR 
experiments (COSY, HMQC and HMBC) of representative compounds were 
carried out to assign protons and carbons of the new structures. High resolution 
mass spectrometry (HRMS) was carried out on a FTMS Bruker APEX Q IV 
spectrometer in electrospray ionization (ESI) or matrix-assisted laser 
desorption/ionization (MALDI) mode at UCM’s mass spectrometry core facility. For 
all final compounds, purity was determined by high-performance liquid 
chromatography coupled to mass spectrometry (HPLC-MS), and satisfactory 
chromatograms confirmed a purity of at least 95% for all tested compounds. HPLC-
MS analysis was performed using an Agilent 1200LC-MSD VL instrument. LC 
separation was achieved with a Zorbax Eclipse XDB-C18 column (5 m, 4.6 mm x 
150 mm) or Zorbax SB-C3 (5 m, 2.1 mm x 50 mm) together with a guard column 
(5 m, 4.6 mm x 12.5 mm). The gradient mobile phases consisted of A (95:5 
water/acetonitrile or water/methanol) and B (5:95 water/acetonitrile or 
water/methanol) with 0.1% ammonium hydroxide and 0.1% formic acid as the 
solvent modifiers, and the gradients are indicated in Table 15. MS analysis was 
performed with an ESI source. The capillary voltage was set to 3.0 kV and the 
fragmentor voltage was set at 25 eV. The drying gas temperature was 350 ºC, the 
drying gas flow was 10 L/min, and the nebulizer pressure was 20 psi. 
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Table 14. HPLC gradients 
Method A Method B 
Column SB-C3 
Buffers water/acetonitrile 
Column XDB-C18 
Buffers water/methanol 
t (min) % B t (min) % B 
0 0 0 0 
2 0 2 0 
8 60 10 50 
20 100 20 100 
25 100 50 100 
30 0 60 0 
 
4.1.1 General procedures 
 Hydrogenation of alkenes and deprotection of dibenzyl phosphates and 
benzyl ethers 
The corresponding alkene or benzylated derivative was dissolved in ethanol 
(0.2 mL/mg) and the solution was pumped through a H-Cube® continuous-flow 
hydrogenation reactor using a 10% Pd/C CatCart® cartridge, under full-H2 mode at 
a flow-rate of 1 mL/min at room temperature (for alkenes and dibenzyl phosphates) 
or 60°C (for benzyl ethers). Solvent was then removed under reduced pressure to 
afford the corresponding compound in quantitative yield that was used without 
further purification. 
 Mesylation of alcohols 
To a cooled (0°C) stirred solution of the corresponding alcohol (1 equiv) and 
triethylamine (3 equiv) in anhydrous dichloromethane (3.5 mL/mmol), 
methanesulfonyl chloride (1.5 equiv) was added dropwise. The reaction mixture 
was stirred at 0°C for 10 minutes and then at room temperature for 1 h. Afterward, 
the mixture was partitioned between ethyl acetate and brine. The organic layer was 
separated, washed with a saturated aqueous solution of NaHCO3 and with brine, 
dried over Na2SO4, filtered and concentrated under reduced pressure to yield the 
corresponding mesylate, which was used in the next step without further 
purification. 
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 Alkylation with di-tert-butyl malonate 
Di-tert-butyl malonate (1.5 equiv) was added dropwise to a stirred suspension 
of NaH (1.5 equiv, 60% dispersion in oil) in a 2:1 mixture of anhydrous DMF/THF 
(6 mL/mmol) at 0ºC, and the mixture was stirred at room temperature for 15 
minutes. A solution of the corresponding mesylate (1 equiv) in anhydrous THF (3 
mL/mmol) was added, followed by NaI (1.1 equiv), and the resulting mixture was 
heated at 80ºC overnight. Afterward, the reaction was cooled to room temperature 
and quenched by addition of a saturated aqueous solution of NH4Cl. The mixture 
was then diluted with water, and extracted with ethyl acetate. The organic phase 
was washed with brine, dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash chromatography to afford the 
corresponding alkylated product. 
 α-Fluorination of malonate derivatives using Selectfluor®  
The corresponding malonate derivative (1 equiv) was added to a suspension 
of NaH (2 equiv, 60% dispersion in oil) in anhydrous THF (4 mL/mmol) at 0ºC, and 
the reaction mixture was warmed up to room temperature and then stirred at 70°C 
for 12 h. The solution was cooled to room temperature and diluted with anhydrous 
THF (8 mL/mmol) and N,N-dimethylformamide (DMF) (8 mL/mmol). Afterward, 
Selectfluor® was added (2 equiv) at 0ºC and the solution was stirred at this 
temperature for 4h and at room temperature overnight. The reaction mixture was 
quenched by addition of water and extracted with diethyl ether. The organic layer 
was dried over Na2SO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography to afford the corresponding 
fluorinated derivative. 
 Deprotection of acetals using polystyrene-supported pTsOH 
The corresponding acetal (1 equiv) was dissolved in methanol (3 mL/g resin) 
and the polystyrene-supported pTsOH (PS-pTsOH) was added (0.3 equiv, 4.56 
mmol pTsOH/g resin). The reaction was stirred at room temperature overnight. 
Afterward, the mixture was filtered and the solvent was evaporated under reduced 
pressure. The crude was purified by flash chromatography to afford the 
corresponding diol.  
 Regioselective esterification of oleoyl chloride with diols 
To a stirred suspension of the corresponding alcohol (1.5 equiv) in anhydrous 
dichloromethane (12 mL/mmol alcohol) at -78°C, 2,4,6-collidine (2 equiv) and 
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oleoyl chloride (1 equiv) were added. The mixture was stirred for 24 h while 
gradually warming to room temperature. After this time, solvent was evaporated 
under reduced pressure and the residue was treated with ethyl acetate, removing 
the 2,4,6-collidine hydrochloride by filtration. The filtrate was concentrated and the 
crude was purified by flash chromatography to yield the corresponding ester.  
 Deprotection of tert-butyl esters and alkyl di-tert-butyl phosphates 
TFA (25 or 75 equiv) was added to a solution of the corresponding tert-butyl 
derivative (1 equiv) in anhydrous dichloromethane (20 mL/mmol) and the reaction 
was stirred at room temperature until disappearance of the starting material. The 
mixture was then treated with brine and the aqueous phase was extracted with 
dichloromethane. The combined organic layers were washed with water and brine, 
dried over Na2SO4 and filtered. The solvent was evaporated under reduced 
pressure to afford the corresponding phosphate or carboxylic acid.  
 Methylation of alcohols with trimethylsilyldiazomethane 
To a vigorously stirred mixture of the corresponding alcohol (1 equiv) and 
HBF4 (1 equiv, 35% aqueous solution) in anhydrous dichloromethane (4 mL/mmol) 
at 0ºC, trimethylsilyldiazomethane (1 equiv, 2 M in diethyl ether) was added 
dropwise, waiting for the yellow colour to disappear before each addition. The 
stirring was continued at 0ºC and three further portions of 
trimethylsilyldiazomethane (0.5 equiv, 0.25 equiv and 0.25 equiv) were added 
dropwise at intervals of 20 min. Afterward, the mixture was stirred at 0ºC for further 
30 min, poured into water and extracted with dichloromethane. The organic layer 
was washed with water, dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography to afford the 
pure compound.  
 Sonogashira coupling reaction of alkynes with methyl-8-bromooctanoate 
1,3-bis(1-adamantyl)imidazolium chloride (0.15 equiv), CuI (0.225 equiv), [(π-
allyl)PdCl]2 (0.075 equiv), and Cs2CO3 (1.4 equiv) were added in turn to a 
thoroughly dried vial. A mixture of anhydrous diethyl ether (1 mL/mmol ester) and 
DMF (0.5 mL/mmol ester) was added, followed by the alkyne (1.3 equiv) and 
methyl-8-bromooctanoate (1 equiv). The vial was sealed with a Teflon-lined cap 
and the heterogeneous reaction mixture was stirred vigorously at 55ºC for 16 
hours. The solvents were then evaporated under reduced pressure and the residue 
was purified by flash chromatography to yield the corresponding alkyne.  
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4.1.1.10 Stereoselective cis-hydrogenation of alkenes with P-2 nickel catalyst 
Ni(OAc)2·4H2O (0.2 equiv) was suspended in absolute ethanol (3 mL/mmol 
alkyne) at room temperature. NaBH4 (0.2 equiv) was added and the mixture was 
stirred for 15 min. Then, argon atmosphere was replaced by H2 (balloon). Freshly 
distilled ethylenediamine was added (1.5 equiv) and the reaction was stirred for 15 
minutes. A solution of the corresponding alkyne (1 equiv) in absolute ethanol (3 
mL/mmol) was then added, and the reaction was stirred under a H2 atmosphere at 
room temperature for 2 h. After this time, the reaction mixture was filtered through 
a pad of Celite, and the solvent was removed under reduced pressure. The residue 
was redissolved in ethyl acetate and washed with water and brine. The organic 
layer was dried over Na2SO4, filtered and concentrated to afford the corresponding 
Z-alkene, which was used in the next step without further purification.  
4.1.1.11 Hydrolysis of methyl esters 
The corresponding methyl ester (1 equiv) was dissolved in THF (10 mL/mmol) 
and a solution of LiOH (2 equiv) in water (1.5 mL/mmol) was added. The reaction 
was stirred at room temperature overnight. Then, the mixture was acidified with a 
20% aqueous solution of HCl and extracted with dichloromethane. The organic 
phase was dried over Na2SO4, filtered and concentrated, affording the 
corresponding carboxylic acid in quantitative yield.  
4.1.1.12 Phosphorylation of alcohols using phosphoramidites 
To a solution of the corresponding alcohol (1 equiv) in anhydrous 
dichloromethane (12 mL/mmol), 1H-tetrazole (3 equiv, 0.45 M in acetonitrile) and 
the corresponding phosphoramidite (2 equiv) were added at room temperature and 
the reaction mixture was stirred until disappearance of the alcohol. Then it was 
cooled to -30ºC, mCPBA (2 equiv) was added and the mixture was stirred at -30ºC 
for 90 min. The reaction was quenched by addition of a 10% aqueous solution of 
Na2S2O3 (12 mL/mmol alcohol) and allowed to warm to room temperature. Then, 
the mixture was extracted with dichloromethane, the extracts were successively 
washed with a 20% aqueous solution of K2CO3 and brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography to afford the corresponding pure phosphate. 
4.1.1.13 Regioselective esterification of carboxylic acids with diols 
To a solution of the corresponding carboxylic acid (1 equiv), DCC (1.1 equiv) 
and DMAP (0.2 equiv) in anhydrous dichloromethane (10 mL/mmol acid) at -20ºC, 
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a solution of the corresponding diol (2 equiv) in anhydrous dichloromethane (2 
mL/mmol) was added and the reaction was warmed to room temperature and 
stirred overnight. Afterward, the mixture was concentrated under reduced pressure, 
and the residue was redissolved in CCl4 and filtered to remove dicyclohexylurea. 
The filtrate was evaporated and purified by flash chromatography to afford the 
corresponding pure ester.  
4.1.1.14 Oxidation of alcohols with nitric acid 
To a cooled (0ºC) solution of fuming nitric acid (50 equiv), the corresponding 
bromoalcohol (1 equiv) was added over a period of 30 minutes, maintaining the 
reaction temperature at 25-30ºC. The solution was stirred at room temperature for 
4 h and then at 80ºC for an additional hour. The reaction mixture was then cooled 
back to room temperature, diluted carefully with water, and extracted with ethyl 
acetate. The organic phase was dried over MgSO4, filtered, and the solvent was 
evaporated under reduced pressure. Flash chromatography afforded the 
corresponding carboxylic acid.  
4.1.1.15 Wittig reaction of ω-bromoacids and aromatic aldehydes 
A mixture of the corresponding ω-bromoacid (1.2 equiv) and 
triphenylphosphine (6 equiv) in anhydrous toluene (2.4 mL/mmol) was refluxed for 
24 h. Then, the mixture was allowed to cool to room temperature, the solvent was 
evaporated and the residue was washed with hexane to remove excess 
triphenylphosphine, and dried. The obtained phosphonium salt (1.2 equiv) was 
dissolved in anhydrous THF (4.2 mL/mmol), and lithium hexamethyldisilazane (2.7 
equiv, 1 M in toluene) was added dropwise at -20ºC, turning the solution orange. 
The mixture was stirred for 30 min followed by addition of the corresponding 
aldehyde (1 equiv) at -20ºC and the stirring was continued overnight at room 
temperature. The reaction mixture was acidified with 1 M HCl and extracted with 
ethyl acetate. The organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude was purified by flash chromatography to yield 
the corresponding alkene.  
4.1.1.16 Ring-opening of epoxides with TBABr 
To a solution of the corresponding oxirane (1 equiv) and TBABr (3 equiv) in 
freshly distilled alcohol-free chloroform (10 mL/mmol), TFA (1.5 equiv) was added 
and the reaction was stirred for 10 minutes at room temperature. Then, the 
reaction mixture was passed through a silica gel column (5 g/mmol) prepared in 
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chloroform and it was washed with the same solvent (100 mL/mmol). The solvent 
was evaporated under reduced pressure to give the corresponding bromoalcohol, 
which was used in the next step without further purification.  
4.1.1.16 Esterification of carboxylic acids with bromoalcohols and primary alcohols 
To a stirred solution of the corresponding carboxylic acid (1 equiv), DCC (1.1 
equiv) and DMAP (0.2 equiv) in anhydrous dichloromethane (10 mL/mmol), a 
solution of the corresponding alcohol (1 equiv) in anhydrous dichloromethane (2 
mL/mmol) was added at room temperature and the reaction was stirred overnight. 
Afterward, the mixture was concentrated under reduced pressure, and the residue 
was redissolved in CCl4 and filtered to remove dicyclohexylurea. The filtrate was 
concentrated and it was purified by flash chromatography to yield the 
corresponding ester.  
4.1.2 Synthesis of final compounds 1a-f 
 Synthesis of diol 38 
tert-Butyl {[(2R)-2,3-bis(benzyloxy)propyl]oxy}acetate, 37 
(S)-(-)-2,3-bis(benzyloxy)propan-1-ol (0.56 mL, 2.20 mmol, 1 equiv) was 
added dropwise to a stirred suspension of NaH (176 mg, 4.40 mmol, 2 equiv, 60% 
dispersion in oil) in anhydrous THF (10 mL) at 0°C. After stirring the mixture at 
room temperature for 30 minutes, tert-butyl bromoacetate (0.49 mL, 3.31 mmol, 1.5 
equiv) and TBAI (41 mg, 0.11 mmol, 0.05 equiv) were added, and the resulting 
mixture was heated at 50°C overnight. After cooling to room temperature, the 
reaction was quenched by addition of water and concentrated under reduced 
pressure. The residue was dissolved with dichloromethane, washed with brine, 
dried over Na2SO4, filtered and the solvents were removed under reduced 
pressure. Flash chromatography of the residue (hexane/ethyl acetate, 9:1 to 8:2) 
afforded pure compound 37 in 22% yield.  
 
Rf: 0.52 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1738 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.36 (s, 9H, 3CH3); 3.47-3.65 (m, 4H, 2CH2); 3.72 
(qt, J = 4.7, 1H, CH); 3.88 (s, 2H, CH2CO2tBu); 4.44 (s, 2H, PhCH2); 4.61 (s, 2H, 
PhCH2); 7.11-7.29 (m, 10H, 10CHAr) 
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13C-NMR (CDCl3, 75 MHz):  28.1 (3CH3); 69.4 (CH2); 70.4 (CH2); 71.7 (CH2); 72.3 
(PhCH2); 73.4 (PhCH2); 77.4 (CH); 81.5 (C); 127.5 (CHAr); 127.6 (CHAr); 127.7 
(2CHAr); 127.8 (2CHAr); 128.3 (2CHAr); 128.4 (2CHAr); 138.4; 138.8 (2CAr); 169.6 
(CO) 
MS (ESI, m/z): 387.7 [M+H]+ 
tert-Butyl {[(2R)-2,3-dihydroxypropyl]oxy}acetate, 38 
Following the general procedure 4.1.1.1, diol 38 was obtained from 37 (190 
mg, 0.49 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.11 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3376 (O-H); 1738 (C=O) 
1H-NMR (methanol-d4, 300 MHz):  1.49 (s, 9H, 3CH3); 3.50-3.64 (m, 4H, 2CH2); 
3.78 (qt, J = 5.3, 1H, CH); 4.87 (s, 2H, CH2CO2tBu) 
13C-NMR (CDCl3, 75 MHz):  28.1 (3CH3); 63.7 (CH2OH); 68.8 (CH2CO2tBu); 70.5 
(CH); 73.4 (CH2O); 82.5 (C); 170.6 (CO) 
MS (ESI, m/z): 229.1 [M+Na]+ 
 Synthesis of diols 41 and 43 
(2R)-2,3-Bis(benzyloxy)propyl methanesulfonate, 39 
Following the general procedure 4.1.1.2, mesylate 39 was obtained from (S)- 
(-)-2,3-bis(benzyloxy)propan-1-ol (0.35 mL, 1.39 mmol) in 80% yield.  
 
Rf: 0.51 (hexane/ethyl acetate, 7:3) 
IR (ATR): 1354 (SO2) 
1H-NMR (CDCl3, 300 MHz):  2.95 (s, 3H, CH3); 3.60 (dd, J = 4.8, 1.5, 2H, 
CH2OBn); 3.86 (m, 1H, CH); 4.31 (dd, J = 11.0, 5.6, 1H, ½CH2OMs); 4.43 (dd, J 
=11.0, 3.7, 1H, ½CH2OMs); 4.54 (s, 2H, PhCH2); 4.66 (s, 2H, PhCH2); 7.27-7.39 
(m, 10H, 10CHAr) 
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13C-NMR (CDCl3, 75 MHz):  37.5 (CH3); 68.5 (CH2); 69.4 (CH2); 72.5 (PhCH2); 
73.6 (PhCH2); 75.7 (CH); 127.8 (2CHAr); 127.9 (2CHAr); 127.91 (2CHAr); 128.0 
(2CHAr); 128.5 (2CHAr); 137.7 (2CAr) 
MS (ESI, m/z): 368.2 [M+NH4]+ 
Di-tert-butyl [(2S)-2,3-bis(benzyloxy)propyl]malonate, 40 
Following the general procedure 4.1.1.3, compound 40 was obtained from 
mesylate 39 (391 mg, 1.12 mmol) in 76% yield. Chromatography: hexane to 
hexane/ethyl acetate, 9:1. 
 
Rf: 0.65 (hexane/ethyl acetate, 9:1) 
IR (ATR): 1727 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.42 (s, 9H, 3CH3); 1.45 (s, 9H, 3CH3); 2.04-2.10 (m, 
2H, CH2CH(CO2tBu)2); 3.46 (dd, J = 8.9, 6.0, 1H, CH(CO2tBu)2); 3.55 (dd, J = 4.8, 
0.8, 2H, CH2OBn); 3.62-3.68 (m, 1H, CHOBn); 4.53 (d, J = 11.5, 1H, ½PhCH2); 
4.54 (s, 2H, PhCH2); 4.69 (d, J = 11.5, 1H, ½PhCH2); 7.31-7.38 (m, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  27.9 (3CH3); 28.0 (3CH3); 31.3 (CH2CH(CO2tBu)2); 
50.4 (CH(CO2tBu)2); 72.4 (PhCH2); 72.8 (PhCH2); 73.4 (CH2OBn); 76.0 (CHOBn); 
81.4 (2C); 127.55 (CHAr); 127.58 (CHAr); 127.6 (2CHAr); 127.9 (2CHAr); 128.3 
(2CHAr); 128.4 (2CHAr); 138.6 (2CAr); 169.0 (2CO) 
MS (ESI, m/z): 471.2 [M+H]+ 
Di-tert-butyl [(2S)-2,3-dihydroxypropyl]malonate, 41 
Following the general procedure 4.1.1.1, diol 41 was obtained from 40 (327 
mg, 0.74 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.37 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3408 (O-H); 1726 (C=O) 
1H-NMR (methanol-d4, 300 MHz):  1.46 (s, 9H, 3CH3); 1.47 (s, 9H, 3CH3); 1.76 
(ddd, J = 14.8, 9.6, 5.3, 1H, ½CH2CH(CO2tBu)2); 2.02 (ddd, J = 14.8, 9.5, 3.3, 1H, 
½CH2CH(CO2tBu)2); 3.39-RN3.48 (m, 3H, CH2OH, CH(CO2tBu)2); 3.52-3.63 (m, 
1H, CHOH) 
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13C-NMR (methanol-d4, 75 MHz):  28.2 (3CH3); 28.23 (3CH3); 33.7 
(CH2CH(CO2tBu)2); 52.0 (CH(CO2tBu)2); 67.4 (CH2OH); 70.9 (CHOH); 82.7 (2C); 
170.4 (CO); 170.8 (CO) 
MS (ESI, m/z): 289.1 [M-H]- 
Di-tert-butyl [(2S)-2,3-bis(benzyloxy)propyl](fluoro)malonate, 42 
Following the general procedure 4.1.1.4, compound 42 was obtained from 40 
(400 mg, 0.85 mmol) in 48% yield. Chromatography: hexane to hexane/ethyl 
acetate, 8:2.  
 
Rf: 0.53 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1736 (C=O); 1148 (C-F) 
1H-NMR (CDCl3, 300 MHz):  1.35 (s, 9H, 3CH3); 1.45 (s, 9H, 3CH3); 2.24-2.38 (m, 
2H, CH2CF); 3.53 (d, J = 4.8, 2H, CH2OBn); 3.85-3.93 (m, 1H, CH); 4.51 (d, J = 
11.3, 1H, ½PhCH2); 4.51 (s, 2H, PhCH2); 4.60 (d, J = 11.3, 1H, ½PhCH2); 7.28-
7.33 (m, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  27.7 (3CH3); 27.8 (3CH3); 36.6 (CH2CF); 72.6 
(PhCH2); 73.0 (PhCH2); 73.3 (CH2OBn); 74.7 (CH); 82.4; 82.8 (2C(CH3)3); 127.5 
(CHAr); 127.5 (CHAr); 127.6 (2CHAr); 128.1 (2CHAr); 128.32 (2CHAr); 128.33 
(2CHAr); 138.35 (CAr); 138.7 (CAr); 169.4 (CO); 170.1 (CO); (CF not observed) 
MS (ESI, m/z): 506.3 [M+NH4]+ 
Di-tert-butyl [(2S)-2,3-dihydroxypropyl](fluoro)malonate, 43 
Following the general procedure 4.1.1.1, diol 43 was obtained from 42 (211 
mg, 0.43 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.14 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3407 (O-H); 1743 (C=O); 1154 (C-F) 
1H-NMR (CDCl3, 300 MHz):  1.51 (s, 18H, 6CH3); 2.18 (dt, J = 15.3, 3.0, 1H, 
½CH2F); 2.34 (ddd, J = 15.3, 9.2, 9.0, 1H, ½CH2F); 2.91-3.20 (br s, 2H, 2OH); 3.50 
(dd, J = 11.3, 6.8, 1H, ½CH2OH); 3.65 (dd, J = 11.3, 3.3, 1H, ½CH2OH); 3.96-4.06 
(m, 1H, CH) 
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13C-NMR (CDCl3, 75 MHz):  27.7 (3CH3); 27.75 (3CH3); 37.2 (d, J = 20.8, CH2CF); 
66.5 (CH2OH); 67.3 (d, J = 2.8, CH); 83.9 (2C(CH3)3); 93.4 (d, J = 196.0, CF); 
165.3 (d, J = 25.0, CO); 165.8 (d, J = 26.1, CO) 
 Synthesis of diol 46 
[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl 4-methylbenzenesulfonate, 44 
To a solution of (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (0.5 mL, 4.05 
mmol, 1 equiv) in 5 mL of dry dichloromethane, pyridine (0.98 mL, 12.15 mmol, 3 
equiv) was added. The reaction mixture was cooled to 0ºC, tosyl chloride (1.16 g, 
6.07 mmol, 1.5 equiv) was added and the mixture was stirred overnight at room 
temperature. Afterward, brine was added and the organic phase was separated, 
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash chromatography (hexane to hexane/ethyl acetate, 1:1), to 
afford pure compound 44 in 86% yield.  
 
Rf: 0.28 (hexane/ethyl acetate, 5:1) 
IR (ATR): 1364 (SO2); 1179 (SO2) 
1H-NMR (CDCl3, 300 MHz):  1.31 (s, 3H, CH3); 1.34 (s, 3H, CH3); 2.45 (s, 3H,  
PhCH3); 3.77 (dd, J = 8.8, 5.1, 1H, ½CH2O); 3.94-4.06 (m, 3H, CH2OS, ½CH2O); 
4.24-4.31 (m, 1H, CH); 7.35 (d, J = 8.1, 2H, 2CHAr); 7.80 (d, J = 8.3, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  21.8 (PhCH3); 25.3 (CH3); 26.8 (CH3); 66.4 (CH2O); 
69.6 (CH2OS); 73.1 (CH); 110.2 (C); 128.2 (2CHAr); 130.1 (2CHAr); 132.8; 145.2 
(2CAr) 
[α]D20: -4.2 (c = 1.41, methanol) 
MS (ESI, m/z): 287.1 [M+H]+ 
2-(4-{[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]methoxy}phenyl)-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane, 45 
Compound 45 was synthesized following the experimental procedure 
previously described for the (R)-isomer.108  
To a solution of tosylate 44 (343 mg, 1.2 mmol, 1.2 equiv) and 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (220 mg, 1 mmol, 1 equiv) in anhydrous 
DMF (5 mL), Cs2CO3 (652 mg, 2 mmol, 2 equiv) was added. The mixture was 
heated at 90ºC for 16 h. Afterward, the mixture was partitioned between ethyl 
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acetate and water and the aqueous layer was extracted with ethyl acetate. The 
organic phase was washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography (hexane to hexane/ethyl acetate, 7:3) to afford pure compound 45 
in 84% yield.  
 
Rf: 0.63 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1362 (B-O) 
1H-NMR (CDCl3, 300 MHz):  1.33 (s, 12H, 4CH3 boronate); 1.40 (s, 3H, CH3 acetal); 
1.46 (s, 3H, CH3 acetal); 3.90 (dd, J = 8.5, 5.8, 1H, ½CH2O); 3.96 (dd, J = 9.6, 6.0, 
1H, ½CH2O); 4.08 (dd, J = 9.5, 5.4, 1H, ½CH2O); 4.17 (dd, J = 8.5, 6.4, 1H, 
½CH2O); 4.48 (qt, J = 5.9, 1H, CH); 6.90 (d, J = 8.7, 2H, 2CHAr); 7.74 (d, J = 8.6, 
2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  25.0 (4CH3 boronate); 25.5; 26.9 (2CH3 acetal); 67.0 
(CH2); 68.7 (CH2); 74.1 (CH); 83.7 (2Cboronate); 109.9 (Cacetal); 114.0 (2CHAr); 136.7 
(2CHAr); 161.2 (CAr); (CB not observed) 
[α]D20: +9.2 (c = 0.6, CHCl3) 
MS (ESI, m/z): 335.2 [M+H]+ 
(2R)-3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propane-1,2-
diol, 46 
Following the general procedure 4.1.1.5, diol 46 was obtained from 45 (425 
mg, 1.27 mmol) in 88% yield. Chromatography: hexane/ethyl acetate, 1:1 to 2:8.  
 
Rf: 0.05 (hexane/ethyl acetate, 7:3) 
IR (ATR): 3372 (O-H); 1361 (B-O) 
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1H-NMR (CDCl3, 300 MHz):  1.33 (s, 12H, 4CH3); 2.76 (br s, 2H, OH); 3.72 (dd, J 
= 11.5, 5.5, 1H, ½CH2OAr); 3.82 (dd, J = 11.5, 3.7, 1H, ½CH2OAr); 4.02-4.04 (m, 
2H, CH2OH); 4.06-4.13 (m, 1H, CH); 6.88 (d, J = 8.7, 2H, 2CHAr); 7.74 (d, J = 8.7, 
2H, 2CHAr)  
13C-NMR (CDCl3, 75 MHz):  25.0 (4CH3); 63.7 (CH2OH); 69.0 (CH2OAr); 70.5 
(CH); 83.8 (2C); 114.0 (2CHAr); 136.7 (2CHAr); 161.1 (CAr); (CB not observed) 
[α]D20: +14.2 (c = 1.7, methanol) 
MS (ESI, m/z): 295.1 [M+H]+; 312.2 [M+NH4]+ 
 Synthesis of alcohols 54 and 56 
3-(Benzyloxy)propyl methanesulfonate, 52 
Following the general procedure 4.1.1.2, mesylate 52 was obtained from 
benzyloxypropan-1-ol (0.19 mL, 1.20 mmol) in 99% yield.  
 
Rf: 0.4 (hexane/ethyl acetate, 5:1) 
1H-NMR (DMSO-d6, 300 MHz):  2.04 (qt, J = 6.1, 2H, CH2CH2OMs); 2.96 (s, 3H, 
CH3); 3.59 (t, J = 5.9, 2H, CH2OBn); 4.36 (t, J = 6.2, 2H, CH2OMs); 4.51 (s, 2H, 
PhCH2); 7.27-7.39 (m, 5H, 5CHAr) 
13C-NMR (DMSO-d6, 75 MHz):  29.6 (CH2CH2OMs); 37.2 (CH3); 65.5 (CH2OMs); 
67.4 (CH2OBn); 73.2 (PhCH2); 127.7 (2CHAr); 127.8 (CHAr); 128.5 (2CHAr); 138.1 
(CAr) 
MS (ESI, m/z): 245.1 [M+H]+; 267.0 [M+Na]+ 
Di-tert-butyl [3-(benzyloxy)propyl]malonate, 53 
Following the general procedure 4.1.1.3, compound 53 was obtained from 
mesylate 52 (270 mg, 1.11 mmol) in 66% yield. Chromatography: hexane to 
hexane/ethyl acetate, 7:3.  
 
Rf: 0.49 (hexane/ethyl acetate, 8:2) 
1H-NMR (DMSO-d6, 300 MHz):  1.45 (s, 18H, 6CH3); 1.60-1.70 (m, 2H, 
CH2CH2CH); 1.86-1.94 (m, 2H, CH2CH); 3.14 (t, J = 7.5, 1H, CH); 3.49 (t, J = 6.4, 
2H, CH2OBn); 4.50 (s, 2H, PhCH2); 7.24-7.37 (m, 5H, 5CHAr) 
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13C-NMR (DMSO-d6, 75 MHz):  25.4 (CH2CH); 27.4 (CH2CH2CH); 28.0 (6CH3); 
53.7 (CH); 69.8 (CH2OBn); 72.9 (PhCH2); 81.3 (2C); 127.5 (CHAr); 127.6 (2CHAr); 
128.4 (2CHAr); 138.5 (CAr); 168.9 (2CO) 
MS (ESI, m/z): 365.3 [M+H]+; 387.1 [M+Na]+ 
Di-tert-butyl (3-hydroxypropyl)malonate, 54 
Following the general procedure 4.1.1.1, alcohol 54 was obtained from 53 
(260 mg, 0.68 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.63 (hexane/ethyl acetate, 1:1) 
1H-NMR (DMSO-d6, 300 MHz):  1.46 (s, 18H, 6CH3); 1.56-1.67 (m, 2H, 
CH2CH2CH); 1.86-1.93 (m, 2H, CH2CH); 3.16 (t, J = 7.4, 1H, CH); 3.65 (t, J = 6.3, 
2H, CH2OH) 
13C-NMR (DMSO-d6, 75 MHz):  24.8 (CH2CH); 27.9 (6CH3); 30.4 (CH2CH2CH); 
53.6 (CH); 62.3 (CH2OH); 81.5 (2C); 169.0 (2CO) 
MS (ESI, m/z): 297.1 [M+Na]+ 
Di-tert-butyl [3-(benzyloxy)propyl](fluoro)malonate, 55 
Following the general procedure 4.1.1.4, compound 55 was obtained from 53 
(250 mg, 0.71 mmol) in 99% yield, which was used in next step without further 
purification. 
 
Rf: 0.82 (hexane/ethyl acetate, 8:2) 
1H-NMR (DMSO-d6, 300 MHz):  1.49 (s, 18H, 6CH3); 1.59-1.77 (m, 2H, 
CH2CH2CF); 2.00-2.24 (m, 2H, CH2CF); 3.46-3.52 (m, 2H, CH2OBn); 4.49 (s, 2H, 
PhCH2); 7.28-7.37 (m, 5H, 5CHAr) 
13C-NMR (DMSO-d6, 75 MHz):  23.6 (d, J = 2.9, CH2CH2CF); 28.2 (6CH3); 31.2 
(d, J = 21.8, CH2CF); 70.0 (CH2OBn); 73.1 (PhCH2); 83.8 (2C(CH3)3); 100.9 (d, J = 
165.6, CF); 127.9 (CHAr); 128.0 (2CHAr); 128.8 (2CHAr); 138.9 (CAr); 165.7 (d, J = 
25.7, 2CO) 
MS (ESI, m/z): 400.2 [M+NH4]+; 405.2 [M+Na]+ 
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Di-tert-butyl fluoro(3-hydroxypropyl)malonate, 56 
Following the general procedure 4.1.1.1, alcohol 56 was obtained from 55 
(329 mg, 0.86 mmol) at 60ºC in quantitative yield.  
 
Rf: 0.31 (hexane/ethyl acetate, 4:1) 
1H-NMR (DMSO-d6, 300 MHz):  1.50 (s, 18H, 6CH3); 1.54-1.71 (m, 2H, 
CH2CH2CF); 1.91-2.20 (m, 2H, CH2CF); 3.45-3.64 (m, 2H, CH2OH) 
13C-NMR (DMSO-d6, 75 MHz):  26.1 (d, J = 2.5, CH2CH2CF); 27.8 (6CH3); 30.2 
(d, J = 21.8, CH2CF); 62.1 (CH2OH); 83.5 (2C(CH3)3); 96.0 (d, J = 196.0, CF); 
165.6 (d, J = 25.8, 2CO) 
MS (ESI, m/z): 293.1 [M+H]+ 
 Synthesis of esters 47-51, 57, and 58 
(2S)-3-(2-tert-Butoxy-2-oxoethoxy)-2-hydroxypropyl (9Z)-octadec-9-enoate, 47 
Method A (Scheme 4):  
To a stirred suspension of diol 38 (50 mg, 0.24 mmol, 2 equiv) in dry 
dichloromethane (2 mL) at 0ºC, oleic acid (40 µL, 0.12 mmol, 1 equiv), DCC (25 
mg, 0.12 mmol, 1 equiv) and DMAP (3 mg, 0.02 mmol, 0.2 equiv) were added. 
Then the reaction was allowed to reach room temperature and stirred overnight. 
Afterward, the mixture was treated with dichloromethane and the resulting 
precipitate was eliminated by filtration. The filtrate was washed with a saturated 
aqueous solution of NaHCO3 and with brine, dried over Na2SO4 and filtered. The 
solvent was evaporated under reduced pressure and the residue was purified by 
flash chromatography (hexane to hexane/ethyl acetate, 8:2) to yield pure 
compound 47 in 15% yield. 
Method B (Scheme 5):  
Following the general procedure 4.1.1.6, ester 47 was obtained from diol 38 
(82 mg, 0.49 mmol) in 36% yield. Chromatography: dichloromethane/ethyl acetate, 
100:1 to 5:1. 
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Rf: 0.52 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3460 (O-H); 1739 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.23-1.36 (m, 20H, 
10CH2); 1.48 (s, 9H, 3CH3); 1.57-1.69 (m, 2H, CH2CH2CO); 1.95-2.06 (m, 4H, 
2CH2CHalkene); 2.34 (t, J = 7.6, 2H, CH2CO); 3.56 (dd, J = 10.0, 6.4, 1H, 
½CHOHCH2O); 3.66 (dd, J = 10.0, 3.6, 1H, ½CHOHCH2O); 3.95-4.07 (m, 3H, 
CH2CO2tBu, CH); 4.11-4.21 (m, 2H, CO2CH2); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8; 25.1 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 28.3 (3CH3); 29.3 (2CH2); 29.32 (CH2); 29.5 (2CH2); 29.7; 29.8; 
29.9; 32.1 (4CH2); 34.3 (CH2CO); 65.2 (CO2CH2); 69.0 (CH); 69.2 (CH2CO2tBu); 
73.4 (CHOHCH2O); 82.4 (C); 129.9; 130.2 (2CHalkene); 170.4 (CO2tBu); 174.0 (CO) 
MS (ESI, m/z): 493.1 [M+Na]+ 
Di-tert-butyl {(2S)-2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl}malonate, 48 
Following the general procedure 4.1.1.6, ester 48 was obtained from diol 41 
(190 mg, 0.72 mmol) in 99% yield. Chromatography: dichloromethane/ethyl 
acetate, 100:1 to 5:1. 
 
Rf: 0.60 (dichloromethane/ethyl acetate, 9:1) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.18-1.37 (m, 20H, 
10CH2); 1.45 (s, 9H, 3CH3); 1.46 (s, 9H, 3CH3); 1.56-1.69 (m, 3H, CH2CH2CO, 
½CH2CH(CO2tBu)2); 1.89-2.08 (m, 5H, 2CH2CHalkene, ½CH2CH(CO2tBu)2); 2.34 (t, 
J = 7.5, 2H, CH2CO); 3.44 (dd, J = 8.1, 6.2, 1H, CH(CO2tBu)2); 3.84-3.95 (m, 1H, 
CHOH); 4.01 (dd, J = 11.3, 6.7, 1H, ½CO2CH2); 4.12 (dd, J = 11.3, 3.7, 1H, 
½CO2CH2); 5.31-5.36 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8; 25.1 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 28.0 (3CH3); 28.1 (3CH3); 29.2 (2CH2); 29.3; 29.5; 29.7 (3CH2); 
29.8 (2CH2); 29.9; 32.1; 32.4 (3CH2); 34.3 (CH2CO); 50.9 (CH(CO2tBu)2); 68.2 
(CHOH); 68.3 (CO2CH2); 82.0 (2C); 129.9; 130.2 (2CHalkene); 168.9; 169.2 
(2CO2tBu); 174.0 (CO) 
MS (ESI, m/z): 555.2 [M+H]+ 
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Di-tert-butyl fluoro{(2S)-2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl} 
malonate, 49 
Following the general procedure 4.1.1.6, ester 49 was obtained from diol 43 
(116 mg, 0.38 mmol) in 60% yield. Chromatography: dichloromethane to 
dichloromethane/ethyl acetate, 9:1. 
 
Rf: 0.56 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3513 (O-H); 1743 (C=O); 1164 (C-F) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.6, 3H, CH3); 1.22-1.37 (m, 20H, 
10CH2); 1.50 (s, 18H, 6CH3); 1.60-1.65 (m, 2H, CH2CH2CO); 1.97-2.03 (m, 4H, 
2CH2CHalkene); 2.23-2.44 (m, 4H, CH2CO, CH2CF); 3.99-4.21 (m, 3H, CO2CH2, 
CH); 5.32-5.36 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.1 (CH3); 22.7; 24.9 (2CH2); 27.2; 27.24 
(2CH2CHalkene); 27.7 (3CH3); 27.78 (3CH3); 29.1; 29.2 (2CH2); 29.3 (2CH2); 29.33; 
29.5; 29.7; 29.8; 31.9 (5CH2); 34.1 (CH2CO); 37.4 (d, J = 20.4, CH2CF); 65.3 (CH); 
67.9 (CO2CH2); 83.8; 83.9 (2C(CH3)3); 129.8; 130.0 (2CHalkene); 165.5 (d, J = 24.8, 
CO2tBu); 166.0 (d, J = 25.7, CO2tBu); 174.4 (CO); (CF not observed) 
MS (ESI, m/z): 590.5 [M+NH4]+ 
(2S)-2-Hydroxy-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy]propyl (9Z)-octadec-9-enoate, 50 
Following the general procedure 4.1.1.6, ester 50 was obtained from diol 46 
(130 mg, 0.44 mmol) in 40% yield. Chromatography: dichloromethane to 
dichloromethane/ethanol, 100:1. 
 
Rf: 0.46 (dichloromethane/ethanol, 20:1) 
IR (ATR): 3459 (O-H); 1737 (C=O); 1362 (B-O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.33 (m, 32H, 10CH2, 
4CH3 boronate); 1.56-1.68 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 2CH2CHalkene); 2.35 
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(t, J = 7.5, 2H, CH2CO); 2.57 (br s, 1H, OH); 4.00-4.09 (m, 2H, CH2OAr); 4.22-4.32 
(m, 3H, CH, CO2CH2); 5.28-5.40 (m, 2H, 2CHalkene); 6.90 (d, J = 8.7, 2H, 2CHAr); 
7.75 (d, J = 8.6, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8 (CH2); 25.0 (4CH3); 25.04 (CH2); 
27.3; 27.4 (CH2CHalkene); 29.2 (2CH2); 29.3 (CH2); 29.5 (2CH2); 29.7; 29.8; 29.9; 
32.0 (4CH2); 34.3 (CH2CO); 65.3 (CO2CH2); 68.6 (CH2OAr); 68.8 (CH); 83.8 (2C); 
114.0 (2CHAr); 129.9; 130.2 (2CHalkene); 136.7 (2CHAr); 161.0 (CAr); 174.1 (CO); 
(CB not observed) 
[α]D20: +1.5 (c = 1, CHCl3)  
MS (ESI, m/z): 557.8 [M-H]- 
Potassium [4-({(2S)-2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl}oxy)phenyl] 
trifluoroborate, 51 
To a solution of boronate 50 (50 mg, 0.09 mmol, 1 equiv) in methanol (2 mL), 
potassium hydrogen fluoride was added (111 µL, 0.50 mmol, 5.6 equiv, 4.5 M in 
water) and the reaction was stirred at room temperature for 30 minutes. Then, 
solvent was evaporated under reduced pressure and the crude was redissolved in 
hot acetone and filtrated. The filtrate was concentrated under reduced pressure to 
afford intermediate 51 as a syrup in quantitative yield.  
 
IR (ATR): 3500 (O-H); 1737 (C=O); 1237 (B-F); 1176 (B-C) 
1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.6, 3H, CH3); 1.30-1.37 (m, 20H, 
10CH2); 1.60-1.64 (m, 2H, CH2CH2CO); 2.02-2.04 (m, 4H, 2CH2CHalkene); 2.36 (t, J 
= 7.4, 2H, CH2CO); 3.94-4.02 (m, 2H, CH2OAr); 4.09-4.28 (m, 3H, CH, CO2CH2); 
5.29-5.40 (m, 2H, 2CHalkene); 6.79 (d, J = 8.0, 2H, 2CHAr); 7.42 (d, J = 8.3, 2H, 
2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  14.5 (CH3); 23.7; 26.0 (2CH2); 28.1 
(2CH2CHalkene); 30.2 (2CH2); 30.3; 30.34; 30.5; 30.6; 30.8; 30.84; 33.1 (7CH2); 34.9 
(CH2CO); 66.5 (CO2CH2); 69.2 (CH); 69.9 (CH2OAr); 114.1 (2CHAr); 130.8; 130.9 
(2CHalkene); 133.6 (2CHAr); 158.8 (CAr); 175.4 (CO); (CB not observed) 
[α]D20: +2.4 (c = 0.9, methanol) 
MS (ESI, m/z): 521.3 [M-OH]- 
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Di-tert-butyl {3-[(9Z)-octadec-9-enoyloxy]propyl}malonate, 57 
Following the general procedure 4.1.1.6, ester 57 was obtained from alcohol 
54 (120 mg, 0.44 mmol) in 70% yield. Cromatography: dichloromethane. 
 
Rf: 0.44 (hexane/ethyl acetate, 1:1) 
1H-NMR (DMSO-d6, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.25-1.29 (m, 20H, 
10CH2); 1.46 (s, 18H, 6CH3); 1.54-1.72 (m, 4H, CH2CH2CO, CH2CH2CH(CO2tBu)2); 
1.83-1.91 (m, 2H, CH2CH(CO2tBu)2); 1.97-2.03 (m, 4H, 2CH2CHalkene); 2.29 (t, J = 
7.6, 2H, CH2CO); 3.14 (t, J = 7.5, 1H, CH); 4.07 (t, J = 6.4, 2H, CO2CH2); 5.28-5.39 
(m, 2H, 2CHalkene) 
13C-NMR (DMSO-d6, 75 MHz):  14.2 (CH3); 22.7; 25.0; 25.2; 26.4 (4CH2); 27.2; 
27.24 (2CH2CHalkene); 27.9 (6CH3); 29.1; 29.18; 29.2 (3CH2); 29.4 (2CH2); 29.6; 
29.7; 29.8; 31.9 (4CH2); 34.3 (CH2CO); 53.5 (CH); 63.7 (CO2CH2); 81.5 (2C); 
129.9; 130.1 (2CHalkene); 168.7 (2CO2tBu); 173.9 (CO) 
Di-tert-butyl fluoro{3-[(9Z)-octadec-9-enoyloxy]propyl}malonate, 58 
Following the general procedure 4.1.1.6, ester 58 was obtained from alcohol 
56 (199 mg, 0.68 mmol) in 59% yield. Chromatography: dichloromethane. 
 
Rf: 0.69 (hexane/ethyl acetate, 1:1) 
1H-NMR (DMSO-d6, 300 MHz):  0.88 (t, J = 6.8, 3H, CH3); 1.23-1.37 (m, 20H, 
10CH2); 1.46 (s, 3H, CH3); 1.50 (s, 15H, 5CH3); 1.56-1.64 (m, 2H, CH2CH2CO); 
1.69-1.79 (m, 2H, CH2CH2CF); 1.97-2.04 (m, 4H, 2CH2CHalkene); 2.07-2.20 (m, 2H, 
CH2CF); 2.29 (t, J = 7.6, 2H, CH2CO); 4.08 (t, J = 6.3, 2H, CO2CH2); 5.29-5.40 (m, 
2H, 2CHalkene) 
13C-NMR (DMSO-d6, 75 MHz):  14.5 (CH3); 22.7 (d, J = 3.2, CH2CH2CF); 23.1; 
25.3 (2CH2); 27.6; 27.61 (2CH2CHalkene); 28.2 (6CH3); 28.3; 29.5; 29.54; 29.6; 29.7; 
29.9; 30.1; 30.2 (8CH2); 30.9 (d, J = 21.9, CH2CF); 32.3 (CH2); 34.7 (CH2CO); 63.9 
(CO2CH2); 84.0 (2C(CH3)3); 94.8 (d, J = 196.5, CF); 130.2; 130.4 (2CHalkene); 165.7 
(d, J = 25.4, 2CO2tBu); 174.2 (CO) 
MS (ESI, m/z): 557.5 [M+H]+ 
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 Synthesis of final compounds 1a-f 
({(2S)-2-Hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl}oxy)acetic acid, 1a 
Following the general procedure 4.1.1.7, compound 1a was obtained from 
tert-butyl ester 47 (48 mg, 84 µmol) and TFA (0.16 mL, 2.10 mmol) in 52% yield. 
Chromatography: ethyl acetate/ethanol, 20:1 to 1:5. 
 
Rf: 0.11 (ethyl acetate/ethanol, 8:2) 
IR (ATR): 3301 (O-H); 1737 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.6, 3H, CH3); 1.26-1.29 (m, 20H, 
10CH2); 1.52-1.65 (m, 2H, CH2CH2CO); 1.93-2.05 (m, 4H, 2CH2CHalkene); 2.30 (t, J 
= 7.5, 2H, CH2CO); 3.32-3.60 (m, 2H, CHOHCH2O); 3.76-3.92 (br s, 2H, 
CH2CO2H); 3.95-4.19 (m, 3H, CO2CH2, CH); 5.26-5.35 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.9; 25.0 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2; 29.3; 29.4; 29.47; 29.48; 29.7; 29.8; 29.9; 32.1 (9CH2); 34.2 
(CH2CO); 64.8 (CO2CH2); 65.8 (CH); 70.5 (CH2CO2H); 72.1 (CHOHCH2O); 130.0; 
130.2 (2CHalkene); 173.4; 173.8 (2CO) 
[α]D20: -1.6 (c = 1, CHCl3) 
HRMS (ESI, m/z): calculated for C23H41O6 ([M-H]-): 413.2909; found: 413.2890 
(5S)-5-{[(9Z)-octadec-9-enoyloxy]methyl}-2-oxotetrahydrofuran-3-carboxylic 
acid, 1b 
Following the general procedure 4.1.1.7, compound 1b was obtained from di-
tert-butyl ester 48 (169 mg, 0.30 mmol) and TFA (0.58 mL, 7.53 mmol) in 88% 
yield. Chromatography: ethyl acetate/ethanol, 20:1 to 1:5.  
 
Rf: 0.13 (ethyl acetate/ethanol, 8:2) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers (1:1):  0.88 (t, J = 7.2, 
3H, CH3); 1.27-1.30 (m, 20H, 10CH2); 1.61-1.64 (m, 2H, CH2CH2CO); 1.97-2.03 
(m, 4H, 2CH2CHalkene); 2.33-2.37 (m, 2H, CH2CO); 2.37-2.41 (m, 1H, 
½CH2CHCO2H); 2.47-2.54 (m, 1H, ½CH2CHCO2H); 2.62-2.68 (m, 1H, 
½CH2CHCO2H); 2.78-2.84 (m, 1H, ½CH2CHCO2H); 3.71-3.76 (m, 1H, CHCO2H); 
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4.19 (dd, J = 12.6, 4.6) and 4.23 (dd, J = 12.5, 5.8, 1H, ½CO2CH2); 4.37 (m, 1H, 
½CO2CH2); 4.74-4.79 (m, 1H, CO2CH2CH); 4.89-4.94 (m, 1H, CO2CH2CH); 5.30-
5.38 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz): Mixture of diastereoisomers (1:1):  14.3 (CH3); 22.8 
(CH2); 24.9 and 24.94 (CH2); 27.3; 27.37 (2CH2CHalkene); 27.9; 29.2; 29.22; 29.3; 
29.5; 29.7; 29.8; 29.9; 31.1 (9CH2); 32.1 (CH2CHCO2H); 34.0 and 34.1 (CH2CO); 
46.0 and 46.2 (CHCO2H); 64.4 and 64.9 (CO2CH2); 76.7 and 76.8 (CO2CH2CH); 
129.85 and 129.8 (CHalkene); 130.17 and 130.19 (CHalkene); 171.9; 172.1 (2CO); 
173.4 and 173.6 (CO) 
HRMS (ESI, m/z): calculated for C23H39O4 ([M-CO2H]-): 379.2854, found: 379.2861 
HPLC (method A, tR, min): 14.37 
(5S)-3-fluoro-5-{[(9Z)-octadec-9-enoyloxy]methyl}-2-oxotetrahydrofuran-3-
carboxylic acid, 1c 
Following the general procedure 4.1.1.7, compound 1c was obtained from di-
tert-butyl ester 49 (80 mg, 0.14 mmol) and TFA (0.27 mL, 3.50 mmol) without 
further purification in quantitative yield. 
 
IR (ATR): 3466 (O-H); 1795 (C=O); 1742 (C=O); 1163 (C-F) 
1H-NMR (CDCl3, 500 MHz): Mixture of diastereoisomers (1:1):  0.88 (t, J = 6.9, 
3H, CH3); 1.20-1.37 (m, 20H, 10CH2); 1.58-1.67 (m, 2H, CH2CH2CO); 1.97-2.05 
(m, 4H, 2CH2CHalkene); 2.36-2.39 (m, 3H, CH2CO, ½CH2CF); 2.46-2.55 (m, 1H, 
½CH2CF); 2.76 (dd, J = 25.8, 7.2, 1H, ½CH2CF); 2.95-3.05 (m, 1H, ½CH2CF); 4.20 
(dd, J = 15.5, 4.8) and 4.32 (dd, J = 15.5, 6.1, 1H, ½CO2CH2); 4.40-4.47 (m, 1H, 
½CO2CH2); 4.90-5.01 (m, 1H, CH); 5.31-5.38 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 125 MHz): Mixture of diastereoisomers (1:1):  14.2 (CH3); 22.8; 
24.9 (2CH2); 27.3; 27.4 (2CH2CHalkene); 29.2; 29.22; 29.3; 29.5; 29.7; 29.81; 29.84; 
29.9; 32.0 (9CH2); 34.0 and 34.08 (CH2CO); 34.9 (d, J = 22.4) and 35.0 (d, J = 
21.7, CH2CF); 63.6 and 63.9 (CO2CH2); 75.7 (d, J = 2.9) and 76.5 (CH); 91.7 (d, J 
= 197.8) and 92.1 (d, J = 200.9, CF); 129.9 (CHalkene); 130.16 and 130.18 (CHalkene); 
167.5 (d, J = 23.3, CO); 167.8 (d, J = 24.7, CO); 173.8 and 173.84 (CO) 
HRMS (ESI, m/z): calculated for C24H38FO6 ([M-H]-): 441.2658, found 441.2667 
HPLC (method A, tR, min): 21.16 
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[4-({(2S)-2-Hydroxy-3-[(9Z)-octadec-9-enoyloxy]propyl}oxy)phenyl]boronic 
acid, 1d 
To a solution of compound 51 (30 mg, 54 µmol, 1 equiv) in acetonitrile (0.5 
mL), water (3 µL, 0.16 mmol, 3 equiv) and trimethylsilyl chloride (20 µL, 0.16 mmol, 
3 equiv) were added and the mixture was stirred for 1 h at room temperature. 
Then, a saturated aqueous solution of NaHCO3 was added, and the reaction 
mixture was extracted with dichloromethane. The organic layer was washed with 
brine, dried over Na2SO4, filtered and evaporated under reduced pressure. Flash 
chromatography of the residue (hexane/ethyl acetate, 10:1 to 1:1, followed by ethyl 
acetate/ethanol, 10:1 to 5:1) afforded compound 1d in 60% yield.  
 
Rf: 0.30 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1740 (C=O); 1368 (B-O); 1242 (B-C) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.5, 3H, CH3); 1.26-1.30 (m, 20H, 
10CH2); 1.63-1.67 (m, 2H, CH2CH2CO); 1.99-2.01 (m, 4H, 2CH2CHalkene); 2.38 (t, J 
= 7.5, 2H, CH2CO); 4.03-4.12 (m, 2H, CH2OAr); 4.24-4.37 (m, 3H, CH, CO2CH2); 
5.27-5.40 (m, 2H, 2CHalkene); 7.02 (d, J = 8.5, 2H, 2CHAr); 8.16 (d, J = 8.4, 2H, 
2CHAr) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 25.1 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2 (2CH2); 29.3 (CH2); 29.5 (2CH2); 29.7; 29.8; 29.9; 32.1 
(4CH2); 34.3 (CH2CO); 65.4 (CO2CH2); 68.6 (CH2OAr); 68.8 (CH); 114.2 (2CHAr); 
129.9; 130.2 (2CHalkene); 137.6 (2CHAr); 141.1 (CAr); 174.2 (CO); (CB not observed) 
[α]D20: limited solubility in DMSO 
HRMS (ESI, m/z): calculated for C27H46BO6 ([M+H]+): 477.3387, found 477.3395  
HPLC (method A, tR, min): 22.85 
{3-[(9Z)-Octadec-9-enoyloxy]propyl}malonic acid, 1e 
Following the general procedure 4.1.1.7, compound 1e was obtained from di-
tert-butyl ester 57 (96 mg, 0.18 mmol) and TFA (0.34 mL, 4.45 mmol) without 
further purification in 90% yield.  
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IR (ATR): 3100 (O-H); 1735 (C=O)  
1H-NMR (DMSO-d6, 300 MHz):  0.87 (t, J = 6.7, 3H, CH3); 1.26-1.30 (m, 20H, 
10CH2); 1.56-1.65 (m, 2H, CH2CH2CH(CO2H)2); 1.70-1.80 (m, 2H, CH2CH2CO); 
1.93-2.07 (m, 6H, 2CH2CHalkene, CH2CH(CO2H)2); 2.30 (t, J = 7.6, 2H, CH2CO); 
3.48 (t, J = 7.4, 1H, CH); 4.11 (t, J = 6.1, 2H, CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (DMSO-d6, 75 MHz):  14.1 (CH3); 22.7; 24.9; 25.3; 26.3 (4CH2); 27.2; 
27.24 (2CH2CHalkene); 27.9; 29.1; 29.2 (3CH2); 29.3 (2CH2); 29.6; 29.7; 29.8; 31.9 
(4CH2); 34.3 (CH2CO); 51.0 (CH); 63.5 (CO2CH2); 129.8; 130.0 (2CHalkene); 174.1 
(2CO2H); 174.3 (CO) 
HRMS (ESI, m/z): calculated for C24H41O6 ([M-H]-): 425.2909, found 425.2898 
HPLC (method A, tR, min): 15.18 
Fluoro{3-[(9Z)-octadec-9-enoyloxy]propyl}vmalonic acid, 1f 
Following the general procedure 4.1.1.7, compound 1f was obtained from di-
tert-butyl ester 58 (61 mg, 0.11 mmol) and TFA (0.21 mL, 2.75 mmol) without 
further purification in 59% yield. 
 
IR (ATR): 1738 (C=O); 1166 (C-F) 
1H-NMR (DMSO-d6, 300 MHz):  0.88 (t, J = 6.6, 3H, CH3); 1.18-1.39 (m, 20H, 
10CH2); 1.54-1.67 (m, 2H, CH2CH2CO); 1.70-1.85 (m, 2H, CH2CH2CF); 1.93-2.04 
(m, 4H, 2CH2CHalkene); 2.20-2.45 (m, 2H, CH2CF); 2.41 (t, J = 7.6, 2H, CH2CO); 
4.02-4.18 (m, 2H, CO2CH2); 5.27-5.41 (m, 2H, 2CHalkene) 
13C-NMR (DMSO-d6, 75 MHz):  14.1 (CH3); 22.7; 24.9 (2CH2); 24.93 (d, J = 2.8, 
CH2CH2CF); 27.2; 27.23 (2CH2CHalkene); 29.1; 29.2 (2CH2); 29.3 (2CH2); 29.5; 
29.7; 29.74; 29.8 (4CH2); 31.1 (d, J = 21.6, CH2CF); 31.9 (CH2); 34.3 (CH2CO); 
63.29 (CO2CH2); 129.7; 130.0 (2CHalkene); 174.7 (CO); (CO2H and CF not 
observed) 
HRMS (ESI, m/z): calculated for C24H40FO6 ([M-H]-): 443.2814, found 443.2824 
HPLC (method A, tR, min): 16.75 
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4.1.3 Synthesis of final compound 1g 
Di-tert-butyl fluoro{(2S)-2-methoxy-3-[(9Z)-octadec-9-enoyloxy]propyl} 
malonate, 59 
Following the general procedure 4.1.1.8, compound 59 was obtained from 49 
(90 mg, 0.16 mmol) in 38% yield. Chromatography: hexane/ethyl acetate, 30:1 to 
5:1. 
 
Rf: 0.41 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1769 (C=O); 1165 (C-F) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.5, 3H, CH3); 1.26-1.29 (m, 20H, 
10CH2); 1.48 (s, 9H, 3CH3); 1.48 (s, 9H, 3CH3); 1.59-1.64 (m, 2H, CH2CH2CO); 
1.99-2.01 (m, 4H, 2CH2CHalkene); 2.16-2.48 (m, 2H, CH2CF); 2.32 (t, J = 7.5, 2H, 
CH2CO); 3.29 (s, 3H, OCH3); 3.57-3.64 (m, 1H, CH); 4.10 (AB system, J = 11.6, 
4.7, 2H, CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 25.0 (2CH2); 27.3; 27.34 
(2CH2CHalkene); 27.8 (3CH3); 27.9 (3CH3); 29.2 (2CH2); 29.3 (CH2); 29.5 (2CH2); 
29.7; 29.8; 29.9; 32.0 (4CH2); 34.3 (CH2CO); 36.7 (d, J = 21.4, CH2CF); 57.9 
(OCH3); 64.9 (CO2CH2); 73.9 (d, J = 3.3, CH); 83.2; 83.6 (2C(CH3)3); 92.5 (d, J = 
195.3, CF); 129.9; 130.1 (2CHalkene); 165.1 (d, J = 27.4, CO2tBu); 165.2 (d, J = 
23.8, CO2tBu); 173.7 (CO) 
[α]D20: +4.1 (c = 0.75, CDCl3) 
MS (ESI, m/z): 609.4 [M+Na]+ 
Fluoro{(2S)-2-methoxy-3-[(9Z)-octadec-9-enoyloxy]propyl}malonic acid, 1g 
Following the general procedure 4.1.1.7, compound 1g was obtained from di-
tert-butyl ester 59 (10 mg, 17 µmol) and TFA (98 µL, 1.28 mmol) without further 
purification in 95% yield.  
 
IR (ATR): 3525 (O-H); 1742 (C=O); 1260 (C-F) 
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1H-NMR (methanol-d4, 700 MHz):  0.90 (t, J = 7.1, 3H, CH3); 1.29-1.33 (m, 20H, 
10CH2); 1.61-1.63 (m, 2H, CH2CH2CO); 2.02-2.05 (m, 4H, 2CH2CHalkene), 2.24-2.30 
(m, 1H, ½CH2CF); 2.35 (t, J = 7.4, 2H, CH2CO); 2.45-2.52 (m, 1H, ½CH2CF); 3.33 
(s, 3H, OCH3); 3.63-3.65 (m, 1H, CH); 4.04 (dd, J = 11.7, 4.9, 1H, ½CO2CH2); 4.25 
(dd, J = 11.7, 3.9, 1H, ½CO2CH2); 5.32-5.37 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 175 MHz):  14.5 (CH3); 23.8; 26.0 (2CH2); 28.1 
(2CH2CHalkene); 30.2 (2CH2); 30.3; 30.4; 30.5; 30.6; 30.8; 30.9; 33.1 (7CH2); 34.9 
(CH2CO); 38.4 (d, J = 20.1, CH2CF); 58.1 (OCH3); 65.9 (CO2CH2); 76.0 (CH); 94.4 
(d, J = 192.5, CF); 130.8; 130.9 (2CHalkene); 170.9 (br s, 2CO2H); 175.2 (CO) 
[α]D20: +29.5 (c = 0.2, methanol) 
HRMS (ESI, m/z): calculated for C25H42FO7 ([M-H]-): 473.2915, found 473.2922 
HPLC (method A, tR, min): 14.51  
4.1.4 Synthesis of final compounds 2a-e 
 Synthesis of non-commercial fatty acids 67-69 
Methyl 8-bromooctanoate, 60 
8-bromooctanoic acid (2.0 g, 8.96 mmol, 1 equiv) was dissolved in methanol 
(10 mL), a catalytic amount of concentrated H2SO4 (0.2 mL) was added and the 
reaction mixture was refluxed overnight. Afterward, the solvent was evaporated 
and the crude was redissolved in ethyl acetate and washed with a saturated 
aqueous solution of NaHCO3 and brine. The residue was filtered and concentrated 
under reduced pressure to yield ester 60 in quantitative yield, which was used in 
the next step without further purification. The spectroscopic data correspond with 
those previously reported.109 
 
Rf: 0.23 (hexane/ethyl acetate, 20:1) 
1H-NMR (CDCl3, 300 MHz):  1.30 (m, 4H, 2CH2); 1.40-1.45 (m, 2H, CH2); 1.57-
1.67 (m, 2H, CH2); 1.84 (qt, J = 7.5, 2H, CH2); 2.30 (t, J = 7.5, 2H, CH2CO); 3.39 (t, 
J = 6.8, 2H, CH2Br); 3.66 (s, 3H, CH3) 
Methyl heptadec-9-ynoate, 61 
Following the general procedure 4.1.1.9, alkyne 61 was obtained from 1-
nonyne (0.27 mL, 1.64 mmol) and methyl 8-bromooctanoate (300 mg, 1.26 mmol) 
in 36% yield. Chromatography: hexane. 
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Rf: 0.32 (hexane/ethyl acetate, 20:1) 
IR (ATR): 1740 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.5, 3H, CH3); 1.28-1.38 (m, 14H, 7CH2); 
1.42-1.49 (m, 4H, 2CH2); 1.58-1.65 (m, 2H, CH2CH2CO); 2.13 (t, J = 6.9, 4H, 
2CH2Calkyne); 2.30 (t, J = 7.5, 2H; CH2CO); 3.66 (s, 3H, OCH3) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 18.87; 18.9 (2CH2Calkyne); 22.8; 25.1; 
28.8; 29.9 (4CH2); 29.0 (2CH2); 29.2; 29.22; 29.3; 31.9 (4CH2); 34.2 (CH2CO); 51.6 
(OCH3); 80.2; 80.5 (2Calkyne); 174.4 (CO) 
Methyl nonadec-9-ynoate, 62 
Following the general procedure 4.1.1.9, alkyne 62 was obtained from 1-
undecyne (0.33 mL, 1.64 mmol) and methyl 8-bromooctanoate (300 mg, 1.26 
mmol) in 38% yield. Chromatography: hexane.  
 
Rf: 0.36 (hexane/ethyl acetate, 20:1) 
IR (ATR): 1742 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.27-1.51 (m, 22H, 
11CH2); 1.57-1.67 (m, 2H, CH2CH2CO); 2.11-2.16 (m, 4H, 2CH2Calkyne); 2.30 (t, J = 
7.5, 2H, CH2CO), 3.66 (s, 3H, OCH3) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 18.88; 18.9 (2CH2Calkyne); 22.8; 25.1; 
28.8; 28.9; 29.0; 29.2; 29.22 (7CH2); 29.3 (2CH2); 29.5; 29.7; 32.1 (3CH2); 34.2 
(CH2CO); 51.6 (OCH3); 80.2; 80.5 (2Calkyne), 174.4 (CO) 
MS (ESI, m/z): 309.3 [M+H]+ 
Methyl icos-9-ynoate, 63 
Following the general procedure 4.1.1.9, alkyne 63 was obtained from 1-
dodecyne (0.32 mL, 1.64 mmol) and methyl 8-bromooctanoate (300 mg, 1.26 
mmol) in 44% yield. Chromatography: hexane. 
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Rf: 0.48 (hexane/ethyl acetate, 20:1) 
IR (ATR): 1740 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.40 (m, 20H, 
10CH2); 1.42-1.49 (m, 4H, 2CH2); 1.57-1.67 (m, 2H, CH2CH2CO); 2.13 (t, J = 6.9, 
4H, 2CH2Calkyne); 2.30 (t, J = 7.5, 2H, CH2CO); 3.66 (s, 3H, OCH3) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 18.88; 18.9 (2CH2Calkyne); 22.8; 25.1; 
28.8; 28.9; 29.0; 29.2; 29.22 (7CH2); 29.3 (2CH2); 29.5; 29.7; 29.74; 32.1 (4CH2); 
34.2 (CH2CO); 51.6 (OCH3); 80.2; 80.5 (2Calkyne); 174.4 (CO) 
Methyl (9Z)-heptadec-9-enoate, 64 
Following the general procedure 4.1.1.10, alkene 64 was obtained from alkyne 
61 (126 mg, 0.45 mmol) in 91% yield.  
 
Rf: 0.32 (hexane/ethyl acetate, 20:1) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.6, 3H, CH3); 1.27-1.29 (m, 18H, 9CH2); 
1.59-1.63 (m, 2H, CH2CH2CO); 1.97-2.06 (m, 4H, 2CH2CHalkene); 2.30 (t, J = 7.5, 
2H, CH2CO); 3.66 (s, 3H, OCH3); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 25.1 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2; 29.26; 29.29; 29.3; 29.4; 29.8; 29.9; 32.0 (8CH2); 34.2 
(CH2CO); 51.6 (OCH3); 129.9; 130.1 (2CHalkene); 174.5 (CO) 
Methyl (9Z)-nonadec-9-enoate, 65 
Following the general procedure 4.1.1.10, alkene 65 was obtained from alkyne 
62 (120 mg, 0.39 mmol) in 92% yield.  
 
Rf: 0.36 (hexane/ethyl acetate, 20:1) 
IR (ATR): 1742 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.30 (m, 22H, 
11CH2); 1.58-1.64 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 2CH2CHalkene); 2.30 (t, J 
= 7.5, 2H, CH2CO); 3.66 (s, 3H, OCH3); 5.29-5.40 (m, 2H, 2CHalkene) 
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13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 25.1 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2; 29.3; 29.31; 29.4; 29.49; 29.7; 29.8; 29.84; 29.9; 32.1 
(10CH2); 34.3 (CH2CO); 51.6 (OCH3); 129.9; 130.2 (2CHalkene); 174.5 (CO) 
MS (ESI, m/z): 311.3 [M+H]+ 
Methyl (9Z)-icos-9-enoate, 66 
Following the general procedure 4.1.1.10, alkene 66 was obtained from alkyne 
63 (128 mg, 0.40 mmol) in 89% yield.  
 
Rf: 0.48 (hexane/ethyl acetate, 20:1)  
IR (ATR): 1743 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7 Hz, 3H, CH3); 1.26-1.30 (m, 24H, 
12CH2); 1.57-1.64 (m, 2H, CH2CH2CO); 1.97-2.04 (m, 4H, 2CH2CHalkene); 2.30 (t, J 
= 7.5 Hz, 2H, CH2CO); 3.66 (s, 3H, OCH3); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 25.1 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2; 29.28; 29.3; 29.4; 29.5; 29.7; 29.8; 29.81; 29.84; 29.9; 32.1 
(11CH2); 34.3 (CH2CO); 51.6 (OCH3); 129.9; 130.2 (2CHalkene); 174.5 (CO) 
(9Z)-Heptadec-9-enoic acid, 67 
Following the general procedure 4.1.1.11, carboxylic acid 67 was obtained 
from ester 64 (115 mg, 0.41 mmol) in quantitative yield. 
 
Rf: 0.43 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3252 (O-H); 1710 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.27-1.31 (m, 18H, 9CH2); 
1.58-1.66 (m, 2H, CH2CH2CO); 1.98-2.04 (m, 4H, 2CH2CHalkene); 2.35 (t, J = 7.5, 
2H, CH2CO); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 24.8 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2; 29.21; 29.3; 29.37; 29.4; 29.8; 29.9; 32.0 (8CH2); 34.2 
(CH2CO); 129.9; 130.2 (2CHalkene); 180.0 (CO) 
MS (ESI, m/z): 267.1 [M-H]- 
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(9Z)-Nonadec-9-enoic acid, 68 
Following the general procedure 4.1.1.11, carboxylic acid 68 was obtained 
from ester 65 (111 mg, 0.36 mmol) in quantitative yield.  
 
Rf: 0.45 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1710 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.31 (m, 22H, 11CH2); 
1.58-1.68 (m, 2H, CH2CH2CO); 1.98-2.04 (m, 4H, 2CH2CHalkene); 2.35 (t, J = 7.5, 
2H, CH2CO); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 24.8 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2; 29.22; 29.3; 29.5; 29.51; 29.7; 29.8; 29.83; 29.9; 32.1 
(10CH2); 34.2 (CH2CO); 129.9; 130.2 (2CHalkene); 180.2 (CO) 
(9Z)-Icos-9-enoic acid, 69 
Following the general procedure 4.1.1.11, carboxylic acid 69 was obtained 
from ester 66 (114 mg, 0.35 mmol) in quantitative yield.  
 
Rf: 0.46 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1711 (C=O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.26-1.31 (m, 24H, 
12CH2); 1.56-1.68 (m, 2H, CH2CH2CO); 1.94-2.04 (m, 4H, 2CH2CHalkene); 2.35 (t, J 
= 7.5, 2H, CH2CO); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.9; 24.8 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2; 29.22; 29.3; 29.5; 29.51; 29.7; 29.8 (7CH2); 29.82 (2CH2); 
29.9; 32.1 (2CH2); 34.1 (CH2CO); 129.9; 130.2 (2CHalkene); 180.0 (CO) 
MS (ESI, m/z): 309.2 [M-H]- 
 Synthesis of phosphorylated diol 71 
(2R)-2,3-Bis(benzyloxy)propyl di-tert-butyl phosphate, 70 
Following the general procedure 4.1.1.12, compound 70 was obtained from 
(S)-2,3-bis(benzyloxy)propan-1-ol (416 mg, 1.53 mmol) and di-tert-butyl N,N-
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diisopropylphosphoramidite (0.85 mL, 3.06 mmol) in 38% yield. Chromatography: 
hexane to hexane/ethyl acetate, 1:1. 
 
Rf: 0.36 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1265 (P=O); 996 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.46 (s, 18H, 6CH3); 3.56-3.66 (m, 2H, CH2OBn); 
3.83 (qt, J = 5.1, 1H, CH); 4.00-4.15 (m, 2H, CH2OP); 4.54 (s, 2H, PhCH2); 4.69 
(AB system, J = 11.9, 2.8, 2H, PhCH2); 7.25-7.37 (m, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  29.9 (3CH3); 30.0 (3CH3); 66.1 (d, J = 6.4, CH2OP); 
69.8 (CH2OBn); 72.4 (PhCH2); 73.5 (PhCH2); 76.9 (d, J = 8.6, CH); 82.4 (d, J = 7.5, 
C); 82.5 (d, J = 7.4, C); 127.7 (4CHAr); 127.9 (2CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 
138.3; 138.5 (2CAr) 
31P-NMR (CDCl3, 121 MHz):  -6.82 
[α]D20: +1.6 (c = 1, CHCl3) 
MS (ESI, m/z): 487.1 [M+Na]+ 
Di-tert-butyl (2R)-2,3-dihydroxypropyl phosphate, 71 
Following the general procedure 4.1.1.1, diol 71 was obtained from 70 (220 
mg, 0.47 mmol) at 60ºC in quantitative yield. 
 
Rf: 0.06 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3345 (O-H); 1025 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.47 (s, 18H, 6CH3); 3.60-3.73 (m, 2H, CH2OH); 
3.86-3.92 (m, 3H, CH, 2OH); 4.02 (dd, J = 9.1, 5.3, 2H, CH2OP) 
13C-NMR (methanol-d4, 75 MHz):  30.1 (3CH3); 30.2 (3CH3); 63.7 (CH2OH); 69.2 
(d, J = 6.8, CH2OP); 71.9 (d, J = 10.1, CH); 84.5 (d, J = 7.7, 2C) 
31P-NMR (CDCl3, 121 MHz):  -6.03 
[α]D20: -1.5 (c = 1.7, methanol) 
MS (ESI, m/z): 307.1 [M+Na]+ 
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 Synthesis of esters 72-76 
(2R)-3-[(Di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-tetradec-9-
enoate, 72 
Following the general procedure 4.1.1.13, ester 72 was obtained from 
myristoleic acid (24 µL, 95 µmol) and diol 71 (54 mg, 0.19 mmol) in 28% yield. 
Chromatography: dichloromethane to dichloromethane/methanol, 95:5. 
 
Rf: 0.88 (dichloromethane/methanol, 95:5) 
IR (ATR): 3365 (O-H); 1739 (C=O); 1257 (P=O); 1000 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.89 (t, J = 7.0, 3H, CH3); 1.24-1.34 (m, 12H, 6CH2); 
1.49 (s, 18H, 6CH3); 1.57-1.64 (m, 2H, CH2CH2CO); 1.94-2.02 (m, 4H, 
2CH2CHalkene); 2.33 (t, J = 7.6, 2H, CH2CO); 3.95-4.13 (m, 3H, CH, CH2OP); 4.15 
(d, J = 4.7, 2H, CO2CH2); 5.27-5.40 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.1 (CH3); 22.5; 25.0 (2CH2); 27.1; 27.3 
(2CH2CHalkene); 29.2; 29.23; 29.3; 29.8 (4CH2); 29.9 (3CH3); 30.0 (3CH3); 32.1 
(CH2); 34.3 (CH2CO); 64.7 (CO2CH2); 68.3 (d, J = 5.8, CH2OP); 69.1 (d, J = 5.0, 
CH); 83.4 (d, J = 7.5, 2C); 129.9; 130.1 (2CHalkene); 173.9 (CO) 
31P-NMR (methanol-d4, 121 MHz):  -5.11 
[α]D20: +2.6 (c = 0.5, methanol) 
MS (ESI, m/z): 515.2 [M+Na]+ 
(2R)-3-[(Di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-hexadec-9-
enoate, 73 
Following the general procedure 4.1.1.13, ester 73 was obtained from 
palmitoleic acid (66 µL, 0.23 mmol) and diol 71 (133 mg, 0.47 mmol) in 49% yield. 
Chromatography: hexane/ethyl acetate, 40:1 to 1:1. 
 
Rf: 0.38 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3363 (O-H); 1739 (C=O); 1251 (P=O); 1000 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.7, 3H, CH3); 1.28 (m, 16H, 8CH2); 1.48 
(s, 18H, 6CH3); 1.56-1.69 (m, 2H, CH2CH2CO); 1.96-2.00 (m, 4H, 2CH2CHalkene); 
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2.32 (t, J = 7.6, 2H, CH2CO); 3.85 (br s, 1H, OH); 3.95-4.09 (m, 3H, CH, CH2OP); 
4.14 (app d, J = 4.6, 2H, CO2CH2); 5.27-5.38 (m, 2H, 2CHalkene)  
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8; 25.0 (2CH2); 27.3; 27.33 
(2CH2CHalkene); 29.1 (CH2); 29.2 (2CH2); 29.3; 29.8; 29.84 (3CH2); 29.9 (3CH3); 
30.0 (3CH3); 31.9 (CH2); 34.2 (CH2CO); 64.7 (CO2CH2); 68.3 (d, J = 6.0, CH2OP); 
69.0 (d, J = 5.2, CH); 83.4 (d, J = 7.5, 2C); 129.9; 130.1 (2CHalkene); 173.9 (CO) 
31P-NMR (CDCl3, 121 MHz):  -5.23 
[α]D20: -1.9 (c = 1.21, CHCl3) 
MS (ESI, m/z): 543.3 [M+Na]+ 
(2R)-3-[(Di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-heptadec-9-
enoate, 74 
Following the general procedure 4.1.1.13, ester 74 was obtained from 
carboxylic acid 67 (92 mg, 0.34 mmol) and diol 71 (195 mg, 0.69 mmol) in 40% 
yield. Chromatography: hexane/ethyl acetate, 20:1 to 2:1. 
 
Rf: 0.36 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3366 (O-H); 1739 (C=O); 1647 (C=C); 1259 (P=O); 1007 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.21-1.30 (m, 18H, 9CH2); 
1.50 (s, 18H, 6CH3); 1.60-1.64 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 
2CH2CHalkene); 2.34 (t, J = 7.6, 2H, CH2CO); 3.71 (br s, 1H, OH); 3.98-4.11 (m, 3H, 
CH, CH2OP); 4.16 (app d, J = 4.9, 2H, CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.1 (CH3); 22.7; 24.9 (2CH2); 27.2; 27.24 
(2CH2CHalkene); 29.1 (2CH2); 29.2; 29.25; 29.3 (3CH2); 29.7 (2CH2); 29.8 (3CH3); 
29.9 (3CH3); 31.9 (CH2); 34.1 (CH2CO); 64.5 (CO2CH2); 68.3 (d, J = 5.4, CH2OP); 
69.1 (d, J = 4.8, CH); 83.3 (d, J = 7.8, 2C); 129.8; 130.0 (2CHalkene); 173.8 (CO) 
31P-NMR (CDCl3, 121 MHz):  -5.01 
[α]D20: +3.5 (c = 0.77, methanol) 
MS (ESI, m/z): 557.3 [M+Na]+ 
(2R)-3-[(di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-nonadec-9-
enoate, 75 
Following the general procedure 4.1.1.13, ester 75 was obtained from 
carboxylic acid 68 (73 mg, 0.25 mmol) and diol 71 (140 mg, 0.49 mmol) in 17% 
yield. Chromatography: hexane/ethyl acetate, 20:1 to 2:1. 
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Rf: 0.37 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3359 (O-H); 1738 (C=O); 1650 (C=C); 1252 (P=O); 1010 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.7, 3H, CH3); 1.26-1.29 (m, 22H, 11CH2); 
1.49 (s, 18H, 6CH3); 1.59-1.64 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 4H, 
2CH2CHalkene); 2.33 (t, J = 7.6, 2H, CH2CO); 3.76 (br s, 1H, OH); 3.95-4.10 (m, 3H, 
CH, CH2OP); 4.15 (app d, J = 4.9, 2H, CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 25.1 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2 (2CH2); 29.3; 29.4; 29.5; 29.7; 29.74; 29.8; 29.9 (7CH2); 29.93 
(3CH3); 30.0 (3CH3); 32.0 (CH2); 34.1 (CH2CO); 64.7 (CO2CH2); 68.3 (d, J = 6.0, 
CH2OP); 69.1 (d, J = 5.0, CH); 83.4 (d, J = 7.5, 2C); 129.9; 130.1 (2CHalkene); 173.9 
(CO) 
31P-NMR (CDCl3, 121 MHz):  -5.15 
[α]D20: -1.7 (c = 1.18, CHCl3) 
MS (ESI, m/z): 449.4 [M-2tBu+H]+; 450.4 [M-2tBu+2H] +  
(2R)-3-[(Di-tert-butoxyphosphoryl)oxy]-2-hydroxypropyl (9Z)-icos-9-enoate, 
76 
Following the general procedure 4.1.1.13, ester 76 was obtained from 
carboxylic acid 69 (65 mg, 0.21 mmol) and diol 71 (121 mg, 0.42 mmol) in 12% 
yield. Chromatography: hexane/ethyl acetate, 20:1 to 2:1. 
 
Rf: 0.43 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3370 (O-H); 1740 (C=O); 1258 (P=O); 1000 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.87 (t, J = 6.7, 3H, CH3); 1.26-1.30 (m, 24H, 
12CH2); 1.50 (s, 18H, 6CH3); 1.60-1.65 (m, 2H, CH2CH2CO), 1.97-2.01 (m, 4H, 
2CH2CHalkene); 2.33 (t, J = 7.6, 2H, CH2CO); 3.72 (d, J = 4.1, 1H, OH); 3.98-4.11 
(m, 3H, CH, CH2OP); 4.16 (app d, J = 4.9, 2H, CO2CH2); 5.28-5.39 (m, 2H, 
2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 25.0 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2 (2CH2); 29.3; 29.4; 29.5; 29.7; 29.78; 29.8; 29.84; 29.9 
(8CH2); 30.0 (6CH3); 32.1 (CH2); 34.3 (CH2CO); 64.7 (CO2CH2); 68.4 (d, J = 5.5, 
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CH2OP); 69.2 (d, J = 4.6, CH); 83.4 (d, J = 7.2, 2C); 129.9; 130.2 (2CHalkene); 173.9 
(CO) 
31P-NMR (CDCl3, 121 MHz):  -5.01 
[α]D20: +3.4 (c = 0.92, methanol) 
MS (MALDI, m/z): 599.4 [M+Na]+ 
 Synthesis of final compounds 2a-e 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-tetradec-9-enoate, 2a 
Following the general procedure 4.1.1.7, compound 2a was obtained from di-
tert-butyl phosphate 72 (7 mg, 14 µmol) and TFA (27 µL, 0.35 mmol) without 
further purification in 99% yield.  
 
IR (ATR): 3375 (O-H); 1737 (C=O); 1182 (P=O); 1058 (P-OH) 
1H-NMR (methanol-d4, 500 MHz):  0.91 (t, J = 7.0, 3H, CH3); 1.29-1.30 (m, 12H, 
6CH2); 1.60-1.63 (m, 2H, CH2CH2CO); 2.02-2.04 (m, 4H, 2CH2CHalkene); 2.36 (t, J = 
7.4, 2H, CH2CO); 3.96-3.98 (m, 3H, CH, CH2OP); 4.07-4.17 (m, 2H, CO2CH2); 
5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 125 MHz):  14.3 (CH3); 23.4; 26.0 (2CH2); 27.9; 28.1 
(2CH2CHalkene); 30.1; 30.2; 30.3; 30.8; 33.1 (5CH2); 34.9 (CH2CO); 66.2 (CO2CH2); 
67.6 (d, J = 5.2, CH2OP); 69.8 (d, J = 6.9, CH); 130.8; 130.83 (2CHalkene); 175.4 
(CO) 
31P-NMR (methanol-d4, 121 MHz):  3.23 
[α]D20: limited solubility in DMSO 
HRMS (ESI, m/z): calculated for C17H32O7P ([M-H]-): 379.2891, found: 379.2848 
HPLC (method A, tR, min): 9.81 min 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-hexadec-9-enoate, 2b 
Following the general procedure 4.1.1.7, compound 2b was obtained from di-
tert-butyl phosphate 73 (24 mg, 46 µmol) and TFA (88 µL, 1.15 mmol) without 
further purification in 90% yield.  
 
IR (ATR): 3392 (O-H); 1737 (C=O); 1176 (=O); 1057 (P-OH) 
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1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.7, 3H, CH3); 1.29-1.33 (m, 16H, 
8CH2); 1.60-1.64 (m, 2H, CH2CH2CO); 2.00-2.04 (m, 4H, 2CH2CHalkene); 2.36 (t, J = 
7.5, 2H, CH2CO); 3.92-4.04 (m, 3H, CH, CH2OP); 4.15 (AB system, J = 11.4, 4.8, 
2H, CO2CH2); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 75 MHz):  14.5 (CH3); 23.7; 26.0 (2CH2); 28.1; 28.2 
(2CH2CHalkene); 30.1 (CH2); 30.2 (2CH2); 30.3; 30.8; 30.84; 32.9 (4CH2); 34.9 
(CH2CO); 66.2 (CO2CH2); 67.6 (d, J = 5.3, CH2OP); 69.8 (d, J = 8.0, CH); 130.8; 
130.9 (2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.79 
[α]D20: limited solubility in DMSO 
HRMS (MALDI, m/z): calculated for C19H37NaO7P ([M+Na]+): 431.2175, found: 
431.2169 
HPLC (method A, tR, min): 10.06  
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-heptadec-9-enoate, 2c 
Following the general procedure 4.1.1.7, compound 2c was obtained from di-
tert-butyl phosphate 74 (6 mg, 12 µmol) and TFA (22 µL, 0.30 mmol) without 
further purification in 99% yield.  
 
IR (ATR): 3347 (O-H); 1737 (C=O); 1652 (C=C); 1186 (P=O); 1082 (P-OH) 
1H-NMR (methanol-d4, 700 MHz):  0.90 (t, J = 6.7, 3H, CH3); 1.29-1.33 (m, 18H, 
9CH2); 1.60-1.64 (m, 2H, CH2CH2CO); 2.01-2.04 (m, 4H, 2CH2CHalkene), 2.36 (t, J = 
7.4, 2H, CH2CO); 3.89-3.91 (m, 2H, CH2OP); 3.95-3.98 (m, 1H, CH); 4.11 (dd, J = 
11.4, 6.2, 1H, ½CO2CH2); 4.18 (dd, J = 11.4, 4.3, 1H, ½CO2CH2); 5.29-5.40 (m, 
2H, 2CHalkene) 
13C-NMR (methanol-d4, 175 MHz):  14.5 (CH3); 23.7; 26.0 (2CH2); 28.1 
(2CH2CHalkene); 30.2; 30.22; 30.3; 30.34; 30.8; 30.82; 30.9; 33.1 (8CH2); 34.9 
(CH2CO); 66.4 (CO2CH2); 67.2 (d, J = 5.2, CH2OP); 70.1 (d, J = 7.9, CH); 130.8; 
130.9 (2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  4.34 
[α]D20: limited solubility in DMSO 
HRMS (MALDI, m/z): calculated for C20H39NaO7P ([M+Na]+): 445.2331, found: 
445.2311 
HPLC (method A, tR, min): 10.42 
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(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-nonadec-9-enoate, 2d 
Following the general procedure 4.1.1.7, compound 2d was obtained from di-
tert-butyl phosphate 75 (24 mg, 43 µmol) and TFA (82 µL, 1.08 mmol) without 
further purification in 99% yield.  
 
IR (ATR): 3360 (O-H); 1738 (C=O); 1181 (P=O); 1060 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.6, 3H, CH3); 1.29-1.33 (m, 22H, 
11CH2); 1.59-1.64 (m, 2H, CH2CH2CO); 2.02-2.04 (m, 4H, 2CH2CHalkene); 2.35 (t, J 
= 7.5, 2H, CH2CO); 3.91-4.05 (m, 3H, CH, CH2OP); 4.15 (AB system, J = 11.3, 4.9, 
2H, CO2CH2); 5.29-5.40 (m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 75 MHz):  14.4 (CH3); 23.7; 26.0 (2CH2); 28.1 
(2CH2CHalkene); 30.2 (2CH2); 30.3 (2CH2); 30.5; 30.6; 30.7 (3CH2); 30.8 (2CH2); 
33.1 (CH2); 34.9 (CH2CO); 66.3 (CO2CH2); 67.5 (d, J = 4.8, CH2OP); 69.9 (d, J = 
7.7, CH); 130.8; 130.9 (2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.88 
[α]D20: limited solubility in DMSO 
HRMS (MALDI, m/z): calculated for C22H43NaO7P ([M+Na]+): 473.2644, found: 
473.2642 
HPLC (method A, tR, min): 11.30 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl (9Z)-icos-9-enoate, 2e 
Following the general procedure 4.1.1.7, compound 2e was obtained from di-
tert-butyl phosphate 76 (9 mg, 16 µmol) and TFA (30 µL, 0.40 mmol) without 
further purification in 92% yield.  
 
IR (ATR): 3350 (O-H); 1738 (C=O); 1179 (P=O); 1059 (P-OH) 
1H-NMR (methanol-d4, 700 MHz):  0.90 (t, J = 7.0, 3H, CH3); 1.29-1.33 (m, 24H, 
12CH2); 1.60-1.63 (m, 2H, CH2CH2CO); 2.02-2.05 (m, 4H, 2CH2CHalkene); 2.35 (t, J 
= 7.5, 2H, CH2CO); 3.94 (app t, J = 5.7, 2H, CH2OP); 3.97-4.00 (m, 1H, CH); 4.11 
(dd, J = 11.4, 6.0, 1H, ½CO2CH2); 4.18 (dd, J = 11.4, 4.3, 1H, ½CO2CH2); 5.32-
5.37 (m, 2H, 2CHalkene) 
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13C-NMR (methanol-d4, 175 MHz):  14.5 (CH3); 23.8; 26.0 (2CH2); 28.1; 28.14 
(2CH2CHalkene); 30.2; 30.3; 30.5; 30.6 (4CH2); 30.7 (2CH2); 30.77 (2CH2); 30.8 
(2CH2); 33.1 (CH2); 34.9 (CH2CO); 66.1 (CO2CH2); 67.6 (d, J = 5.3, CH2OP); 69.7 
(d, J = 7.6, CH); 130.8; 130.9 (2CHalkene); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.16 
[α]D20: limited solubility in DMSO 
HRMS (MALDI, m/z): calculated for C23H45NaO7P ([M+Na]+): 487.2801, found: 
487.2798 
HPLC (method A, tR, min): 12.35 
4.1.5 Synthesis of final compounds 3a and 2f-j 
 Synthesis of carboxylic acids 77, 80, and 81 
10-Phenyldecanoic acid, 77 
To a stirred solution of 10-phenyldecanol (500 mg, 2.10 mmol, 1 equiv) in dry 
DMF (2 mL), pyridinium dichromate was added (2.92 g, 3.89 mmol, 3.7 equiv) and 
the reaction was stirred at room temperature overnight. Then, solvent was 
evaporated under reduced pressure and the crude was purified by flash 
chromatography (dichloromethane to dichloromethane/methanol, 10:1), affording 
carboxylic acid 77 in 52% yield.  
 
Rf: 0.6 (dichloromethane/methanol, 9:1) 
1H-NMR (CDCl3, 300 MHz):  1.32 (m, 10H, 5CH2); 1.63-1.65 (m, 4H, 2CH2); 2.34 
(t, J = 7.4, 2H, CH2CO); 2.60 (t, J = 7.5, 2H, PhCH2); 7.18-7.22 (m, 3H, 3CHAr); 
7.27-7.33 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  24.8; 29.2; 29.4; 29.41; 29.5; 29.6; 31.6 (7CH2); 34.2 
(CH2CO); 36.1 (PhCH2); 125.7 (CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 
180.3 (CO) 
(7E,Z)-8-Phenyloct-7-enoic acid, 78 
Following the general procedure 4.1.1.15, alkene 78 was obtained from 7-
bromoheptanoic acid (441 mg, 2.11 mmol) and benzaldehyde (103 µL, 1.00 mmol) 
in 61% yield. Chromatography: hexane to hexane/ethyl acetate, 1:1. 
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Rf: 0.61 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3057 (O-H); 1707 (C=O) 
1H-NMR (CDCl3, 300 MHz): Mixture E:Z (2.3:1):  1.36-1.53 (m, 4H, 2CH2); 1.59-
1.73 (m, 2H, CH2); 2.23 (q, J = 6.8, 2H, CH2CHalkene(E)); 2.30-2.40 (m, 4H, 
CH2CHalkene(Z), CH2CO); 5.65 (dt, J = 11.7, 7.2, 1H, CH2CHalkene(Z)); 6.21 (dt, J = 
15.8, 6.8, 1H, CH2CHalkene(E)); 6.39 (d, J = 15.6, 1H, PhCHalkene(E)); 6.43 (d, J = 11.7, 
1H, PhCHalkene(Z)); 7.16-7.36 (m, 5H, 5CHAr) 
13C-NMR (CDCl3, 75 MHz): Mixture E:Z (2.3:1):  24.7 (CH2); 28.5 (CH2 Z); 28.7 
(CH2 E); 28.9 (CH2 Z); 29.1 (CH2 E); 32.9 (CH2CHalkene); 34.1 (CH2CO); 126.1 (2CHAr 
E); 126.6 (CHAr Z); 127.0 (CHAr E); 128.3 (2CHAr Z); 128.6 (2CHAr E); 128.9 (2CHAr Z); 
129.2 (CH alkene(Z)); 130.2 (CHalkene(E)); 130.8 (CHalkene(E)); 132.8 (CHalkene(Z)); 137.9 
(CAr Z); 138.0 (CAr E); 179.9 (CO) 
MS (ESI, m/z): 217.1 [M-H]- 
(8E,Z)-9-Phenylnon-8-enoic acid, 79 
Following the general procedure 4.1.1.15, alkene 79 was obtained from 8-
bromooctanoic acid (1g, 4.48 mmol) and benzaldehyde (0.36 mL, 3.58 mmol) in 
70% yield. Chromatography: hexane to hexane/ethyl acetate, 1:1. 
 
Rf: 0.52 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3024 (O-H); 1706 (C=O) 
1H-NMR (CDCl3, 300 MHz): Mixture E:Z (1.5:1):  1.33-1.41 (m, 4H, 2CH2); 1.45-
1.52 (m, 2H, CH2); 1.59-1.72 (m, 2H, CH2); 2.22 (q, J = 6.9, 2H, CH2CHalkene(E)); 
2.37 (app q, J = 7.6, 4H, CH2CHalkene(Z), CH2CO); 5.66 (dt, J = 11.7, 7.3, 1H, 
CH2CHalkene(Z)); 6.23 (dt, J = 15.8, 6.8, 1H, CH2CHalkene(E)); 6.39 (d, J = 15.5, 1H, 
PhCHalkene(E)); 6.44 (d, J = 11.5, 1H, PhCHalkene(Z)); 7.17-7.37 (m, 5H, 5CHAr) 
13C-NMR (CDCl3, 75 MHz): Mixture E:Z (1.5:1):  24.7 and 24.75 (CH2); 28.6; 28.9; 
29.0; 29.3 and 29.9 (3CH2 Z,E); 33.1 (CH2CHalkene); 34.1 and 34.14 (CH2CO); 126.0 
(2CHAr E); 126.6 (CHAr Z); 126.9 (CHAr E); 128.2 (2CHAr Z); 128.6 (2CHAr E); 128.9 
(2CHAr Z); 129.0 (CHalkene(Z)); 130.0 (CHalkene(E)); 131.06 (CHalkene(E)); 133.10 
(CHalkene(Z)); 137.9 (CAr Z); 138.0 (CAr E); 180.1 (CO) 
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MS (ESI, m/z): 231.1 [M-H]- 
8-Phenyloctanoic acid, 80 
Following the general procedure 4.1.1.1, carboxylic acid 80 was obtained from 
alkene 78 (60 mg, 0.27 mmol) at room temperature in 97% yield. The 
spectroscopic data correspond with those previously reported.110  
 
Rf: 0.60 (hexane/ethyl acetate, 8:2) 
1H-NMR (CDCl3, 300 MHz):  1.41 (app s, 6H, 3CH2); 1.70 (br s, 4H, 2CH2); 2.42 
(t, J = 7.5, 2H, CH2CO); 2.67 (t, J = 7.7, 2H, PhCH2); 7.23-7.26 (m, 3H, 3CHAr); 
7.32-7.37 (m, 2H, 2CHAr) 
9-Phenylnonanoic acid, 81 
Following the general procedure 4.1.1.1, carboxylic acid 81 was obtained from 
alkene 79 (300 mg, 1.29 mmol) at room temperature in 81% yield.  
 
Rf: 0.61 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3063 (O-H); 1707 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.32 (app s, 8H, 4CH2); 1.56-1.65 (m, 4H, 2CH2); 
2.35 (t, J = 7.5, 2H, CH2CO); 2.60 (t, J = 7.7, 2H, PhCH2); 7.16-7.19 (m, 3H, 
3CHAr); 7.25-7.30 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  24.8; 29.2; 29.3; 29.35; 29.4; 31.6 (6CH2); 34.2 
(CH2CO); 36.1 (PhCH2); 125.7 (CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 
180.5 (CO)  
MS (ESI, m/z): 233.1 [M-H]- 
 Synthesis of the phosphorylated diols 83 and 86 
[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl diethyl phosphate, 82 
To a solution of (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (0.3 mL, 2.43 
mmol, 1 equiv) in 8 mL of anhydrous dichloromethane, diethyl chlorophosphate 
(0.44 mL, 3.04 mmol, 1.25 equiv) and potassium tert-butoxide (408 mg, 3.64 mmol, 
1.5 equiv) were added and the mixture was stirred at room temperature for 48 h. 
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Then, the reaction was quenched with a saturated aqueous solution of NH4Cl (3.5 
mL/mmol of base) and stirred for 10 additional minutes. The mixture was extracted 
with dichloromethane and the organic phase was dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography (dichloromethane/ethyl acetate, 10:1 to 1:1), to afford pure 
product 82 in 92% yield. 
 
Rf: 0.26 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 1021 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.31 (td, J = 7.1, 0.9, 6H, 2CH2CH3); 1.33 (s, 3H, 
CH3 acetal); 1.39 (s, 3H, CH3 acetal); 3.81 (dd, J = 8.6, 5.5, 1H, ½CH2O); 3.92-4.05 (m, 
3H, ½CH2O, CH2OP); 4.07-4.16 (m, 4H, 2CH2CH3): 4.24-4.33 (m, 1H, CH) 
13C-NMR (CDCl3, 75 MHz):  16.2 (d, J = 6.7, 2CH2CH3); 25.4 (CH3 acetal); 26.8 
(CH3 acetal); 64.1 (d, J = 5.7, 2CH2CH3); 66.3 (CH2O); 67.4 (d, J = 5.8, CH2OP); 74.2 
(d, J = 8.2, CH); 109.9 (C) 
 (2R)-2,3-Dihydroxypropyl diethyl phosphate, 83 
Following the general procedure 4.1.1.5, diol 83 was obtained from 82 (600 
mg, 2.24 mmol) in 50% yield. Chromatography: dichloromethane/methanol, 50:1 to 
10:1. 
 
Rf: 0.11 (dichloromethane/methanol, 10:1) 
IR (ATR): 3405 (O-H); 1256 (P=O); 1027 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.34 (t, J = 7.1, 6H, 2CH3); 3.21 (br s, 2H, 2OH); 
3.60-3.73 (m, 2H, CH2OP); 3.75-3.83 (m, 1H, ½CH2OH); 3.86-3.94 (m, 1H, CH); 
4.06-4.18 (m, 5H, ½CH2OH, 2CH2CH3) 
13C-NMR (CDCl3, 75 MHz):  16.2 (d, J = 6.7, 2CH3); 62.9 (CH2OH); 64.5 (d, J = 
6.0, 2CH2CH3); 68.5 (d, J = 5.8, CH2OP); 70.8 (d, J = 5.5, CH) 
[α]D20: -6.5 (c = 1.11, methanol) 
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Dibenzyl [(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl phosphate, 85 
Following the general procedure 4.1.1.12, compound 85 was obtained from 
(S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (0.2 mL, 1.62 mmol) and 
dibenzyl N,N-diisopropylphosphoramidite (0.97 mL, 2.91 mmol) in 76% yield. 
Chromatography: hexane to hexane/ethyl acetate, 1:1. 
 
Rf: 0.4 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1255 (P=O); 991 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.32 (s, 3H, CH3); 1.38 (s, 3H, CH3); 3.72 (dd, J = 
8.6, 5.5, 1H, ½CH2O); 3.87-4.04 (m, 3H, ½CH2O, CH2OP); 4.20 (qt, J = 5.7, 1H, 
CH); 4.97-5.13 (m, 4H, 2PhCH2); 7.34 (app s, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  25.3; 26.8 (2CH3); 66.2 (CH2O); 67.5 (d, J = 5.9, 
CH2OP); 69.5 (d, J = 5.6, 2PhCH2); 74.0 (d, J = 8.3, CH); 109.9 (C); 128.1 (4CHAr); 
128.7 (6CHAr); 135.8 (d, J = 6.6, 2CAr) 
31P-NMR (CDCl3, 121 MHz):  2.03 
[α]D20: +1.6 (c = 1, methanol) 
MS (ESI, m/z): 393.1 [M+H]+ 
Dibenzyl (2R)-2,3-dihydroxypropyl phosphate, 86 
Following the general procedure 4.1.1.5, diol 86 was obtained from 85 (390 
mg, 0.99 mmol) in 65% yield. Chromatography: ethyl acetate to ethyl 
acetate/ethanol, 7:3. 
 
Rf: 0.56 (ethyl acetate) 
IR (ATR): 3368 (O-H); 1255 (P=O); 1013 (P-O) 
1H-NMR (CDCl3, 300 MHz):  2.53 (br s, 2H, OH); 3.52-3.65 (m, 2H, CH2OP); 3.78-
3.85 (m, 1H, CH); 4.03 (dd, J = 9.5, 5.0, 2H, CH2OH); 4.98-5.11 (m, 4H, 2PhCH2); 
7.35 (app s, 10H, 10CHAr) 
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13C-NMR (CDCl3, 75 MHz):  62.7 (CH2OH); 68.8 (d, J = 5.9, CH2OP); 69.9 (d, J = 
5.8, 2PhCH2); 70.7 (d, J = 5.2, CH); 128.2 (4CHAr); 128.8 (4CHAr); 128.9 (2CHAr); 
135.60 (d, J = 6.6, 2CAr) 
31P-NMR (CDCl3, 121 MHz):  3.19 
[α]D20: -4.6 (c = 0.99, methanol) 
MS (ESI, m/z): 353.0 [M+H]+ 
 Synthesis of carboxylic acids 93, 96, and 100 
(6E)-7-Biphenyl-4-ylhept-6-enoic acid, 92 
Following the general procedure 4.1.1.15, alkene 92 was obtained from 6-
bromohexanoic acid (1 g, 5.13 mmol) and biphenyl-4-carbaldehyde (540 mg, 2.96 
mmol) in 72% yield. Chromatography: dichloromethane to dichoromethane/ethyl 
acetate, 5:1.  
 
Rf: 0.39 (dichoromethane/ethyl acetate, 8:2) 
IR (ATR): 3026 (O-H); 1700 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.51-1.61 (m, 2H, CH2); 1.67-1.78 (m, 2H, CH2); 2.27 
(q, J = 6.7, 2H, CH2CHalkene); 2.41 (t, J = 7.4, 2H, CH2CO); 6.25 (dt, J = 15.8, 6.8, 
1H, CHCH2); 6.44 (d, J = 15.9, 1H, ArCH); 7.33 (t, J = 7.3, 1H, CHAr); 7.40-7.46 (m, 
4H, 4CHAr); 7.53-7.62 (m, 4H, 4CHAr) 
13C-NMR (CDCl3, 75 MHz):  24.4; 28.9 (2CH2); 32.8 (CH2CHalkene); 33.9 (CH2CO); 
126.5 (2CHAr); 127.0 (2CHAr); 127.30 (CHAr); 127.34 (2CHAr); 128.9 (2CHAr); 130.0; 
130.5 (2CHalkene); 136.9; 139.8; 141.0 (3CAr); 179.5 (CO) 
MS (ESI, m/z): 279.1 [M-H]- 
7-Biphenyl-4-ylheptanoic acid, 93 
Following the general procedure 4.1.1.1, carboxylic acid 93 was obtained from 
alkene 92 (300 mg, 1.07 mmol) at room temperature as a white solid in 95% yield. 
The spectroscopic data correspond with those previously reported.103 
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Rf: 0.43 (dichloromethane/ethyl acetate, 8:2) 
m.p.: 70-71ºC (lit.103 m.p.: 69-70ºC) 
1H-NMR (CDCl3, 300 MHz):  1.37-1.42 (m, 4H, 2CH2); 1.61-1.71 (m, 4H, 2CH2); 
2.36 (t, J = 7.5, 2H, CH2CO); 2.65 (t, J = 7.5, 2H, ArCH2); 7.25 (d, J = 8.7, 2H, 
2CHAr); 7.32 (t, J = 7.3, 1H, CHAr); 7.43 (t, J = 7.4, 2H, 2CHAr); 7.51 (d, J = 8.2, 2H, 
2CHAr); 7.56-7.60 (m, 2H, 2CHAr) 
MS (ESI, m/z): 281.1 [M-H]- 
9-Bromononanoic acid, 94 
Following the general procedure 4.1.1.14, carboxylic acid 94 was obtained 
from 9-bromononanol (1 g, 4.48 mmol) in 61% yield. Chromatography: 
dichloromethane to dichloromethane/ethyl acetate 5:1. The spectroscopic data 
correspond with those previously reported.111 
 
Rf: 0.67 (dichloromethane/ethyl acetate, 8:2) 
1H-NMR (CDCl3, 300 MHz):  1.32-1.37 (m, 6H, 3CH2); 1.40-1.44 (m, 2H, CH2); 
1.58-1.69 (m, 2H, CH2); 1.80-1.90 (m, 2H, CH2); 2.36 (t, J = 7.5, 2H, CH2CO); 3.40 
(t, J = 6.8, 2H, CH2Br); 8.81 (br s, 1H, OH) 
(9E,Z)-10-Biphenyl-4-yldec-9-enoic acid, 95 
Following the general procedure 4.1.1.15, alkene 95 was obtained from 94 
(650 mg, 5.13 mmol) and biphenyl-4-carbaldehyde (400 mg, 2.19 mmol) in 51% 
yield. Chromatography: dichloromethane to dichloromethane/ethyl acetate, 5:1.  
 
Rf: 0.5 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3030 (O-H); 1705 (C=O) 
1H-NMR (CDCl3, 300 MHz): Mixture E:Z (1.5:1):  1.36-1.39 (m, 6H, 3CH2); 1.48 
(m, 2H, CH2); 1.59-1.66 (m, 2H, CH2); 2.23 (q, J = 6.7, 2H, CH2CHalkene(E)); 2.32-
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2.42 (m, 4H, CH2CHalkene(Z), CH2CO); 5.69 (dt, J = 11.8, 7.3, 1H, CH2CHalkene(Z)); 
6.27 (dt, J = 15.8, 6.7, 1H, CH2CHalkene(E)); 6.42 (d, J = 15.9, 1H, ArCHalkene(E)); 6.44 
(d, J = 11.5, 1H, ArCHalkene(Z)); 7.31-7.47 (m, 5H, 5CHAr); 7.53-7.63 (m, 4H, 4CHAr) 
13C-NMR (CDCl3, 75 MHz): Mixture E:Z (1.5:1):  24.7 and 24.8 (CH2); 28.9; 28.93; 
29.0; 29.1; 29.2; 29.4 and 30.0 (4CH2 E,Z); 33.1 and 33.2 (CH2CHalkene); 34.2 (br s, 
CH2CO); 126.4 (2CHAr E); 126.9 (2CHAr Z); 127.0 (2CHAr E); 127.1 (2CHAr Z); 127.3 
(CHAr E); 127.31 (2CHAr E); 128.5 (CHAr Z); 128.8 (2CHAr E); 128.9 (2CHAr Z); 129.3 
(2CHAr Z); 129.5 (CHalkene(Z)); 131.3 (CHalkene(E)); 132.3 (CHalkene(E)); 133.4 
(CHalkene(Z)); 137.0 and 137.1 (CAr); 139.3 and 139.6 (CAr); 140.9 and 141.0 (CAr); 
180.3 (CO) 
MS (ESI, m/z): 321.1 [M-H]- 
10-Biphenyl-4-yldecanoic acid, 96 
Following the general procedure 4.1.1.1, carboxylic acid 96 was obtained from 
alkene 95 (240 mg, 0.75 mmol) at room temperature as a white solid in 83% yield.  
 
Rf: 0.5 (dichloromethane/ethyl acetate, 8:2) 
m.p.: 92-95ºC 
IR (ATR): 3032 (O-H); 1696 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.31-1.39 (m, 10H, 5CH2); 1.68 (m, 4H, 2CH2); 2.40 
(t, J = 7.5, 2H, CH2CO); 2.69 (t, J = 7.5, 2H, ArCH2); 7.31 (d, J = 8.1, 2H, 2CHAr); 
7.37 (t, J = 7.3, 1H, CHAr); 7.48 (t, J = 7.5, 2H, 2CHAr); 7.56 (d, J = 8.1, 2H, 2CHAr); 
7.62-7.65 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  24.8; 29.2; 29.3; 29.4; 29.5; 29.6; 31.6 (7CH2); 34.2 
(CH2CO); 35.7 (ArCH2); 127.1 (CHAr); 127.12 (4CHAr); 128.8 (2CHAr); 129.0 
(2CHAr); 138.7; 141.3; 142.2 (3CAr), 180.2 (CO) 
MS (ESI, m/z): 323.3 [M-H]- 
12-Bromododecan-1-ol, 97 
To a suspension of 1,12-dodecanodiol (1.00 g, 4.94 mmol, 1 equiv) in 
cyclohexane (15 mL), 47% aq. HBr (15 mL) was added and the reaction was 
refluxed for 6 h. Then, the mixture was extracted with hexane and the organic 
phase was washed with a saturated aqueous solution of NaHCO3 and with brine, 
dried over Na2SO4, filtered and evaporated under reduced pressure. The crude 
was purified by flash cromatography (hexane to dichloromethane) to afford 
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bromoalcohol 97 as in 65% yield. The spectroscopic data correspond with those 
previously reported.112 
 
Rf: 0.71 (dichloromethane/ethyl acetate, 8:2) 
1H-NMR (CDCl3, 300 MHz):  1.27-1.44 (m, 16H, 8CH2); 1.52-1.61 (m, 2H, CH2); 
1.80-1.90 (m, 2H, CH2); 3.40 (t, J = 6.9, 2H, CH2Br); 3.64 (t, J = 6.6, 2H, CH2OH) 
12-Bromododecanoic acid, 98 
Following the general procedure 4.1.1.14, carboxylic acid 98 was obtained 
from bromoalcohol 97 (850 mg, 3.2 mmol) in 43% yield. Chromatography: 
dichloromethane to dichloromethane/ethyl acetate, 5:1. The spectroscopic data 
correspond with those previously reported.112 
 
Rf: 0.51 (dichloromethane/ethyl acetate, 8:2) 
1H-NMR (CDCl3, 300 MHz):  1.28 (app s, 12H, 6CH2); 1.39-1.44 (m, 2H, CH2); 
1.58-1.65 (m, 2H, CH2); 1.80-1.89 (m, 2H, CH2); 2.35 (t, J = 7.5, 2H, CH2CO); 3.40 
(t, J = 6.8, 2H, CH2Br) 
(12E,Z)-13-Biphenyl-4-yltridec-12-enoic acid, 99 
Following the general procedure 4.1.1.15, alkene 99 was obtained from 98 
(800 mg, 2.87 mmol) and biphenyl-4-carbaldehyde (422 mg, 2.32 mmol) in 38% 
yield. Chromatography: dichloromethane to dichloromethane/ethyl acetate, 5:1. 
 
Rf: 0.46 (dichoromethane/ethyl acetate, 8:2) 
IR (ATR): 3030 (O-H); 1703 (C=O) 
1H-NMR (CDCl3, 300 MHz): Mixture E:Z (1:1):  1.26-1.29 (m, 10H, 5CH2); 1.45-
1.50 (m, 2H, CH2); 1.60-1.66 (m, 4H, 2CH2); 2.23 (q, J = 6.9, 2H, CH2CHalkene(Z)); 
2.32-2.39 (m, 4H, CH2CHalkene(E), CH2CO); 5.70 (dt, J = 11.7, 7.2, 1H, 
CH2CHalkene(Z)); 6.27 (dt, J = 15.8, 6.7, 1H, CH2CHalkene(E)); 6.43 (d, J = 11.6, 1H, 
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ArCHalkene(Z)); 6.47 (d, J = 15.2, 1H, ArCHalkene(E)); 7.33-7.47 (m, 5H, 5CHAr); 7.52-
7.63 (m, 4H, 4CHAr) 
13C-NMR (CDCl3, 75 MHz): Mixture E:Z (1:1):  24.8 (CH2); 28.9; 29.2; 29.4; 29.5; 
29.53; 29.6; 29.7 and 30.1 (7CH2 Z,E); 31.7 and 33.3 (CH2CHalkene); 34.1 (CH2CO); 
126.4; 126.9; 127.0; 127.1; 127.2; 127.3; 128.4; 128.8 and 128.9 (7CHAr Z,E); 129.0 
(CHalkene Z/E); 129.3 (2CHAr Z/E); 129.4 (CHalkene Z/E); 131.6 and 133.7 (CHalkene Z,E); 
137.0 and 137.2 (CAr); 138.8 and 139.3 (CAr); 140.2 and 141.0 (CAr); 179.7 (CO) 
MS (ESI, m/z): 363.2 [M-H]- 
13-Biphenyl-4-yltridecanoic acid, 100 
Following the general procedure 4.1.1.1, carboxylic acid 100 was obtained 
from alkene 99 (300 mg, 0.82 mmol) at room temperature as a white solid in 96% 
yield.  
 
Rf: 0.46 (dichoromethane/ethyl acetate, 8:2) 
m.p.: 103-105ºC 
IR (ATR): 3027 (O-H); 1696 (C=O) 
1H-NMR (CDCl3, 300 MHz):  1.22-1.46 (m, 16H, 8CH2); 1.57-1.73 (m, 4H, 2CH2); 
2.35 (t, J = 7.5, 2H, CH2CO); 2.65 (t, J = 7.5, 2H, ArCH2); 7.26 (d, J = 8.0, 2H, 
2CHAr); 7.32 (t, J = 7.3, 1H, CHAr); 7.43 (t, J = 7.5, 2H, 2CHAr); 7.52 (d, J = 8.1, 2H, 
2CHAr); 7.59 (d, J = 7.6, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  24.8; 29.2; 29.4; 29.5; 29.6; 29.7 (6CH2); 29.72 
(2CH2); 29.8; 31.7 (2CH2); 34.2 (CH2CO); 35.8 (ArCH2); 127.1 (CHAr); 127.12 
(4CHAr); 128.8 (2CHAr); 129.0 (2CHAr); 138.7; 141.3; 142.3 (3CAr); 180.0 (CO) 
MS (ESI, m/z): 365.2 [M-H]- 
 Synthesis of esters 84, 87-91 and 101-103 
(2R)-3-[(Diethoxyphosphoryl)oxy]-2-hydroxypropyl 10-phenyldecanoate, 84 
Following the general procedure 4.1.1.13, ester 84 was obtained from 
carboxylic acid 77 (136 mg, 0.55 mmol) and diol 83 (250 mg, 1.10 mmol) in 30% 
yield. Chromatography: dichloromethane/methanol, 200:1 to 50:1. 
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Rf: 0.45 (dichloromethane/methanol, 10:1) 
1H-NMR (CDCl3, 300 MHz):  1.28 (app s, 10H, 5CH2); 1.35 (td, J = 7.1, 0.9, 6H, 
2CH3); 1.55-1-62 (m, 4H, 2CH2); 2.33 (t, J = 7.6, 2H, CH2CO); 2.59 (t, J = 7.7, 2H, 
PhCH2); 4.02 – 4.26 (m, 9H, CH, 2CH2CH3, CH2OP, CH2CO2); 7.14-7.18 (m, 3H, 
3CHAr); 7.24-7.30 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  16.2 (d, J = 6.6, 2CH3); 25.0; 29.2; 29.4; 29.41; 29.5; 
29.6; 31.6 (7CH2); 34.2 (CH2CO); 36.1 (PhCH2); 64.4 (d, J = 1.9, 2CH2CH3); 64.5 
(CO2CH2); 68.8 (d, J = 5.7, CH2OP); 69.0 (d, J = 5.5, CH); 125.7 (CHAr); 128.3 
(2CHAr); 128.5 (2CHAr); 143.0 (CAr); 174.0 (CO) 
MS (ESI, m/z): 459.2 [M+H]+ 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 7-phenylheptanoate 
87 
 Following the general procedure 4.1.1.13, ester 87 was obtained from 7-
phenylheptanoic acid (35 mg, 0.17 mmol) and diol 86 (120 mg, 0.34 mmol) in 39% 
yield. Chromatography: dichloromethane/ethyl acetate, 100:1 to 7:3. 
 
Rf: 0.32 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3384 (O-H); 1736 (C=O); 1253 (P=O); 1007 (P-O) 
1H-NMR (C6D6, 300 MHz):  1.22-1.27 (m, 4H, 2CH2); 1.53-1.63 (m, 4H, 2CH2); 
2.20 (t, J = 7.5, 2H, CH2CO); 2.57 (t, J = 7.5, 2H, PhCH2); 4.11-4.21 (m, 3H, CH, 
CH2OP); 4.27-4.38 (m, 2H, CO2CH2); 4.47 (br s, 1H, OH); 5.00-5.14 (m, 4H, 
2OCH2Ph); 7.13-7.24 (m, 9H, 9CHAr); 7.29-7.35 (m, 6H, 6CHAr) 
13C-NMR (C6D6, 75 MHz):  25.1; 29.2; 29.22; 31.6 (4CH2); 34.1 (CH2CO); 36.2 
(PhCH2); 64.6 (CO2CH2); 69.0 (d, J = 5.5, CH); 69.4 (d, J = 5.8, CH2OP); 69.7 (d, J 
= 4.9, OCH2Ph); 69.74 (d, J = 5.1, OCH2Ph); 126.0 (CHAr); 128.4 (2CHAr); 128.41 
(2CHAr); 128.6 (2CHAr); 128.7 (2CHAr); 128.76 (2CHAr); 128.78 (4CHAr); 136.4 (d, J 
= 6.7, 2CAr); 142.9 (CAr); 173.1 (CO) 
31P-NMR (C6D6, 121 MHz):  3.65 
MS (ESI, m/z): 523.2 [M-H2O+H]+; 541.3 [M+H]+ 
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(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 8-phenyloctanoate, 
88 
Following the general procedure 4.1.1.13, ester 88 was obtained from 
carboxylic acid 80 (37 mg, 0.17 mmol) and diol 86 (120 mg, 0.34 mmol) in 53% 
yield. Chromatography: dichloromethane to dichloromethane/methanol, 95:5. 
 
Rf: 0.44 (dichloromethane/methanol, 95:5) 
IR (ATR): 3382 (O-H); 1738 (C=O); 1265 (P=O); 1016 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.22-1.35 (m, 6H, 3CH2); 1.48-1.64 (m, 4H, 
2CH2); 2.19-2.32 (m, 2H, CH2CO); 2.52-2.59 (m, 2H, PhCH2); 3.42-4.70 (m, 1H, 
½CH2OP); 3.91-4.36 (m, 4H, CH, ½CH2OP, CO2CH2); 5.01-5.10 (m, 4H, 
2OCH2Ph); 7.09-7.14 (m, 3H, 3CHAr); 7.20-7.25 (m, 2H, 2CHAr); 7.30-7.39 (m, 10H, 
10CHAr)  
13C-NMR (methanol-d4, 75 MHz):  26.0; 30.07; 30.1; 30.2; 32.6 (5CH2); 34.7 
(CH2CO); 36.9 (PhCH2); 65.4 (CO2CH2); 68.9 (d, J = 7.9, CH); 69.5 (d, J = 6.1, 
CH2OP); 70.9 (d, J = 5.9, 2OCH2Ph); 126.6 (CHAr); 129.2 (2CHAr); 129.24 (2CHAr); 
129.4 (4CHAr); 129.7 (4CHAr); 129.8 (2CHAr); 137.1 (d, J = 6.4, 2CAr); 143.9 (CAr); 
175.1 (CO) 
31P-NMR (methanol-d4, 121 MHz):  1.54 
[α]D20: +1.6 (c = 1.19, methanol) 
MS (ESI, m/z): 537.2 [M-H2O+H]+; 555.2 [M+H] + 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 9-phenylnonanoate, 
89 
Following the general procedure 4.1.1.13, ester 89 was obtained from 
carboxylic acid 81 (90 mg, 0.38 mmol) and diol 86 (271 mg, 0.76 mmol) in 58% 
yield. Chromatography: dichloromethane to dichloromethane/methanol, 95:5. 
 
Rf: 0.44 (dichloromethane/methanol, 95:5) 
IR (ATR): 3325 (O-H); 1736 (C=O); 1245 (P=O); 1013 (P-O) 
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1H-NMR (methanol-d4, 300 MHz):  1.25-1.35 (m, 8H, 4CH2); 1.55-1.64 (m, 4H, 
2CH2); 2.30 (t, J = 7.4, 2H, CH2CO); 2.58 (t, J = 7.7, 2H, PhCH2); 3.91-3.98 (m, 1H, 
CH); 3.98-4.03 (m, 2H, CH2OP); 4.07 (dd, J = 5.1, 1.5, 2H, CO2CH2); 5.05 (s, 2H, 
OCH2Ph); 5.08 (s, 2H, OCH2Ph); 7.10-7.16 (m, 3H, 3CHAr); 7.21-7.26 (m, 2H, 
2CHAr); 7.36 (app s, 10H, 10CHAr) 
13C-NMR (methanol-d4, 75 MHz):  26.8; 30.1; 30.2; 30.3; 30.4; 32.7 (6CH2); 34.9 
(CH2CO); 36.9 (PhCH2); 65.4 (CO2CH2); 68.9 (d, J = 8.0, CH); 69.6 (d, J = 6.4, 
CH2OP); 70.9 (d, J = 5.8, 2OCH2Ph); 126.6 (CHAr); 129.20 (4CHAr); 129.24 
(2CHAr); 129.4 (2CHAr); 129.7 (4CHAr); 129.8 (2CHAr); 137.2 (d, J = 6.5, 2CAr); 
144.0 (CAr); 175.2 (CO) 
31P-NMR (methanol-d4, 121 MHz):  1.61 
[α]D20: +0.02 (c = 0.65, methanol) 
MS (ESI, m/z): 551.2 [M-H2O+H]+; 569.3 [M+H] + 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 10-phenyl 
decanoate, 90 
Following the general procedure 4.1.1.13, ester 90 was obtained from 
carboxylic acid 77 (82 mg, 0.33 mmol) and diol 86 (233 mg, 0.66 mmol) in 16% 
yield. Chromatography: dichloromethane/ethyl acetate, 100:1 to 1:1. 
 
Rf: 0.43 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3028 (O-H); 1738 (C=O); 1022 (P-O) 
1H-NMR (C6D6, 300 MHz):  1.15-1.20 (m, 10H, 5CH2); 1.49-1.58 (m, 4H, 2CH2); 
2.11 (t, J = 7.5, 2H, CH2CO); 2.51 (t, J = 7.5, 2H, PhCH2); 3.95-4.06 (m, 3H, CH, 
CH2OP); 4.12-4.24 (m, 2H, CO2CH2); 4.86-5.00 (m, 4H, 2OCH2Ph); 7.03-7.12 (m, 
9H, 9CHAr); 7.16-7.22 (m, 6H, 6CHAr) 
13C-NMR (C6D6, 75 MHz):  25.2; 29.4; 29.6; 29.7; 29.8; 29.9; 31.9 (7CH2); 34.2 
(CH2CO); 36.4 (PhCH2); 64.6 (CO2CH2); 69.0 (d, J = 5.4, CH); 69.4 (d, J = 5.9, 
CH2OP); 69.7 (d, J = 5.0, OCH2Ph); 69.8 (d, J = 5.1, OCH2Ph); 126.0 (CHAr); 128.5 
(2CHAr); 128.6 (2CHAr); 128.8 (2CHAr); 128.83 (2CHAr); 128.9 (6CHAr); 136.4 (d, J = 
6.7, 2CAr), 143.0 (CAr); 173.2 (CO) 
31P-NMR (C6D6, 121 MHz):  3.92 
MS (ESI, m/z): 565.2 [M-H2O+H]+; 583.3 [M+H]+ 
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(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 15-phenyl 
pentadecanoate, 91 
Following the general procedure 4.1.1.13, ester 91 was obtained from 15-
phenylpentadecanoic acid (80 mg, 0.25 mmol) and diol 86 (177 mg, 0.50 mmol) in 
18% yield. Chromatography: dichloromethane/ethyl acetate, 100:1 to 1:1. 
 
Rf: 0.55 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3334 (O-H); 1740 (C=O); 1259 (P=O); 1017 (P-O) 
1H-NMR (C6D6, 500 MHz):  1.20-1.36 (m, 20H, 10CH2); 1.54-1.58 (m, 4H, 2CH2); 
2.10 (t, J = 7.5, 2H, CH2CO); 2.52 (t, J = 7.5, 2H, PhCH2); 3.84-3.89 (m, 1H, CH); 
3.91-3.99 (m, 2H, CH2OP); 4.07 (dd, J = 11.4, 5.3, 1H, ½CO2CH2); 4.11 (dd, J = 
11.4, 5.7, 1H, ½CO2CH2); 4.85-4.96 (m, 4H, 2OCH2Ph); 7.04-7.12 (m, 8H, 8CHAr); 
7.15-7.22 (m, 7H, 7CHAr) 
13C-NMR (C6D6, 125 MHz):  25.3; 29.5; 29.7; 29.72; 29.9; 30.0; 30.08; 30.1; 30.14 
(9CH2); 30.2 (2CH2); 32.0 (CH2); 34.2 (CH2CO); 36.4 (PhCH2); 64.5 (CO2CH2); 
69.2 (d, J = 4.8, CH); 69.4 (d, J = 5.6, CH2OP); 69.7 (d, J = 5.5, OCH2Ph); 69.74 
(d, J = 5.5, OCH2Ph); 126.2 (CHAr); 128.5 (4CHAr); 128.54 (2CHAr); 128.8 (2CHAr); 
128.84 (2CHAr); 128.9 (4CHAr); 136.4 (d, J = 6.5, 2CAr); 143.1 (CAr); 173.1 (CO) 
31P-NMR (C6D6, 121 MHz):  4.60 
MS (ESI, m/z): 653.4 [M+H]+ 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 7-biphenyl-4-yl 
heptanoate, 101 
Following the general procedure 4.1.1.13, ester 101 was obtained from 
carboxylic acid 93 (100 mg, 0.35 mmol) and diol 86 (249 mg, 0.71 mmol) in 17% 
yield. Chromatography: dichloromethane/ethyl acetate, 100:1 to 1:1. 
 
Rf: 0.54 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3385 (O-H); 1736 (C=O); 1259 (P=O); 1017 (P-O) 
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1H-NMR (C6D6, 300 MHz):  1.25-1.29 (m, 4H, 2CH2); 1.58-1.64 (m, 4H, 2CH2); 
2.21 (t, J = 7.5, 2H, CH2CO); 2.59 (t, J = 7.5, 2H, ArCH2); 4.11-4.19 (m, 3H, CH, 
CH2OP); 4.25-4.36 (m, 2H, CO2CH2); 4.41 (br s, 1H, OH); 4.97-5.11 (m, 4H, 
2OCH2Ph); 7.11-7.37 (m, 15H, 15CHAr); 7.58-7.65 (m, 4H, 4CHAr) 
13C-NMR (C6D6, 75 MHz):  25.1; 29.16; 29.2; 31.6 (4CH2); 34.1 (CH2CO); 35.8 
(ArCH2); 64.6 (CO2CH2); 68.9 (d, J = 5.6, CH); 69.3 (d, J = 5.7, CH2OP); 69.6 (d, J 
= 4.9, OCH2Ph); 69.7 (d, J = 5.1, OCH2Ph); 127.2 (CHAr); 127.3 (2CHAr); 127.4 
(2CHAr); 128.3 (2CHAr); 128.5 (2CHAr); 128.6 (2CHAr); 128.7 (4CHAr); 129.0 
(2CHAr); 129.2 (2CHAr); 136.3 (d, J = 6.7, 2CAr); 139.2; 141.7; 142.0 (3CAr); 173.1 
(CO) 
31P-NMR (C6D6, 121 MHz):  3.77 
MS (ESI, m/z): 599.7 [M-H2O+H]+; 617.7 [M+H]+ 
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 10-biphenyl-4-yl 
decanoate, 102 
Following the general procedure 4.1.1.13, ester 102 was obtained from 
carboxylic acid 96 (92 mg, 0.28 mmol) and diol 86 (200 mg, 0.57 mmol) in 24% 
yield. Chromatography: dichloromethane to dichloromethane/ethyl acetate, 6:4. 
 
Rf: 0.51 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 3384 (O-H); 1738 (C=O); 1259 (P=O); 1016 (P-O) 
1H-NMR (C6D6, 300 MHz):  1.17-1.24 (m, 10H, 5CH2); 1.54-1.62 (m, 4H, 2CH2); 
2.12 (t, J = 7.4, 2H, CH2CO); 2.51-2.58 (m, 2H, ArCH2); 4.00-4.07 (m, 3H, CH, 
CH2OP); 4.13-4.24 (m, 3H, CO2CH2, OH); 4.86-5.00 (m, 4H, 2OCH2Ph); 7.01-7.26 
(m, 15H, 15CHAr); 7.48-7.54 (m, 4H, 4CHAr) 
13C-NMR (C6D6, 75 MHz):  25.2; 29.5; 29.6; 29.7; 29.8; 29.9; 31.9 (7CH2); 34.2 
(CH2CO); 36.0 (ArCH2); 64.6 (CO2CH2); 69.0 (d, J = 5.4, CH); 69.4 (d, J = 5.9, 
CH2OP); 69.7 (d, J = 5.0, OCH2Ph); 69.74 (d, J = 5.0, OCH2Ph); 127.3 (CHAr); 
127.4 (2CHAr); 127.5 (2CHAr); 128.4 (2CHAr); 128.42 (2CHAr); 128.7 (2CHAr); 128.8 
(4CHAr); 129.1 (2CHAr); 129.3 (2CHAr); 136.4 (d, J = 6.7, 2CAr,); 139.3; 141.7; 142.1 
(3CAr); 173.2 (CO) 
31P-NMR (C6D6, 121 MHz):  3.93 
[α]D20: +0.7 (c = 1.5, methanol) 
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MS (ESI, m/z): 641.7 [M-H2O+H]+; 659.7 [M+H]+  
(2R)-3-{[Bis(benzyloxy)phosphoryl]oxy}-2-hydroxypropyl 13-biphenyl-4-yl 
tridecanoate, 103 
Following the general procedure 4.1.1.13, ester 103 was obtained from 
carboxylic acid 100 (104 mg, 0.28 mmol) and diol 86 (200 mg, 0.57 mmol) in 10% 
yield. Chromatography: dichloromethane/ethyl acetate, 100:1 to 1:1. 
 
Rf: 0.42 (dichloromethane/ethyl acetate, 8:2) 
IR (ATR): 1738 (C=O); 1260 (P=O); 1018 (P-O) 
1H-NMR (C6D6, 300 MHz):  1.14-1.30 (m, 16H, 8CH2); 1.54-1.64 (m, 4H, 2CH2); 
2.11 (t, J = 7.5, 2H, CH2CO); 2.57 (t, J = 7.5, 2H, ArCH2); 3.92 (br s, 2H, CH, OH); 
3.99 (dd, J = 10.0, 3.3, 2H, CH2OP); 4.15 (AB system, J = 11.3, 4.5, 2H, CO2CH2); 
4.84-5.00 (m, 4H, 2OCH2Ph); 7.03-7.27 (m, 15H, 15CHAr); 7.48-7.55 (m, 4H, 
4CHAr) 
13C-NMR (C6D6, 75 MHz):  25.3; 29.5 (2CH2); 29.7 (2CH2); 29.9; 30.0 (2CH2); 
30.1 (2CH2); 30.13; 32.0 (2CH2); 34.2 (CH2CO); 36.0 (ArCH2); 64.6 (CO2CH2); 69.1 
(d, J = 5.0, CH); 69.4 (d, J = 5.8, CH2OP); 69.7 (d, J = 5.0, OCH2Ph); 69.74 (d, J = 
5.1, OCH2Ph); 127.3 (CHAr); 127.4 (2CHAr); 127.5 (2CHAr); 128.4 (2CHAr); 128.41 
(2CHAr); 128.7 (2CHAr); 128.8 (4CHAr); 129.1 (2CHAr); 129.3 (2CHAr); 136.4 (d, J = 
6.8, 2CAr); 139.3; 141.8; 142.1 (3CAr); 173.1 (CO) 
31P-NMR (C6D6, 121 MHz):  4.61 
MS (ESI, m/z): 683.4 [M-H2O+H] +; 701.4 [M+H] + 
 Synthesis of final compounds 3a and 2f-j 
(1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl 10-phenyldecanoate, 3a 
Thoroughly dried diethyl phosphate 84 (76 mg, 0.17 mmol, 1 equiv) was 
dissolved in anhydrous dichloromethane (2 mL) and TMSBr (0.22 mL, 1.66 mmol, 
10 equiv) was added dropwise at room temperature. The reaction mixture was 
stirred for 4 h at room temperature, after which the solvent was evaporated at 
reduced pressure and the crude was redissolved in methanol (5 mL) and stirred for 
an additional hour. Evaporation of the solvent afforded compound 3a in 90% yield.  
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IR (ATR): 3360 (O-H); 1738 (C=O), 1199 (P=O); 1025 (P-OH) 
1H-NMR (methanol-d4, 500 MHz):  1.32 (m, 10H, 5CH2); 1.60-1.65 (m, 4H, 2CH2); 
2.37 (t, J = 7.3, 2H, CH2CO); 2.59 (t, J = 7.6, 2H, PhCH2); 3.58 (dd, J = 10.9, 5.9, 
1H, ½CH2Br); 3.66 (dd, J = 10.9, 4.9, 1H, ½CH2Br); 4.12-4.18 (m, 2H, CH2OP); 
5.14-5.19 (m, 1H, CH); 7.11-7.17 (m, 3H, 3CHAr); 7.23 (t, J = 7.5, 2H, 2CHAr) 
13C-NMR (methanol-d4, 125 MHz):  26.0; 30.1; 30.3; 30.31 (4CH2); 30.5 (2CH2); 
30.8 (CH2Br); 32.7 (CH2); 34.9 (CH2CO); 36.9 (PhCH2); 66.3 (d, J = 5.0, CH2OP); 
72.5 (d, J = 8.3, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 (CAr); 
174.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.10 
[α]D20: +1.6 (c = 0.5, methanol) 
HRMS (ESI, m/z): calculated for C19H2979BrO6P ([M(79Br)-H]-: 463.0891, found: 
463.0902; calculated for C19H2981BrO6P ([M(81Br)-H]-: 465.0870, found: 465.0880 
HPLC (method B, tR, min): 26.05 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 7-phenylheptanoate, 2f 
Following the general procedure 4.1.1.1, compound 2f was obtained from 
dibenzyl phosphate 87 (30 mg, 56 µmol) at room temperature in 85% yield.  
 
IR (ATR): 1737 (C=O); 1258 (P=O); 1025 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  1.33-1.36 (m, 4H, 2CH2); 1.56-1.67 (m, 4H, 
2CH2); 2.35 (t, J = 7.4, 2H, CH2CO); 2.60 (t, J = 7.5, 2H, PhCH2); 3.95-4.01 (m, 3H, 
CH, CH2OP); 4.10 (dd, J = 11.3, 5.4, 1H, ½CO2CH2); 4.17 (dd, J = 11.3, 4.3, 1H, 
½CO2CH2); 7.10-7.17 (m, 3H, 3CHAr); 7.21-7.26 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  25.9; 29.9; 30.0; 32.6 (4CH2); 34.8 (CH2CO); 
36.8 (PhCH2); 65.9 (CO2CH2); 68.1 (d, J = 5.7, CH2OP); 69.3 (d, J = 8.3, CH); 
126.6 (CHAr); 129.3 (2CHAr); 129.4 (2CHAr); 143.9 (CAr); 175.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.09 
[α]D20: +5.3 (c = 0.47, methanol) 
HRMS (ESI, m/z): calculated for C16H24O7P ([M-H]-): 359.1265, found: 359.1273 
HPLC (method B, tR, min): 21.72 
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(2R)-2-Hydroxy-3-(phosphonooxy)propyl 8-phenyloctanoate, 2g 
Following the general procedure 4.1.1.1, compound 2g was obtained from 
dibenzyl phosphate 88 (63 mg, 0.11 mmol) at room temperature in 80% yield.  
 
IR (ATR): 1737 (C=O); 1027 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.33 (app s, 6H, 3CH2); 1.58-1.60 (m, 4H, 
2CH2); 2.27-2.37 (m, 2H, CH2CO); 2.59 (t, J = 7.5, 2H, PhCH2); 3.59-3.61 (m, 3H, 
CH, CH2OP); 3.99-4.41 (m, 2H, CO2CH2); 7.10-7.16 (m, 3H, 3CHAr); 7.21-7.26 (m, 
2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  25.9; 30.07; 30.1; 30.2; 32.6 (5CH2); 34.8 
(CH2CO); 36.9 (PhCH2); 65.8 (CO2CH2); 68.1 (d, J = 5.0, CH2OP); 69.3 (br s, CH); 
126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 143.9 (CAr); 175.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.04 
[α]D20: +2.8 (c = 1.58, methanol) 
HRMS (ESI, m/z): calculated for C17H26O7P ([M-H]-): 373.1422, found: 373.1432 
HPLC (method A, tR, min): 8.07  
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 9-phenylnonanoate, 2h 
Following the general procedure 4.1.1.1, compound 2h was obtained from 
dibenzyl phosphate 89 (90 mg, 0.16 mmol) at room temperature in 99% yield.  
 
IR (ATR): 3355 (O-H); 1737 (C=O); 1259 (P=O); 1029 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.32 (app s, 8H, 4CH2); 1.60 (br s, 4H, 2CH2); 
2.34 (t, J = 7.4, 2H, CH2CO); 2.59 (t, J = 7.8, 2H, PhCH2); 3.67-3.79 (m, 1H, CH); 
3.98-4.00 (m, 2H, CH2OP); 4.07-4.21 (m, 2H, CO2CH2); 7.09-7.17 (m, 3H, 3CHAr); 
7.21-7.26 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  25.9; 30.1; 30.2; 30.3; 30.4; 32.7 (6CH2); 34.8 
(CH2CO); 36.9 (PhCH2); 65.8 (CO2CH2); 68.1 (d, J = 6.0, CH2OP); 69.3 (d, J = 8.3, 
CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 143.9 (CAr); 175.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.05 
[α]D20: +2.5 (c = 1.13, methanol) 
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HRMS (ESI, m/z): calculated for C18H28O7P ([M-H]-): 387.1578, found: 387.1591 
HPLC (method A, tR, min): 8.34 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 10-phenyldecanoate, 2i 
Following the general procedure 4.1.1.1, compound 2i was obtained from 
dibenzyl phosphate 90 (20 mg, 34 µmol) at room temperature in 80% yield.  
 
IR (ATR): 1739 (C=O); 1051 (P-OH) 
1H-NMR (methanol-d4, 500 MHz):  1.29-1.32 (m, 10H, 5CH2); 1.61 (m, 4H, 2CH2); 
2.35 (t, J = 7.5, 2H, CH2CO); 2.59 (t, J = 7.6, 2H, PhCH2); 3.96-4.01 (m, 3H, CH, 
CH2OP); 4.11 (dd, J = 11.3, 5.3, 1H, ½CO2CH2); 4.17 (dd, J = 11.3, 4.1, 1H, 
½CO2CH2); 7.11-7.16 (m, 3H, 3CHAr); 7.23 (t, J = 7.5, 2H, 2CHAr) 
13C-NMR (methanol-d4, 125 MHz):  26.0; 30.2; 30.3; 30.34 (4CH2); 30.5 (2CH2); 
32.7 (CH2); 34.9 (CH2CO); 36.9 (PhCH2); 65.9 (CO2CH2); 68.1 (d, J = 5.7, CH2OP); 
69.4 (d, J = 8.1, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 (CAr); 
175.4 (CO) 
31P-NMR (methanol-d4, 202 MHz):  3.14 
[α]D20: +2.3 (c = 0.4, methanol) 
HRMS (ESI, m/z): calculated for C19H30O7P ([M-H]-): 401.1735, found: 401.1734 
HPLC (method B, tR, min): 24.37 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 15-phenylpentadecanoate, 2j 
Following the general procedure 4.1.1.1, compound 2j was obtained from 
dibenzyl phosphate 91 (20 mg, 31 µmol) at room temperature in 90% yield.  
 
IR (ATR): 1738 (C=O); 1259 (P=O); 1083 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  1.28-1.32 (m, 20H, 10CH2); 1.57-1.64 (m, 4H, 
2CH2); 2.35 (t, J = 7.4, 2H, CH2CO); 2.59 (t, J = 7.5, 2H, PhCH2); 3.97-4.35 (m, 5H, 
CO2CH2, CH, CH2OP); 7.08-7.16 (m, 3H, 3CHAr); 7.21-7.26 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  26.0; 30.2; 30.3; 30.4; 30.59; 30.6; 30.7 (7CH2); 
30.73 (2CH2); 30.75 (2CH2); 32.8 (CH2); 34.9 (CH2CO); 36.9 (PhCH2); 64.9 
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(CO2CH2); 67.1 (d, J = 5.3, CH2OP); 68.3 (d, J = 8.3, CH); 126.6 (CHAr); 129.2 
(2CHAr); 129.4 (2CHAr); 144.0 (CAr); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.11 
[α]D20: +4.2 (c = 0.4, methanol) 
HRMS (ESI, m/z): calculated for C24H40O7P ([M-H]-): 471.2517, found: 471.2520 
HPLC (method B, tR, min): 33.42 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 7-biphenyl-4-ylheptanoate, 2k 
Following the general procedure 4.1.1.1, compound 2k was obtained from 
dibenzyl phosphate 101 (27 mg, 43 µmol) at room temperature in 74% yield.  
 
IR (ATR): 1720 (C=O); 1058 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  1.36-1.40 (m, 4H, 2CH2); 1.60-1.70 (m, 4H, 
2CH2); 2.36 (t, J = 7.4, 2H, CH2CO); 2.64 (t, J = 7.5, 2H, ArCH2); 3.97-4.01 (m, 3H, 
CH, CH2OP); 4.11 (dd, J = 11.3, 5.3, 1H, ½CO2CH2); 4.17 (dd, J = 11.3, 4.1, 1H, 
½CO2CH2); 7.24 (d, J = 8.1, 2H, 2CHAr); 7.30 (t, J = 7.5, 1H, CHAr); 7.40 (t, J = 7.6, 
2H, 2CHAr); 7.51 (d, J = 8.2, 2H, 2CHAr); 7.58 (d, J = 7.7, 2H, 2CHAr) 
13C-NMR (methanol-d4, 125 MHz):  25.9; 29.9; 30.0; 32.5 (4CH2); 34.9 (CH2CO); 
36.4 (ArCH2); 65.9 (CO2CH2); 68.1 (d, J = 5.4, CH2OP); 69.3 (d, J = 8.3, CH); 
127.8 (2CHAr); 127.84 (2CHAr); 128.0 (CHAr); 129.8 (2CHAr); 129.9 (2CHAr); 139.9; 
142.4; 143.1 (3CAr); 175.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.11 
[α]D20: +7.6 (c = 0.67, methanol) 
HRMS (ESI, m/z): calculated for C22H28O7P ([M-H]-): 435.1578, found: 435.1562 
HPLC (method B, tR, min): 26.61 
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 10-biphenyl-4-yldecanoate, 2l 
Following the general procedure 4.1.1.1, compound 2l was obtained from 
dibenzyl phosphate 102 (20 mg, 30 µmol) at room temperature in 85% yield.  
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IR (ATR): 3314 (O-H); 1654 (C=O); 1015 (P-O) 
1H-NMR (methanol-d4, 500 MHz,):  1.28-1.35 (m, 10H, 5CH2); 1.58-1.66 (m, 4H, 
2CH2); 2.35 (t, J = 7.4, 2H, CH2CO); 2.64 (t, J = 7.5, 2H, ArCH2); 3.96-4.00 (m, 3H, 
CH, CH2OP); 4.11 (dd, J = 11.4, 5.4, 1H, ½CO2CH2); 4.17 (dd, J = 11.4, 4.2, 1H, 
½CO2CH2); 7.24 (d, J = 8.1, 2H, 2CHAr); 7.29 (t, J = 7.4, 1H, CHAr); 7.40 (t, J = 7.7, 
2H, 2CHAr); 7.51 (d, J = 8.2, 2H, 2CHAr); 7.58 (dd, J = 8.3, 1.1, 2H, 2CHAr) 
13C-NMR (methanol-d4, 125 MHz):  26.0; 30.2; 30.3; 30.4; 30.5; 30.52; 32.7 
(7CH2); 34.9 (CH2CO); 36.5 (ArCH2); 65.9 (CO2CH2); 68.1 (d, J = 5.6, CH2OP); 
69.3 (d, J = 8.2, CH); 127.8 (2CHAr); 127.83 (2CHAr); 128.0 (CHAr); 129.8 (2CHAr); 
129.9 (2CHAr); 139.9; 142.5; 143.2 (3CAr); 175.4 (CO) 
31P-NMR (methanol-d4, 121 MHz):  3.11 
HRMS (ESI, m/z): calculated for C25H34O7P ([M-H]-): 477.2048, found: 477.2029 
HPLC (method A, tR, min): 10.49  
(2R)-2-Hydroxy-3-(phosphonooxy)propyl 13-biphenyl-4-yltridecanoate, 2m 
Following the general procedure 4.1.1.1, compound 2m was obtained from 
dibenzyl phosphate 103 (37 mg, 53 µmol) at room temperature as a white solid in 
91% yield.  
 
m.p.: 95-97ºC 
IR (ATR): 1730 (C=O); 1258 (P=O); 1027 (P-O) 
1H-NMR (DMSO-d6, 500 MHz):  1.23-1.29 (m, 16H, 8CH2); 1.49-1.52 (m, 2H, 
CH2); 1.57-1.60 (m, 2H, CH2); 2.28 (t, J = 7.4, 2H, CH2CO); 2.60 (t, J = 7.6, 2H, 
ArCH2); 3.35 (br s, 1H, OH); 3.73-3.76 (m, 2H, CH2OP); 3.79-3.85 (m, 1H, CH); 
3.94 (dd, J = 11.2, 6.0, 1H, ½CO2CH2); 4.02 (dd, J = 11.2, 4.3, 1H, ½CO2CH2); 
7.27 (d, J = 8.1, 2H, 2CHAr); 7.33 (t, J = 7.3, 1H, CHAr); 7.44 (t, J = 7.7, 2H, 2CHAr); 
7.56 (d, J = 8.1, 2H, 2CHAr); 7.63 (d, J = 7.3, 2H, 2CHAr) 
13C-NMR (DMSO-d6, 126 MHz):  26.4; 28.5; 28.6; 28.7; 28.8; 28.9 (6CH2); 28.98 
(2CH2); 29.0; 30.9 (2CH2); 33.4 (CH2CO); 34.7 (ArCH2); 64.9 (CO2CH2); 66.1 (d, J 
= 5.3, CH2OP); 67.3 (d, J = 7.8, CH); 126.4 (2CHAr); 126.5 (2CHAr); 127.1 (CHAr); 
128.85 (2CHAr); 128.87 (2CHAr); 137.5; 140.1; 141.6 (3CAr); 172.9 (CO) 
31P-NMR (DMSO-d6, 121 MHz):  2.16 
[α]D20: limited solubility in DMSO 
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HRMS (ESI, m/z): calculated for C28H40O7P ([M-H]-): 519.2517, found: 519.2508 
HPLC (method A, tR, min): 12.15 
4.1.6 Synthesis of final compounds 3b-d 
 Synthesis of bromoalcohols 105 and 109 
Dibenzyl (2R)-oxiran-2-ylmethyl phosphate, 104  
Following the general procedure 4.1.1.12, compound 104 was obtained from 
(2S)-oxiran-2-ylmethanol (0.3 mL, 4.52 mmol) and dibenzyl N,N-
diisopropylphosphoramidite (3.04 mL, 9.04 mmol) in 76% yield. Chromatography: 
dichloromethane to dichloromethane/ethyl acetate, 20:1. 
 
Rf: 0.35 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1275 (P=O); 1013 (P-O) 
1H-NMR (CDCl3, 300 MHz):  2.59 (dd, J = 4.8, 2.6, 1H, ½CH2 epox); 2.78 (t, J = 4.7, 
1H, ½CH2 epox); 3.04-3.25 (m, 1H, CH); 3.89 (ddd, J = 11.7, 8.5, 5.9, 1H, ½CH2OP); 
4.12-4.27 (m, 1H, ½CH2OP); 4.97-5.15 (m, 4H, 2PhCH2); 7.35 (app s, 10H, 
10CHAr) 
13C-NMR (CDCl3, 75 MHz):  44.7 (CH2 epox); 50.0 (d, J = 8.0, CH); 68.1 (d, J = 5.5, 
CH2OP); 69.6 (d, J = 5.3, PhCH2); 69.61 (d, J = 5.5, PhCH2); 128.1 (4CHAr); 128.7 
(6CHAr); 135.8 (d, J = 6.8, 2CAr) 
31P-NMR (CDCl3, 121 MHz):  2.03 
[α]D20: -8.8 (c = 1, methanol) 
MS (ESI, m/z): 335.9 [M+H]+ 
Dibenzyl (2S)-3-bromo-2-hydroxypropyl phosphate, 105 
Following the general procedure 4.1.1.16, bromoalcohol 105 was obtained 
from oxirane 104 (990 mg, 2.96 mmol) in 89% yield.  
 
Rf: 0.41 (dichloromethane/ethyl acetate, 10:1) 
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IR (ATR): 3371 (O-H); 1009 (P=O) 
1H-NMR (CDCl3, 300 MHz):  2.96 (br s, 1H, OH); 3.36 (d, J = 5.7, 2H, CH2Br); 
3.88-3.95 (m, 1H, CH); 4.06-4.12 (m, 2H, CH2OP); 5.00-5.12 (m, 4H, 2PhCH2); 
7.36 (app s, 10H, 10CHAr) 
13C-NMR (CDCl3, 75 MHz):  33.3 (CH2Br); 69.2 (d, J = 6.0, CH2OP); 69.7 (d, J = 
6.6, CH); 70.3 (d, J = 5.8, PhCH2); 70.4 (d, J = 5.6, PhCH2); 128.3 (4CHAr); 128.9 
(4CHAr); 129.1 (2CHAr); 135.3 (d, J = 6.3, 2CAr) 
31P-NMR (CDCl3, 121 MHz):  2.48 
[α]D20: -2.1 (c = 1.44, methanol) 
MS (ESI, m/z): 414.8 [M(79Br)+H]+; 416.8 [M(81Br)+H]+ 
Di-tert-butyl (2R)-oxiran-2-ylmethyl phosphate, 108 
Following the general procedure 4.1.1.12, compound 108 was obtained from 
(2S)-oxiran-2-ylmethanol (0.18 mL, 2.69 mmol) and di-tert-butyl N,N-
diisopropylphosphoramidite (1.7 mL, 5.39 mmol) in 52% yield. Chromatography: 
hexane to ethyl acetate.  
 
Rf: 0.5 (hexane/ethyl acetate, 1:1) 
IR (ATR): 1263 (P=O and ring st); 999 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.48 (s, 9H, 3CH3); 1.49 (s, 9H, 3CH3); 2.66 (dd, J = 
4.7, 2.6, 1H, ½CH2 epox); 2.83 (t, J = 4.7, 1H, ½CH2 epox); 3.21-3.27 (m, 1H, CH); 
3.85-3.94 (m, 1H, ½CH2OP); 4.10-4.18 (m, 1H, ½CH2OP) 
13C-NMR (CDCl3, 75 MHz):  29.9 (3CH3); 30.0 (3CH3); 44.9 (CH2 epox); 50.3 (d, J = 
9.0, CH); 67.4 (d, J = 5.8, CH2OP); 82.8 (d, J = 7.4, C); 82.83 (d, J = 7.4, C) 
31P-NMR (CDCl3, 121 MHz):  -6.90 
[α]D20: -9.2 (c = 1.02, methanol) 
MS (ESI, m/z): 289.0 [M+Na]+ 
(2S)-3-Bromo-2-hydroxypropyl di-tert-butyl phosphate, 109  
Following the general procedure 4.1.1.16, bromoalcohol 109 was obtained 
from oxirane 108 (210 mg, 0.79 mmol) in 95% yield.  
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Rf: 0.37 (hexane/ethyl acetate, 1:1) 
IR (ATR): 3342 (O-H); 1251 (P=O); 996 (P-O) 
1H-NMR (CDCl3, 300 MHz):  1.50 (s, 18H, 6CH3); 3.49 (d, J = 6.0, 2H, CH2Br); 
4.00-4.06 (m, 1H, CH); 4.12-4.17 (m, 2H, CH2OP); 6.34 (br s, 1H, OH) 
13C-NMR (CDCl3, 75 MHz):  29.9 (3CH3); 30.0 (3CH3); 33.4 (CH2Br); 68.5 (d, J = 
6.3, CH2OP); 70.1 (d, J = 6.2, CH); 84.5 (d, J = 7.4, C); 84.53 (d, J = 7.4, C) 
31P-NMR (CDCl3, 121 MHz):  -7.05  
[α]D20: +3.2 (c = 1.11, methanol) 
MS (ESI, m/z): 369.0 [M(79Br)+Na)]+; 371.0 [M(81Br)+Na)]+ 
 Synthesis of esters 106, 107 and 110 
(1S)-2-{[Bis(benzyloxy)phosphoryl]oxy}-1-(bromomethyl)ethyl 7-phenyl 
heptanoate, 106 
Following the general procedure 4.1.1.17, ester 106 was obtained from 7-
phenylheptanoic acid (80 mg, 0.39 mmol) and bromoalcohol 105 (161 mg, 0.39 
mmol) in 64% yield. Chromatography: dichloromethane to dichloromethane/ethyl 
acetate, 5:1. 
 
Rf: 0.79 (dichloromethane/ethyl acetate, 10:1) 
IR (ATR): 1741 (C=O); 1276 (P=O); 1015 (P-O) 
1H-NMR (C6D6, 300 MHz):  1.08-1.13 (m, 4H, 2CH2); 1.40-1.52 (m, 4H, 2CH2); 
2.08 (t, J = 7.5, 2H, CH2CO); 2.44 (t, J = 7.5, 2H, PhCH2); 3.04 (AB system, J = 
11.0, 5.5, 2H, CH2Br); 3.95-4.12 (m, 2H, CH2OP); 4.83-5.00 (m, 4H, 2OCH2Ph); 
5.01-5.08 (m, 1H, CH); 7.00-7.11 (m, 9H, 9CHAr); 7.15-7.23 (m, 6H, 6CHAr)  
13C-NMR (C6D6, 75 MHz):  25.0 (CH2); 29.1 (2CH2); 30.0 (CH2Br); 31.6 (CH2); 
34.1 (CH2CO); 36.2 (PhCH2); 66.3 (d, J = 5.3, CH2OP); 69.5 (d, J = 5.3, 
2OCH2Ph); 70.8 (d, J = 7.5, CH); 126.0 (CHAr); 128.4 (4CHAr); 128.6 (2CHAr); 128.7 
(2CHAr); 128.76 (2CHAr); 128.79 (4CHAr); 136.4 (d, J = 6.5, CAr); 136.5 (d, J = 6.5, 
CAr); 142.9 (CAr); 172.3 (CO) 
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31P-NMR (CDCl3, 121 MHz):  1.94 
MS (ESI, m/z): 602.8 [M(79Br)+h]+; 604.8 [M(81Br)+H]+ 
(1S)-2-{[Bis(benzyloxy)phosphoryl]oxy}-1-(bromomethyl)ethyl 15-phenyl 
pentadecanoate, 107  
Following the general procedure 4.1.1.17, ester 107 was obtained from 15-
phenylpentadecanoic acid (80 mg, 0.25 mmol) and bromoalcohol 105 (104 mg, 
0.25 mmol) in 50% yield. Chromatography: dichloromethane to 
dichloromethane/ethyl acetate, 5:1. 
 
Rf: 0.83 (dichloromethane/ethyl acetate, 10:1) 
IR (ATR): 1742 (C=O); 1263 (P=O); 1015 (P-O) 
1H-NMR (C6D6, )(300 MHz):  1.12-1.35 (m, 20H, 10CH2); 1.50-1.65 (m, 4H, 
2CH2); 2.13 (t, J = 7.5, 2H, CH2CO); 2.52 (t, J = 7.5, 2H, PhCH2); 3.06 (AB system, 
J = 11.0, 5.5, 2H, CH2Br); 3.95-4.13 (m, 2H, CH2OP); 4.84-5.00 (m, 4H, 
2OCH2Ph); 5.02-5.09 (m, 1H, CH); 7.01-7.24 (m, 15H, 15CHAr) 
13C-NMR (C6D6, )(75 MHz):  25.1; 29.3 (2CH2); 29.6 (2CH2); 29.9; 29.91; 29.95 
(3CH2); 30.0 (2CH2); 30.08 (CH2); 30.1 (2CH2); 32.0 (CH2); 34.1 (CH2CO); 36.3 
(PhCH2); 66.2 (d, J = 5.2, CH2OP); 69.4 (d, J = 5.4, 2OCH2Ph); 70.7 (d, J = 7.3, 
CH); 126.0 (CHAr); 128.3 (4CHAr); 128.6 (2CHAr); 128.63 (2CHAr); 128.7 (6CHAr); 
136.4 (d, J = 6.2, CAr); 136.5 (d, J = 6.3, CAr); 143.0 (CAr); 172.3 (CO) 
31P-NMR (CDCl3, 121 MHz):  3.24 
MS (MALDI, m/z): 737.2 [M(79Br)+Na]+; 739.2 [M(81Br)+Na]+ 
(1S)-2-Bromo-1-{[(di-tert-butoxyphosphoryl)oxy]methyl}ethyl (9Z)-octadec-9-
enoate, 110 
To a stirred solution of bromoalcohol 109 (80 mg, 0.23 mmol, 1.1 equiv) in 1.5 
mL of anhydrous dichloromethane at room temperature, pyridine (34 µL, 0.42 
mmol, 2 equiv) was added, followed by oleoyl chloride (69 µL, 0.21 mmol, 1 equiv). 
The reaction mixture was stirred overnight at room temperature. Afterward, the 
reaction mixture was concentrated under reduced pressure and purified by flash 
chromatography (alumina, hexane to hexane/ethyl acetate, 10:1) to afford pure 
ester 110 in 15% yield. 
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Rf: 0.64 (dichloromethane/ethyl acetate, 20:1) 
IR (ATR): 1744 (C=O); 1002 (P-O) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.5, 3H, CH3); 1.18-1.39 (m, 20H, 
10CH2); 1.49 (s, 18H, 6CH3); 1.57-1.71 (m, 2H, CH2); 1.95-2.06 (m, 4H, 
2CH2CHalkene); 2.35 (t, J = 7.7, 2H, CH2CO); 3.52 (dd, J = 10.9, 5.2, 1H, ½CH2Br); 
3.61 (dd, J = 10.9, 5.4, 1H, ½CH2Br); 4.05-4.20 (m, 2H, CH2OP); 5.15 (qt, J = 5.2, 
1H, CH); 5.27-5.43 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.3 (CH3); 22.8; 25.0 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 29.2; 29.24; 29.3 (3CH2); 29.5 (2CH2); 29.7; 29.8; 29.9 (3CH2); 
29.95 (3CH3); 30.0 (3CH3); 30.1 (CH2Br); 32.1 (CH2); 34.3 (CH2CO); 65.1 (d, J = 
5.9, CH2OP); 70.7 (d, J = 9.3, CH); 83.0 (d, J = 7.4, C); 83.05 (d, J = 7.4, C); 129.9; 
130.2 (2CHalkene); 172.9 (CO) 
31P-NMR (CDCl3, 121 MHz):  -7.14 
[α]D20: +4.9 (c = 0.66, methanol) 
MS (ESI, m/z): 633.3 [M(79Br)+Na]+; 635.3 [M(81Br)+Na]+ 
 Synthesis of final compounds 3b-d 
(1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl 7-phenylheptanoate, 3b 
Following the general procedure 4.1.1.1, compound 3b was obtained from 
dibenzyl phosphate 106 (114 mg, 0.19 mmol) at room temperature in 85% yield.  
 
IR (ATR): 1740 (C=O); 1026 (P-O) 
1H-NMR (methanol-d4, 300 MHz):  1.28-1.41 (m, 4H, 2CH2); 1.57-1.68 (m, 4H, 
2CH2); 2.37 (t, J = 7.3, 2H, CH2CO); 2.60 (t, J = 7.5, 2H, PhCH2); 3.55-3.68 (m, 2H, 
CH2Br); 4.10-4.18 (m, 2H, CH2OP); 5.12-5.21 (m, 1H, CH); 7.10-7.26 (m, 5H, 
5CHAr) 
13C-NMR (methanol-d4, 75 MHz):  25.9; 29.9; 29.94 (3CH2); 30.7 (CH2Br); 32.6 
(CH2); 34.9 (CH2CO); 36.8 (PhCH2); 66.3 (d, J = 5.1, CH2OP); 72.5 (d, J = 8.3, 
CH); 126.6 (CHAr); 129.3 (2CHAr); 129.4 (2CHAr); 143.9 (CAr); 174.3 (CO) 
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31P-NMR (methanol-d4, 121 MHz):  2.77 
[α]D20: +4.8 (c = 0.75, methanol) 
HRMS (ESI, m/z): calculated for C16H2379BrO6P ([M(79Br)-H]-): 421.0421, found: 
421.0435; calculated for C16H2381BrO6P ([M(81Br)-H]-): 423.0401, found: 423.0414 
HPLC (method B, tR, min): 24.23 
(1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl 15-phenylpentadecanoate, 3c 
Following the general procedure 4.1.1.1, compound 3c was obtained from 
dibenzyl phosphate 107 (70 mg, 98 µmol) at room temperature in 86% yield. 
 
IR (ATR): 1740 (C=O); 1027 (P-OH) 
1H-NMR (methanol-d4, 300 MHz):  1.21-1.43 (m, 20H, 10CH2); 1.52-1.71 (m, 4H, 
2CH2); 2.37 (t, J = 7.3, 2H, CH2CO); 2.59 (t, J = 7.5, 2H, PhCH2); 3.62 (AB system, 
J = 11.0, 5.5, 2H, CH2Br); 4.11-4.17 (m, 2H, CH2OP); 5.17 (qt, J = 5.0, 1H, CH); 
7.09-7.17 (m, 3H, 3CHAr); 7.20-7.27 (m, 2H, 2CHAr) 
13C-NMR (methanol-d4, 75 MHz):  26.0; 30.2; 30.3; 30.4 (4CH2); 30.6 (2CH2); 30.7 
(3CH2); 30.74 (3CH2); 32.8 (CH2); 34.9 (CH2CO); 36.9 (PhCH2); 66.3 (d, J = 5.0, 
CH2OP); 72.5 (d, J = 8.3, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 
(CAr); 174.3 (CO) 
31P-NMR (methanol-d4, 121 MHz):  2.76 
[α]D20: +1.2 (c = 1.03, methanol) 
HRMS (ESI, m/z): calculated for C24H3979BrO6P ([M(79Br)-H]-): 533.1673, found: 
533.1694; calculated for C24H3981BrO6P ([M(81Br)-H]-): 535.1654, found: 533.1673 
(1S)-2-Bromo-1-[(phosphonooxy)methyl]ethyl (9Z)-octadec-9-enoate, 3d 
Following the general procedure 4.1.1.7, compound 3d was obtained from di-
tert-butyl phosphate 110 (5 mg, 8.17 µmol) and TFA (15 µL, 204 µmol) without 
further purification in 81% yield.  
 
IR (ATR): 1739 (C=O); 1666 (C=C); 1071 (P-O) 
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1H-NMR (methanol-d4, 700 MHz):  0.90 (t, J = 7.0, 3H, CH3); 1.28-1.35 (m, 20H, 
10CH2); 1.62-1.65 (m, 2H, CH2CH2CO); 2.02-2.05 (m, 4H, 2CH2CHalkene); 2.37 (td, 
J = 7.4, 3.2, 2H, CH2CO); 3.60 (dd, J = 11.0, 6.1, 1H, ½CH2Br); 3.68 (dd, J = 11.0, 
4.6, 1H, ½CH2Br); 4.07-4.12 (m, 2H, CH2OP); 5.14-5.18 (m, 1H, CH); 5.32-5.37 
(m, 2H, 2CHalkene) 
13C-NMR (methanol-d4, 175 MHz):  14.5 (CH3); 23.8; 26.0 (2CH2); 28.1 
(2CH2CHalkene); 30.1; 30.2; 30.3; 30.4; 30.5; 30.6; 30.8; 30.9; 31.1; 33.1 (10CH2); 
35.0 (CH2CO); 66.0 (d, J = 3.1, CH2OP); 72.8 (d, J = 5.5, CH) 130.8; 130.9 
(2CHalkene); 174.4 (CO) 
31P-NMR (methanol-d4, 202 MHz):  3.36 
[α]D20: +3.3 (c = 0.33, methanol) 
HRMS (ESI, m/z): calculated for C21H3979BrO6P ([M(79Br)-H]-): 497.1673, found: 
497.1664; calculated for C21H3981BrO6P ([M(81Br)-H]-): 499.1653, found: 499.1642 
HPLC (method B, tR, min): 25.58 
4.1.7 Synthesis of final compounds 4a-c 
 Synthesis of final compound 4a 
(2S)-2-[(Benzyloxy)methyl]oxirane, 111 
To a suspension of NaH (65 mg, 1.62 mmol, 1.2 equiv, 60% dispersion in oil) 
in DMF (3 mL) at 0ºC, (2R)-oxiran-2-ylmethanol (100 mg, 1.35 mmol, 1 equiv) was 
added, followed by benzyl bromide (0.21 mL, 1.76 mmol, 1.3 equiv). The reaction 
was allowed to warm up to room temperature and stirred overnight. Afterward, 
water was added and the mixture was extracted with dichloromethane. The organic 
layer was washed with water and brine, dried over Na2SO4 and filtered. The 
solvent was evaporated under reduced pressure to afford product 111 in 
quantitative yield, which was used in the next step without further purification. 
Spectroscopic data correspond with those previously reported.113 
 
1H-NMR (CDCl3, 300 MHz):  2.62 (dd, J = 5.0, 2.7, 1H, ½CH2 epox); 2.81 (dd, J = 
4.9, 4.1, 1H, ½CH2 epox); 3.17-3.22 (m, 1H, CH); 3.45 (dd, J = 11.4, 5.8, 1H, 
½CH2O); 3.77 (dd, J = 11.4, 3.0, 1H, ½CH2O); 4.59 (dd, J = 19.4, 11.9, 2H, 
OCH2Ph); 7.27-7.39 (m, 5H, 5CHAr) 
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tert-Butyl (5S)-5-((benzyloxy)methyl)-2-oxotetrahydrofuran-3-carboxylate, 112 
Di-tert-butyl malonate (0.97 mL, 1.58 mmol, 2 equiv) was added dropwise to a 
stirred suspension of NaH (63 mg, 1.58 mmol, 2 equiv, 60% dispersion in oil) in a 
2:1 mixture of anhydrous DMF:THF (6 mL) at 0°C, and the mixture was stirred at 
room temperature for 30 minutes. A solution of 111 (130 mg, 0.79 mmol, 1 equiv) 
in dry THF (2 mL) was then added, and the resulting mixture was stirred at 80°C 
for 6 hours. After cooling to room temperature, the reaction was quenched by 
addition of a saturated aqueous solution of NH4Cl, diluted with water, and extracted 
with ethyl acetate. The organic phase was washed with brine, dried over Na2SO4, 
filtered and the solvents were removed under reduced pressure. The residue was 
purified by flash chromatography (dichloromethane) to afford lactone 112 in 62% 
yield.  
 
Rf: 0.36 (hexane/ethyl acetate, 9:1) 
IR (ATR): 1777 (C=O); 1729 (C=O); 1147 (C-O) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (3:2):  1.48 (s, 9H, 
3CH3 B); 1.49 (s, 9H, 3CH3 A); 2.36 (ddd, J = 13.0, 9.7, 4.7, 2H, CH2CHCO2tBuB); 
2.42-2.49 (m, 1H, ½CH2CHCO2tBuA); 2.60-2.70 (m, 1H, ½CH2CHCO2tBuA); 3.47-
3.71 (m, 3H, CHCO2tBu, OCH2CH); 4.50-4.65 (m, 3H, PhCH2, OCH2CHB); 4.71-
4.78 (m, 1H, OCH2CHA); 7.26-7.38 (m, 5H, 5CHAr) 
13C-NMR (CDCl3, 75 MHz):  28.0 (3CH3); 28.3 (CH2CHCO2tBuB); 28.5 
(CH2CHCO2tBuA); 47.6 (CHCO2tBuB); 47.8 (CHCO2tBuA); 71.2 (PhCH2); 73.6 
(OCH2CHB); 73.7 (OCH2CHA); 77.7 (OCH2CHB); 77.8 (OCH2CHA); 82.8 (CA); 82.9 
(CB); 127.7 (2CHAr A); 127.8 (2CHAr B); 127.9 (CHAr B); 128.0 (CHAr A); 128.6    
(2CHAr B); 128.62 (2CHAr A); 137.6 (CAr A); 137.7 (CAr B); 166.8 (CO2tBuB); 167.3 
(CO2tBuA); 171.9 (COlactone B); 172.6 (COlactone A) 
tert-Butyl (5S)-5-[(benzyloxy)methyl]-3-fluoro-2-oxotetrahydrofuran-3-
carboxylate, 113 
Following the general procedure 4.1.1.4, compound 113 was obtained from 
lactone 112 (1.70 g, 5.54 mmol) in 99% yield, which was used in the next step 
without further purification.  
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Rf: 0.80 (dichloromethane) 
IR (ATR): 1794 (C=O); 1756 (C=O); 1157 (C-F) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (2.3:1):  1.48 (s, 9H, 
3CH3 B); 1.50 (s, 9H, 3CH3 A); 2.48-2.81 (m, 2H, CH2CF); 3.60-3.76 (m, 2H, 
OCH2CH); 4.59 (s, 2H, PhCH2); 4.69-4.78 (m, 1H, CHA); 4.81-4.89 (m, 1H, CHB); 
7.29-7.38 (m, 5H, 5CHAr) 
13C-NMR (CDCl3, 75 MHz):  27.8 (3CH3 B); 27.9 (3CH3 A); 35.1 (d, J = 21.9, 
CH2CFB); 35.2 (d, J = 22.4, CH2CFA); 69.8 (PhCH2); 73.7 (OCH2CHB); 73.8 
(OCH2CHA); 76.5 (d, J = 4.9, CHA); 76.6 (CHB); 85.3 (C(CH3)3 B); 85.6 (C(CH3)3 A); 
127.7 (2CHAr B); 127.8 (2CHAr A); 128.0 (CHAr B); 128.1 (CHAr A); 128.56 (2CHAr B); 
128.59 (2CHAr A); 137.2 (CAr A); 137.5 (CAr B); 168.5 (d, J = 24.8, COlactone); (CF and 
CO2tBu not observed) 
MS (ESI, m/z): 342.1 [M+NH4]+ 
tert-Butyl (5S)-3-fluoro-5-(hydroxymethyl)-2-oxotetrahydrofuran-3-
carboxylate, 114 
 Following the general procedure 4.1.1.1, alcohol 114 was obtained from 113 
(480 mg, 1.48 mmol) at 60ºC in quantitative yield. 
 
Rf: 0.25 (dichloromethane) 
IR (ATR): 3318 (O-H); 1689 (C=O) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (1.2:1):  1.52 (s, 9H, 
3CH3); 2.51-2.95 (m, 2H, CH2CF); 3.66-3.75 (m, 1H, ½CH2OH); 3.96-4.03 (m, 1H, 
½CH2OH); 4.67-4.75 (m, 1H, CHB); 4.78-4.86 (m, 1H, CHA) 
13C-NMR (CDCl3, 75 MHz):  27.9 (3CH3); 34.2 (d, J = 22.4) and 34.3 (d, J = 21.9) 
(CH2CF); 62.5 and 62.8 (CH2OH); 78.2 (d, J = 4.7) and 78.9 (CH); 85.5 and 85.7 
(C(CH3)3); 92.2 (d, J = 198) and 92.4 (d, J = 199, CF); 164.5 (d, J = 26.9, CO2tBu); 
168.7 (d, J = 25.0, COlactone) 
MS (ESI, m/z): 177.9 [M-tBu]+; 159.9 [M-F-tBu]+ 
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tert-Butyl (5S)-3-fluoro-2-oxo-5-{[(10-phenyldecanoyl)oxy]methyl} 
tetrahydrofuran-3-carboxylate, 115 
Following the general procedure 4.1.1.17, ester 115 was obtained from 
carboxylic acid 77 (64 mg, 0.26 mmol) and alcohol 114 (60 mg, 0.26 mmol) in 35% 
yield. Chromatography: dichloromethane.  
 
Rf: 0.85 (dichloromethane) 
IR (ATR): 1743 (C=O); 1156 (C-F) 
1H-NMR (CDCl3, 300 MHz): Mixture of diastereoisomers A:B (1.7:1):  1.28-1.29 
(m, 10H, 5CH2); 1.53 (s, 9H, 3CH3 B); 1.54 (s, 9H, 3CH3 A); 1.58-1.63 (m, 4H, 
2CH2); 2.36 (t, J = 7.6, 2H, CH2CO); 2.41-2.91 (m, 2H, CH2CF); 2.59 (t, J = 7.8, 
2H, PhCH2); 4.17-4.28 (m, 1H, ½CO2CH2 B); 4.24 (dd, J = 11.4, 5.4, 1H, ½CO2CH2 
A); 4.39 (app t, J = 3.6, 1H, ½CO2CH2 A); 4.43 (app t, J = 3.7, 1H, ½CO2CH2 B); 
4.79-4.86 (m, 1H, CHB); 4.87-4.96 (m, 1H, CHA); 7.16-7.18 (m, 3H, 3CHAr); 7.24-
7.30 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  24.9 (CH2); 28.0 (3CH3); 29.2; 29.3; 29.4; 29.5; 29.6; 
31.6 (6CH2); 34.1 (CH2CO); 35.1 (d, J = 22.8) and 35.14 (d, J = 21.8, CH2CF); 36.1 
(PhCH2); 63.6 and 63.9 (CO2CH2); 75.1 (d, J = 4.6) and 75.7 (CH); 85.7 and 85.9 
(C(CH3)3); 125.7 (CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 143.02 and 143.04 (CAr); 
164.3 (CO2tBu); 167.8 (d, J = 23.8, COlactone); 173.4 and 173.45 (CO); (CF not 
observed) 
MS (ESI, m/z): 482.3 [M+NH4]+ 
(5S)-3-Fluoro-2-oxo-5-{[(10-phenyldecanoyl)oxy]methyl}tetrahydrofuran-3-
carboxylic acid, 4a 
Following the general procedure 4.1.1.7, compound 4a was obtained from 
tert-butyl ester 115 (30 mg, 65 µmol) and TFA (0.37 mL, 4.84 mmol) in 90% yield.  
 
IR (ATR): 3506 (O-H); 1795 (C=O); 1795 (C=O); 1741 (C=O) 
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1H-NMR (CDCl3, 500 MHz): Mixture of diastereoisomers:  1.26-1.30 (m, 10H, 
5CH2); 1.59-1.62 (m, 4H, 2CH2); 2.36 (t, J = 7.3, 2H, CH2CO); 2.49-3.06 (m, 2H, 
CH2CF); 2.59 (t, J = 7.7, 2H, PhCH2); 4.28-4.30 (m, 1H, ½CO2CH2); 4.42 (m, 1H, 
½CO2CH2); 4.95 (m, 1H, CH); 7.16-7.18 (m, 3H, 3CHAr); 7.25-7.28 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 125 MHz):  24.9; 29.2; 29.3; 29.4; 29.5; 29.6; 31.6 (7CH2); 34.0 
and 34.1 (CH2CO); 35.1 (br d, J = 25.0, CH2CF); 36.1 (PhCH2); 63.5 and 63.9 
(CO2CH2); 75.6 (br s) and 76.3 (CH); 125.6 and 125.7 (CHAr); 128.4 (2CHAr); 128.5 
(2CHAr); 143.0 and 143.1 (CAr); 168.0 (br s, CO2H and COlactone); 173.6 and 173.8 
(CO); (CF not observed) 
HRMS (ESI, m/z): calculated for C22H28FO6 ([M-H]-): 407.1875, found: 407.1875 
HPLC (method A, tR, min): 10.31 
 Synthesis of final compound 4b 
Di-tert-butyl fluoro{(2S)-2-hydroxy-3-[(10-phenyldecanoyl)oxy]propyl} 
malonate, 116 
 Following the general procedure 4.1.1.13, ester 116 was obtained from 
carboxylic acid 77 (65 mg, 0.26 mmol) and diol 43 (161 mg, 0.52 mmol) in 75% 
yield. Chromatography: dichloromethane to dichloromethane/methanol, 99:1. 
 
Rf: 0.43 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3387 (O-H); 1743 (C=O); 1154 (C-F) 
1H-NMR (CDCl3, 300 MHz):  1.29 (m, 10H, 5CH2); 1.50 (s, 18H, 6CH3); 1.56-1.62 
(m, 4H, 2CH2); 2.17-2.44 (m, 2H, CH2CF); 2.33 (t, J = 7.5, 2H, CH2CO); 2.59 (t, J = 
7.8, 2H, PhCH2); 4.00-4.20 (m, 3H, CH, CO2CH2); 7.17 (d, J = 6.5, 3H, 3CHAr); 
7.24-7.27 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  25.0 (CH2); 27.9 (3CH3); 28.0 (3CH3); 29.2; 29.4; 
29.41; 29.5; 29.6; 31.6 (6CH2); 34.3 (CH2CO); 36.1 (PhCH2); 37.5 (d, J = 20.8, 
CH2CF); 65.4 (d, J = 3.5, CH); 68.0 (CO2CH2); 83.9; 84.0 (2C(CH3)3); 93.2 (d, J = 
196.7, CF); 125.7 (CHAr); 128.3 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 165.2 (d, J = 
24.6, CO2tBu); 165.6 (d, J = 25.9, CO2tBu); 173.9 (CO) 
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Di-tert-butyl fluoro{(2S)-2-methoxy-3-[(10-phenyldecanoyl)oxy]propyl} 
malonate, 117  
Following the general procedure 4.1.1.8, compound 117 was obtained from 
116 (100 mg, 0.19 mmol) in 30% yield. Chromatography: hexane to hexane/ethyl 
acetate, 8:2. 
 
Rf: 0.73 (hexane/ethyl acetate, 8:2) 
IR (ATR): 1707 (C=O); 1163 (C-F) 
1H-NMR (CDCl3, 300 MHz):  1.25-1.29 (m, 10H, 5CH2); 1.48 (s, 9H, 3CH3); 1.49 
(s, 9H, 3CH3); 1.58-1.62 (m, 4H, 2CH2); 2.16-2.50 (m, 2H, CH2CF); 2.32 (t, J = 7.5, 
2H, CH2CO); 2.59 (t, J = 7.7, 2H, PhCH2); 3.30 (s, 3H, OCH3); 3.57-3.65 (m, 1H, 
CH); 4.05 (dd, J = 11.7, 4.8, 1H, ½CO2CH2); 4.17 (dd, J = 11.7, 4.6, 1H, 
½CO2CH2); 7.14-7.19 (m, 3H, 3CHAr); 7.24-7.29 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  25.0 (CH2); 27.9 (3CH3); 27.92 (3CH3); 29.3; 29.4; 
29.42; 29.5; 29.6; 31.6 (6CH2); 34.3 (CH2CO); 36.1 (PhCH2); 36.7 (d, J = 21.4, 
CH2CF); 57.8 (OCH3); 64.9 (CO2CH2); 74.0 (d, J = 3.4, CH); 83.4; 83.6 (2C(CH3)3); 
92.6 (d, J = 195.4, CF); 125.7 (CHAr); 128.4 (2CHAr); 128.5 (2CHAr); 143.0 (CAr); 
165.2 (d, J = 27.5, CO2tBu); 165.24 (d, J = 23.9, CO2tBu); 173.7 (CO) 
[α]D20: +3.0 (c = 1.69, methanol) 
MS (MALDI, m/z): 570.9 [M+NH4]+ 
Fluoro{(2S)-2-methoxy-3-[(10-phenyldecanoyl)oxy]propyl}malonic acid, 4b 
Following the general procedure 4.1.1.7, compound 4b was obtained from di-
tert-butyl ester 117 (44 mg, 80 µmol) and TFA (0.46 mL, 5.97 mmol) without further 
purification in 68% yield.  
 
IR (ATR): 3342 (O-H); 1736 (C=O) 
1H-NMR (methanol-d4, 300 MHz):  1.28-1.31 (m, 10H, 5CH2); 1.58-1.62 (m, 4H, 
2CH2); 2.22-2.54 (m, 2H, CH2CF); 2.34 (t, J = 7.4, 2H, CH2CO); 2.59 (t, J = 7.7, 
2H, PhCH2); 3.32 (s, 3H, OCH3); 3.60-3.65 (m, 1H, CH); 4.04 (dd, J = 11.8, 4.8, 
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1H, ½CO2CH2); 4.25 (dd, J = 11.7, 4.1, 1H, ½CO2CH2); 7.09-7.16 (m, 3H, 3CHAr); 
7.21-7.26 (m, 2H, 2CHAr) 
13C-NMR (CDCl3, 75 MHz):  26.0; 30.1; 30.2; 30.3 (4CH2); 30.5 (2CH2); 32.7 
(CH2); 34.9 (CH2CO); 36.9 (PhCH2); 38.1 (d, J = 21.3, CH2CF); 58.1 (OCH3); 65.8 
(CO2CH2); 75.8 (d, J = 3.4, CH); 126.6 (CHAr); 129.2 (2CHAr); 129.4 (2CHAr); 144.0 
(CAr); 175.2 (CO); (CF and CO2H not observed) 
[α]D20: limited solubility in DMSO 
HRMS (ESI, m/z): calculated for C23H32FO6 ([M-H]-): 439.2138, found: 439.2119 
HPLC (method A, tR, min): 10.25  
 Synthesis of final compound 4c 
Di-tert-butyl fluoro{(2S)-3-[(9Z)-hexadec-9-enoyloxy]-2-hydroxypropyl} 
malonate, 118 
Following the general procedure 4.1.1.13, ester 118 was obtained from 
palmitoleic acid (95 mg, 0.37 mmol) and diol 43 (230 mg, 0.75 mmol) in 44% yield. 
Chromatography: dichloromethane to dichloromethane/methanol, 8:2.  
 
Rf: 0.61 (hexane/ethyl acetate, 8:2) 
IR (ATR): 3401 (O-H); 1744 (C=O); 1150 (C-F) 
1H-NMR (CDCl3, 300 MHz):  0.86 (t, J = 6.6, 3H, CH3); 1.28 (m, 16H, 8CH2); 1.48 
(s, 18H, 6CH3); 1.58-1.63 (m, 2H, CH2CH2CO); 1.96-2.02 (m, 4H, 2CH2CHalkene); 
2.16-2.49 (m, 2H, CH2CF); 2.32 (t, J = 7.5, 2H, CH2CO); 3.97-4.18 (m, 3H, CH, 
CO2CH2); 5.27-5.38 (m, 2H, 2CHalkene) 
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8; 25.0 (2CH2); 27.2; 27.3 
(2CH2CHalkene); 27.8 (3CH3); 27.9 (3CH3); 29.1; 29.19; 29.2; 29.3; 29.8; 29.83; 31.9 
(7CH2); 34.2 (CH2CO); 37.5 (d, J = 20.7, CH2CF); 65.3 (d, J = 3.5, CH); 68.0 
(CO2CH2); 83.9; 84.0 (2C(CH3)3); 93.1 (d, J = 198.2, CF); 129.8; 130.1 (2CHalkene); 
165.3 (d, J = 24.6, CO2tBu); 165.7 (d, J = 25.8, CO2tBu); 173.9 (CO) 
[α]D20: +6.7 (c = 1.04, methanol) 
MS (ESI, m/z): 562.4 [M+NH4]+; 567.4 [M+Na]+ 
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Di-tert-butyl fluoro{(2S)-3-[(9Z)-hexadec-9-enoyloxy]-2-methoxypropyl} 
malonate, 119 
Following the general procedure 4.1.1.8, compound 119 was obtained from 
118 (86 mg, 0.16 mmol) in 27% yield. Chromatography: hexane to hexane/ethyl 
acetate, 8:2. 
 
Rf: 0.81 (hexane/ethyl acetate, 8:2) 
1H-NMR (CDCl3, 300 MHz):  0.88 (t, J = 6.7, 3H, CH3); 1.29 (m, 16H, 8CH2); 1.48 
(s, 9H, 3CH3); 1.49 (s, 9H, 3CH3); 1.60-1.64 (m, 2H, CH2CH2CO); 1.97-2.01 (m, 
4H, 2CH2CHalkene); 2.17-2.50 (m, 2H, CH2CF); 2.33 (t, J = 7.6, 2H, CH2CO); 3.30 (s, 
3H, OCH3); 3.57-3.64 (m, 1H, CH); 4.05 (dd, J = 11.6, 4.9, 1H, ½CO2CH2); 4.17 
(dd, J = 11.6, 4.7, 1H, ½CO2CH2); 5.28-5.39 (m, 2H, 2CHalkene)  
13C-NMR (CDCl3, 75 MHz):  14.2 (CH3); 22.8; 25.0 (2CH2); 27.3; 27.4 
(2CH2CHalkene); 27.9 (3CH3); 27.91 (3CH3); 29.1 (CH2); 29.2 (2CH2); 29.3; 29.8; 
29.9; 31.9 (4CH2); 34.3 (CH2CO); 36.7 (d, J = 21.2, CH2CF); 57.8 (OCH3); 64.9 
(CO2CH2); 74.0 (d, J = 3.4, CH); 83.2; 83.6 (2C(CH3)3); 92.6 (d, J = 195.3, CF); 
129.9; 130.1 (2CHalkene); 165.2 (d, J = 27.3, CO2tBu); 165.2 (d, J = 24.0, CO2tBu); 
173.7 (CO)  
Fluoro{(2S)-3-[(9Z)-hexadec-9-enoyloxy]-2-methoxypropylmalonic acid, 4c 
Following the general procedure 4.1.1.7, compound 4c was obtained from di-
tert-butyl ester 119 (20 mg, 36 µmol) and TFA (0.21 mL, 2.68 mmol) without further 
purification in 93% yield. 
 
IR (ATR): 1740 (C=O); 1164 (C-F) 
1H-NMR (methanol-d4, 300 MHz):  0.90 (t, J = 6.3, 3H, CH3); 1.29-1.32 (m, 16H, 
8CH2); 1.57-1.64 (m, 2H, CH2CH2CO); 2.02-2.04 (m, 4H, 2CH2CHalkene), 2.10-2.59 
(m, 2H, CH2CF); 2.35 (t, J = 7.4, 2H, CH2CO); 3.32 (s, 3H, OCH3); 3.60-3.67 (m, 
1H, CH), 4.04 (dd, J = 11.8, 4.8, 1H, ½CO2CH2); 4.25 (dd, J = 11.7, 4.1, 1H, 
½CO2CH2); 5.29-5.39 (m, 2H, 2CHalkene) 
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13C-NMR (methanol-d4, 75 MHz):  14.4 (CH3); 23.7; 26.0 (2CH2); 28.1; 28.2 
(2CH2CHalkene); 30.0 (CH2); 30.1 (2CH2); 30.2; 30.8; 30.82; 32.9 (4CH2); 34.9 
(CH2CO); 38.3 (d, J = 21.3, CH2CF); 58.1 (OCH3); 65.9 (CO2CH2); 75.9 (br s, CH); 
130.8; 130.9 (2CHalkene); 175.2 (CO); (CF and CO2H not seen) 
[α]D20: +14.1 (c = 0.79, methanol) 
HRMS (ESI, m/z): calculated for C23H38FO7 ([M-H]-): 445.2607, found: 445.2618 
HPLC (method A, tR, min): 11.89 
4.2 Biological assays 
Collagen, poly-D-lysine, poly-L-lysine and LPA were purchased from Aldrich. 
Ionomycin was purchased from Cayman. RH7777 hepatoma cells stably 
expressing the LPA1 receptor and their corresponding non-transfected controls 
were kindly provided by Prof. Gabor Tigyi (University of Tennessee Health Science 
Center, Memphis, Tennessee) and B103 neuroblastoma cells were provided by 
Prof. Jerold Chun (The Scripps Research Institute, La Jolla, California). Retrovirus 
expression vector (LZRS-EGFP) and Phoenix retrovirus producer cell lines were 
provided by Prof. Garry P. Nolan (Stanford University, Stanford, California). 
4.2.1 Cell culture 
All reagents were from Gibco. All cells were grown in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% 
non-essential aminoacids, 1% sodium pyruvate, 100 U/mL penicillin, and 100 
g/mL streptomycin in a 5% CO2 humidified atmosphere at 37 ºC. For passage, 
cells were rinsed with phosphate buffered saline (PBS) and incubated with 0.125% 
trypsin, 0.02% EDTA solution for 2 min at 37 ºC. Detached cells were resuspended 
in growth medium, counted if necessary and splitted onto fresh dishes. 
4.2.2 Generation of LPA1-5 overexpressing cell lines 
Cell lines stably expressing LPA1-5 receptors were generated by retroviral 
infection of B103 cells. Lipofectamine 2000 transfection reagent (Invitrogen) was 
used to transfect the Phoenix ecotropic packaging cell line with retroviral constructs 
expressing FLAG-tagged human LPA1-3 and LPA5, and mouse LPA4 cDNAs and 
EGFP. An internal ribosomal entry site (IRES) allowed dual expression of both the 
LPA1-5 receptors and EGFP. Retroviral supernatant was harvested 48 h post-
transfection, filtered through a 0.45 µm filter and added to B103 cells in the 
presence of Polybrene (Sigma). Cells were centrifugued for 90 minutes at 28ºC, 
after which the retroviral supernatant was replaced by DMEM. B103 cells 
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expressing high levels of LPA1-5 and high levels of EGFP were isolated by FACS 
using a Vantage DiVa I instrument. Control B103 cells transfected with empty 
vector were also obtained and used as control throughout the experiments. 
4.2.3 Evaluation of receptor activation by Ca2+ mobilization assay 
Changes in intracellular calcium levels were measured by using the 
fluorescent calcium sensitive dye Fluo-4NW (Invitrogen). RH7777 cells or B103 
cells were plated on poly-D-lysine or collagen-coated, respectively, black-wall 
clear-bottom 96-well plates (Corning) at a density of 50000 cells/well and cultured 
overnight. The culture medium was then replaced with Fluo-4 NW dye loading 
solution containing 2.5 µM of probenecid and incubated for 30 minutes at 37ºC 
followed by an additional 30 minutes at room temperature. Fluorescence changes 
were registered in a FluoStar Optima instrument (BMG Labtech) at 525 nm using 
an excitation wavelength of 494 nm. Each well was monitored for 240 s. 20 µL of 
the test compound from a 6x stock solution in assay buffer were added after 120 s 
of starting the measurement. Ca2+ transient increase was quantified by calculating 
the difference between maximum and baseline values for each well. As positive 
controls, 10 µM LPA and 10 µM ionomycin were included in every experiment. At 
this concentration, LPA induced a response about 30-33% of the one shown by 
ionomycin, which is in agreement with previously described results.99  
The data presented are from two to four independent experiments carried out 
in triplicate or quadruplicate. Dose-response curves were generated and 
EC50 values calculated by nonlinear regression analysis using PRISM software 
version 5 (GraphPad Software Inc, San Diego, CA, USA). 
4.2.4 Receptor internalization and neurite retraction assay 
B103 neuroblastoma cells overexpressing LPA1 receptor were plated on poly-
L-lysine-coated glass coverslips in 24-well plates (5·104 cells per well) and serum-
starved overnight. For the experiment, media was replaced with 1 mL fresh serum-
free DMEM, supplemented with 0.1% FAF BSA, 1 µM LPA, or compound. After 15 
minutes, cells were fixed with 4% paraformaldehyde and permeabilized with 
0.025% Triton X-100/PBS for 15 min. F-actin was detected with rhodamine-
phalloidin (Sigma) in PBS and nuclei with DAPI (Sigma). For neurite retraction, 
samples were visualized on a fluorescence microscopy (Carl Zeiss). For receptor 
internalization cells were analysed using confocal fluorescence microscopy (Carl 
Zeiss). 
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4.2.5 Migration assay 
Cell migration was measured in Transwell chambers (PET membrane with 8 
µm pore size, Becton Dickinson). Bottom membrane of transwells was precoated 
overnight at 4 °C with 10 μg/ml of collagen solution in PBS. B103 neuroblastoma 
cells overexpressing LPA1 receptor were serum-starved overnight, and then 
harvested with 0.125% trypsin containing 0.02% EDTA, washed once, counted and 
resuspended in serum-free DMEM. The cells were seeded into the upper chamber 
(2.5·105 cells per transwell), and 0.1% FAF BSA, 1 µM LPA or compound under 
study were placed in the lower chamber. Cells were allowed to migrate for 5 h at 
37°C. Non-migrated cells were removed from the top filter surface with a cotton 
swab. Migrated cells attached to the underside of the transwells were washed with 
PBS, stained with 0.1% crystal violet solution and counted under a microscope.  
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 RESUMEN 
5.1 Introducción 
La función biológica de los fosfolípidos ha estado tradicionalmente 
relacionada con un papel estructural, ya que son uno de los componentes 
mayoritarios de las membranas biológicas. Sin embargo, recientemente se ha 
descubierto la implicación de algunos de ellos en la regulación de procesos 
fisiológicos y patológicos de importancia.1,2 
Los fosfolípidos se dividen en dos familias: (i) glicerofosfolípidos,3 basados en 
el esqueleto de glicerol y (ii) esfingofosfolípidos, en el aminoalcohol esfingosina. 
Todos ellos presentan una cabeza polar con un grupo fosfato y dos cadenas 
hidrofóbicas. Cuando una de estas dos cadenas no está presente, las moléculas 
derivadas se denominan lisofosfolípidos. Estas moléculas, a pesar de su presencia 
minoritaria en el cuerpo humano, están ganando atención e importancia debido a 
su capacidad de señalizar a través de GPCRs. De entre ellas, destacan el ácido 
lisofosfatídico (LPA) y la esfingosina 1-fosfato (S1P), por su relevante papel en 
diversos procesos fisiológicos y patológicos.4  
 
Figura 1. Estructura general de los glicerofosfolípidos (A) y esfingofosfolípidos (B). 
Estructura del LPA (C) y S1P (D).  
En el caso del LPA, destacan sus efectos en el sistema nervioso central, los 
cuales parecen mediados fundamentalmente por el receptor LPA1. Éste fue 
identificado como el primer receptor de LPA en 1996, y en la actualidad se han 
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identificado cinco subtipos adicionales de este receptor (LPA2-LPA6). Los subtipos 
LPA1-LPA3 comparten una elevada similitud entre sí, mientras que el LPA4 y el 
LPA5 presentan notables diferencias en cuanto a homología de secuencia. 
El receptor LPA1 (364 aminoácidos, masa molecular 41 kDa) está expresado 
principalmente en el sistema nervioso, y también se ha detectado en diversos 
tejidos tales como corazón, placenta, bazo, riñón, colon, intestino, próstata, 
testículo, ovario, páncreas, músculo esquelético y timo. El receptor LPA1 está 
acoplado a tres tipos de proteínas G (Gi/o, Gq y G12/13) y su activación induce un 
amplio número de respuestas celulares.  
El LPA1 está presente de forma mayoritaria en la mayoría de los tipos 
celulares del sistema nervioso tanto en condiciones fisiológicas como patológicas. 
En el cerebro, el LPA1 se localiza de forma preferente en células progenitoras 
neuronales (NPCs, neural progenitor cells), jugando un papel importante en el 
desarrollo del cerebro embrionario, el cual está relacionado con la posterior 
aparición de enfermedades neuropsiquiátricas. Asimismo, su expresión en 
oligodendrocitos lo relaciona con el proceso de mielinización y el dolor 
neuropático.34  
Además de su papel en el sistema nervioso, el receptor LPA1 ha sido 
recientemente relacionado con el desarrollo de enfermedades tales como la 
fibrosis, la artritis reumatoide, la obesidad o el cáncer.  
Dada la implicación del receptor LPA1 en diversas patologías, el 
descubrimiento de ligandos potentes y selectivos es crucial para determinar su 
potencial como diana terapéutica. Sin embargo, hasta este momento no existe 
ningún fármaco en el mercado que actúe sobre los receptores de LPA. El único 
fármaco dirigido a un receptor lisofosfolipídico es Fingolimod (Gilenya®), un pan-
agonista de S1P, comercializado para el tratamiento de la esclerosis múltiple.  
 
Aunque en los últimos años se han descrito una gran variedad ligandos 
agonistas y antagonistas para los receptores del LPA, todos ellos presentan una 
selectividad muy limitada y han sido escasamente validados in vivo. Estos 
compuestos pueden clasificarse dos grandes tipos: (i) miméticos del LPA y (ii) 
pequeñas moléculas no lipídicas identificadas mediante high throughput screening.  
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Entre los primeros, destaca el ligando NAEPA (2-[(9Z)-octadec-9-
enoilamino]etil dihidrogeno fosfato), el primer agonista descrito para LPA, con 
actividad en los receptores LPA1 y LPA2.68 Algunas de las modificaciones 
estructurales de este ligando han permitido mejorar la actividad, obteniéndose 
tanto agonistas como antagonistas. Como ejemplo, cabe destacar el ligando 
VPC51098, un antagonista dual de los receptores LPA1 y LPA3 con actividad 
nanomolar.82 Otro importante análogo de LPA es el bromofosfonato denominado 
BrP-LPA, un pan-antagonista de los receptores LPA1-4 e inhibidor de autotaxina in 
vitro.83 Ésta molécula ha contribuido a elucidar la implicación de los receptores de 
LPA en la inhibición del crecimiento tumoral, así como de la atenuación de la 
artritis en modelos animales.  
 
Entre las moléculas no lipídicas destaca Ki16425, un antagonista dual de 
LPA1/3 que presenta actividad in vivo.86 Las variaciones en el esqueleto de esta 
molécula han sido ampliamente estudiadas, destacando los antagonistas BMS-
986020 y SAR100842, que actualmente están en fases clínicas para el tratamiento 
de la fibrosis y la esclerosis sistémica, respectivamente.58,66 
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Por tanto, para contribuir a la elucidación de los roles del receptor LPA1 tanto 
en condiciones fisiológicas como patológicas, es necesario desarrollar agonistas y 
antagonistas potentes y selectivos, lo que constituye el principal objetivo de este 
trabajo.  
5.2 Objetivos 
En este proyecto de Tesis Doctoral se pretende validar el receptor de ácido 
lisofosfatídico LPA1 como diana terapéutica. Para ello, en primer lugar, se 
abordará el diseño de ligandos utilizando como punto de partida la estructura del 
LPA. Así, se han diseñado dos series de compuestos de estructura general I y II. 
Estos ligandos serán evaluados como agonistas del receptor LPA1, estudiándose 
también su posible carácter antagonista así como su selectividad frente a los 
demás receptores de LPA. Asimismo, para los agonistas óptimos, se llevarán a 
cabo diversos ensayos celulares. 
5.3 Resultados y discusión 
En la etapa inicial de este proyecto, la información disponible acerca de los 
receptores de LPA era muy escasa, ya que no se conocía la estructura 3D de 
ninguno de ellos, ni se habían descrito ligandos potentes y selectivos. Por tanto, la 
búsqueda de nuevas moléculas con actividad en el receptor LPA1 se basó en la 
modificación de la estructura del ligando endógeno LPA. Para ello, se diseñaron 
inicialmente dos series de compuestos: la serie I, en la que se modifica el grupo 
ácido, y la serie II, que incluye modificaciones en la subunidad hidrofóbica (Figura 
2) 
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Figura 2. Diseño de nuevos ligandos para el receptor LPA1. 
5.3.1 Diseño y síntesis de la serie I 
Diversos estudios de relación estructura-actividad40 destacan la dificultad de 
modificar el grupo fosfato del LPA para lograr ligandos con alta actividad, 
subrayando la importancia de la existencia de cargas negativas a pH fisiológico, 
así como de mantener un pKa similar al del grupo fosfato. De hecho, esta parte de 
la molécula ha sido extensamente modificada sin haberse logrado resultados 
positivos hasta el momento. Por tanto, en la serie I se planteó la sustitución del 
grupo fosfato por otros fragmentos miméticos de éste, tales como ácidos 
carboxílicos y borónicos (Figura 3).96  
 
Figura 3. Grupos ácidos propuestos para la serie I. 
Para ello, en primer lugar se sintetizaron los fragmentos de glicerol 
necesarios para su posterior reacción de esterificación regioselectiva con el 
cloruro del ácido oleico (Esquema 1). La desprotección del éster carboxílico con 
ácido trifluoroacético (TFA) permitió la obtención del producto final deseado 1a. 
Sin embargo, en el caso de los ésteres malónicos, el tratamiento con TFA condujo 
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a la formación de las lactonas 1b y 1c, como mezcla de diastereoisómeros en 
proporción 1:1, por reacción de ciclación intramolecular del ácido carboxílico con el 
grupo hidroxilo en posición γ. Finalmente, el producto 1d se obtuvo mediante la 
transformación del derivado de éster de pinacolboronato en la correspondiente sal 
de trifluoroborato, seguido de hidrólisis en presencia de cloruro de trimetilsilano 
para obtener el ácido borónico.  
 
Esquema 1 
Los compuestos obtenidos 1a-d se ensayaron como agonistas del receptor 
LPA1, empleando para ello un ensayo de movilización de calcio en una línea 
celular que sobreexpresa dicho receptor.  
5.3.2 Determinación de la actividad agonista de los compuestos 1a-d por el 
receptor LPA1 
La capacidad para activar el receptor LPA1 se determinó mediante 
experimentos de movilización de calcio en células RH7777 transfectadas de 
forma estable con este receptor, puesto que tanto el LPA como los ligandos 
agonistas producen un aumento en los niveles de calcio intracelular, y esta 
variación puede ser cuantificada mediante el empleo de sondas fluorescentes. 
Tras diversas optimizaciones experimentales, finalmente se seleccionó la sonda 
Fluo-4NW para monitorizar la concentración intracelular de calcio. Para ello, las 
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células se incubaron en presencia de dicha sonda y de los compuestos objeto de 
estudio y se midió la intensidad de fluorescencia (longitud de onda de excitación 
de 494 nm y de emisión de 516 nm). Como control positivo se empleó ionomicina 
10 µM y como control negativo se realizó el experimento con células RH7777 no 
transfectadas con el receptor LPA1.  
Los compuestos se ensayaron a una dosis fija de 10 µM, expresándose la 
activación máxima del receptor (Emax) como porcentaje respecto a la respuesta 
inducida por el LPA a una concentración de 10 µM. La curva dosis-respuesta se 
determinó para aquellos compuestos con Emax mayor de 30%. 
Este experimento permitió identificar al compuesto 1c como agonista del 
receptor LPA1, con un valor de activación máxima del receptor (Emax) del 33% y 
un valor de concentración efectiva 50 (EC50) de 1.7 µM. Por tanto, con objeto de 
obtener los derivados del ácido malónico propuestos inicialmente y evitar el 
proceso de ciclación intramolecular, se sintetizaron los compuestos 1e-g, 
siguiendo el procedimiento que se indica en el Esquema 2. De entre ellos, 
destaca el compuesto 1g con EC50 = 6 µM.  
 
Esquema 2 
En resumen, la modificación del grupo ácido del LPA ha permitido identificar 
dos agonistas del receptor LPA1, 1c (Emax = 33%; EC50 = 1.7 µM) y 1g (Emax = 
74%; EC50 = 6 µM), confirmando que es posible mimetizar el grupo fosfato 
presente en el ligando endógeno LPA con otras subunidades polares. Con objeto 
de seguir optimizando la estructura, se estudió a continuación la influencia de la 
cadena hidrofóbica.  
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5.3.3 Diseño y síntesis de la serie II 
Para la serie II, se estudió exhaustivamente la influencia de la subunidad 
hidrofóbica, incluyendo cambios en la longitud total de la cadena de ácido graso, 
así como la incorporación de anillos aromáticos, según se indica en la Figura 4.  
 
Figura 4. Diseño de los compuestos de la serie II. 
 Derivados de la serie II que contienen cadenas alifáticas 
La modificación de la longitud total de la cadena hidrofóbica implicó la síntesis 
de los correspondientes ácidos alquinilcarboxílicos para su posterior 
semihidrogenación. El fragmento de glicerol fosforilado se sintetizó empleando el 
grupo terc-butilo como protector del grupo fosfato (Esquema 3).  
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Esquema 3. (A) Esquema restrosintético. (B) Síntesis de las cadenas alifáticas. (C) 
Obtención del fragmento de glicerol fosforilado 
Finalmente, los ácidos miristoleico (n = 3) y palmitoleico (n = 5) comerciales, 
así como los ácidos carboxílicos preparados previamente se esterificaron con el 
fragmento de glicerol, seguido de la desprotección del grupo fosfato por 
tratamiento con TFA, para obtener los productos finales 2a-e (Esquema 4). Una 
vez sintetizados, se determinó la actividad agonista de los nuevos compuestos en 
el receptor LPA1 (Tabla 1).  
 
Esquema 4 
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Tabla 1. Actividad agonista de los compuestos 2a-e en el receptor LPA1 
 
La Tabla 1 muestra la gran influencia que ejerce la longitud de la cadena 
hidrofóbica en la actividad, con cambios apreciables incluso en variaciones de 
una única unidad metilénica. De estos datos se desprende que la cadena óptima 
es la correspondiente al ácido (9Z)-hexadec-9-enoico, presente en el derivado 2b 
(Emax = 205%; EC50 = 0.45 µM), que es el compuesto más potente de la serie y 
con mejores valores de actividad que el propio LPA (Emax = 100%; EC50 = 0.83 
µM). 
 Derivados de la serie II que contienen anillos aromáticos 
La síntesis de estos derivados implicó la preparación de los ácidos 
carboxílicos no comerciales, así como la síntesis del fragmento de glicerol, 
empleando en este caso el grupo etilo como protector del grupo fosfato.  
 
Compuesto 
 
Emax (%)a EC50 (µM)b 
2a 
 
127± 1 2.8 ± 0.1 
2b 
 
205 ± 9 0.45 ± 0.01 
2c 
 
202 ± 1 2.1 ± 0.3 
2d 
 
88 ± 2 3.63 ± 0.2 
2e 
 
N.E.c - 
LPA 
 
100 0.83 ± 0.02 
aEmax = eficacia máxima del compuesto/eficacia máxima del LPA, expresado como porcentaje.
 
bPara Emax > 30%, los valores de EC50 corresponden al valor medio ± E.E. obtenido en un 
mínimo de dos experimentos independientes realizados por triplicado. cNo se observa efecto a 
la máxima concentración ensayada (10 µM). 
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Esquema 5. (A) Síntesis de los ácidos carboxílicos no comerciales. (B) Síntesis del 
fragmento de glicerol fosforilado.  
Con el objeto de acceder a los productos finales diseñados, en primer lugar 
se llevó a cabo la reacción de esterificación entre el ácido 10-fenilcarboxílico y el 
glicerol fosforilado, obteniéndose el éster correspondiente. La desprotección del 
grupo fosfato de dicho éster se realizó empleando bromuro de trimetilsililo, lo que 
condujo al producto final bromado 3a en lugar de al derivado deseado (Esquema 
6). La formación de este derivado bromado a partir del correspondiente fosfato de 
dietilo se puede explicar considerando una migración de la cadena acilo al grupo 
hidroxilo secundario y la posterior sustitución nucleófila del grupo hidroxilo 
primario por bromuro. 
 
Esquema 6 
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A pesar de que se ensayaron distintas condiciones de reacción para la 
desprotección del fosfato de dietilo, en ningún caso fue posible aislar el producto 
deseado, por lo cual se modificó la ruta sintética prevista, empleándose en este 
caso el grupo bencilo como protector del grupo fosfato para la síntesis de los 
productos finales 2f-j (Esquema 7).  
 
Esquema 7 
En el caso de los compuestos 2k-m, que presentan un resto de bifenilo en su 
estructura, su obtención se detalla en el Esquema 8, siguiendo un planteamiento 
análogo al de los derivados de fenilo. 
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Esquema 8 
Los nuevos compuestos 2f-m y 3a fueron ensayados como agonistas del 
receptor LPA1. Los datos obtenidos sugieren de nuevo una estrecha relación entre 
actividad y longitud de la cadena (Tabla 2). En este caso, de entre todos los 
compuestos analizados, destacan los derivados 2i y 3a, que presentan nueve 
unidades metilénicas en su cadena, con Emax > 100% y valores de EC50 de 0.5 y 
0.24 µM, respectivamente.  
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Tabla 2. Actividad agonista de los compuestos 2f-m y 3a en el receptor LPA1 
 
Compuesto  
 
Emax (%)a EC50 (µM)b 
2f 
 
N. E.c - 
2g 
 
N. E. - 
2h 
 
74 ± 4 2.1 ± 0.3 
2i 
 
112 ± 3 0.5 ± 0.1 
2j 
 
N. E. - 
2k 
 
N. E. - 
2l 
 
127 ± 9 3.3 ± 0.6 
2m 
 
37 ± 1 19 ± 2 
3a 
 
118 ± 24 0.24 ± 0.09 
LPA 
 
100 0.83 ± 0.02 
aEmax = eficacia máxima del compuesto/eficacia máxima del LPA, expresado como porcentaje.
 
bPara Emax > 30%, los valores de EC50 corresponden al valor medio ± E.E. obtenido en un 
mínimo de dos experimentos independientes realizados por triplicado. cNo se observa efecto a 
la máxima concentración ensayada (10 µM). 
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 Análogos de 3a 
Considerando la excelente actividad mostrada por el derivado 3a (Emax = 
118%, EC50 = 0.24 µM) se decidió extender el estudio de esta estructura, 
analizando tanto cambios en la longitud de la cadena alifática, como la 
introducción de la cadena de ácido oleico. Así, se sintetizaron los compuestos 3b-
d (Esquema 9) 
 
Esquema 9 
De entre los compuestos sintetizados, únicamente el derivado 3d presentó 
actividad agonista frente al receptor LPA1 (Emax = 39%; EC50 = 3.2 µM) 
5.3.4 Combinación de las subunidades ácidas e hidrofóbicas 
La combinación de los fragmentos presentes en los compuestos que 
resultaron más activos en el receptor LPA1 (1c, 1g, 2b, 2i, 2l, 3a y 3d, Figura 5A) 
sirvió como punto de partida para el comienzo del proceso de combinación (Figura 
5B). Los derivados 4a-c fueron sintetizados como se indica en los Esquemas 10-
12 y evaluados como agonistas del receptor LPA1. Únicamente el compuesto 4c 
fue capaz de activar el receptor LPA1 (Emax = 43 %, EC50 = 1.4 µM). 
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Figura 5. (A) Estructura de los compuestos 1c, 1g, 2b, 2i, 2l, 3a y 3d. (B) Diseño de 
nuevos compuestos mediante combinación de las subunidades hidrofóbicas y los grupos 
ácidos óptimos. 
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Esquema 10 
 
Esquema 11 
 
Esquema 12 
En resumen, en este trabajo de investigación se han identificado nuevos 
agonistas con actividad en el receptor LPA1. A partir de las dos series propuestas 
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para mimetizar el grupo fosfato (serie I) y la cadena hidrofóbica (serie II) del 
ligando endógeno LPA se han identificado nuevos esqueletos capaces de activar 
el receptor. Estos resultados han permitido comenzar con el proceso hit to lead, el 
cual se encuentra actualmente en curso en nuestro grupo de investigación.  
De entre todos los compuestos obtenidos hasta el momento, el derivado 3a 
destaca como el primer agonista estructuralmente diferente al ligando LPA, con 
excelentes valores de actividad, por lo que fue seleccionado para una 
caracterización biológica más profunda.  
5.3.5 Determinación de la actividad antagonista en el receptor LPA1 
La necesidad de antagonistas para el estudio del receptor LPA1 en diversos 
procesos biológicos y patológicos es clara. Dado que pequeños cambios 
estructurales provocan cambios de actividad entre agonistas y antagonistas, 
todos los compuestos que resultaron inactivos como agonistas en el receptor 
LPA1 fueron evaluados como antagonistas en dicho receptor.  
Para ello, células RH7777 transfectadas de forma estable con el receptor 
LPA1 se incubaron en presencia de la sonda Fluo 4-NW y de los compuestos 
objeto de estudio a una dosis fija de 10 µM. A continuación se añadió LPA 10 µM 
y la capacidad antagonista se determinó como la disminución en la intensidad de 
fluorescencia en la señal del LPA. Ninguno de los compuestos analizados 
presentó una actividad antagonista significativa.  
5.3.6 Selectividad sobre otros receptores 
Con objeto de determinar la selectividad de los compuestos sintetizados a lo 
largo de la presente Tesis Doctoral por los diferentes subtipos de los receptores de 
LPA (LPA1-5) se generaron cinco líneas celulares que sobreexpresan de forma 
estable uno de los cinco subtipos de receptores de LPA (LPA1-5) mediante 
transfección de células B103 con el plásmido correspondiente que contiene el 
receptor de interés LPA1-5 fusionado a la proteína verde fluorescente (enhanced 
green fluorescent protein, EGFP). Las células con mayor expresión de EGFP 
fueron seleccionadas mediante citometría de flujo. Este trabajo se llevó a cabo 
durante una estancia predoctoral en el laboratorio del Prof. Jerold Chun, en The 
Scripps Research Institute (La Jolla, California). 
Hasta este momento, se ha completado el análisis de la actividad de todos los 
compuestos sintetizados en el receptor LPA2. De entre los derivados analizados, 
siete compuestos presentaron actividad por este receptor. La Tabla 3 resume los 
Resumen 
  - 165 - 
compuestos activos identificados hasta el momento. Cabe destacar que el 
compuesto 3a no presenta actividad por el receptor LPA2.  
 
Tabla 3. Actividad agonista de los compuestos en los receptores LPA1 y LPA2 
  LPA1  LPA2  
Compuesto Emax (%)a EC50 (µM)b Emax (%) EC50 (µM) 
1c 
 
33 ± 5 1.7 ± 0.2 N. E. c  - 
1g 
 
74 ± 14 6 ± 1 N. E. - 
2a 
 
127 ± 1 2.8 ± 0.1 42 ± 5 8.1 ± 0.8 
2b 
 
205 ± 9 0.45 ± 0.01 N. E. - 
2c 
 
202 ± 1 2.1 ± 0.3 N. E. - 
2d 
 
88 ± 2 3.6 ± 0.2 N. E. - 
2h 
 
74 ± 4 2.1 ± 0.3 59 ± 2 12 ± 2 
2i 
 
112 ± 3 0.5 ± 0.1 74 ± 6 5.3 ± 0.6 
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Tabla 3 (cont.). Actividad agonista de los compuestos en los receptores LPA1 y LPA2 
 LPA1 LPA2 
Compuesto Emax (%)
a EC50 (µM)b Emax (%)a EC50 (µM)b 
2l 
 
127 ± 9 3.3 ± 0.6 N. E. - 
2m 
 
37 ± 1 19 ± 2 N. E. - 
3a 
 
118 ± 24 0.24 ± 0.09 N. E.  - 
3c 
 
N. E.  - 57 ± 7 5 ± 1 
3d 
 
39 ± 3 3.2 ± 0.4 67 ± 8 4.9 ± 0.2 
4b 
 
N. E.  - 55 ± 10  4.8 ± 0.1 
4c 
 
43 ± 6  1.4 ± 0.4 81 ± 1 10.8 ± 0.8 
aEmax = eficacia máxima del compuesto/eficacia máxima del LPA, expresado como porcentaje.
 bPara 
Emax > 30%, los valores de EC50 corresponden al valor medio ± E.E. obtenido en un mínimo de dos 
experimentos independientes realizados por triplicado. cNo se observa efecto a la máxima 
concentración ensayada (10 µM). 
 
5.3.7 Caracterización in vitro del compuesto 3a 
La activación del receptor LPA1 a través de proteínas G provoca diversas 
respuestas celulares tales como cambios en la morfología de la célula, que en el 
caso de las células neuronales B103 consisten en la pérdida de las 
prolongaciones que exhiben en condiciones normales para adquirir una 
morfología esférica.17 Otras de las respuestas estudiadas fueron la migración 
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celular106 y la internalización del receptor tras su estimulación. De entre los 
compuestos ensayados, el compuesto 3a presenta un comportamiento 
comparable al del ligando endógeno LPA en los ensayos de internalización, 
migración y redondeamiento celular. El compuesto 1c se ensayó también con 
fines comparativos. Las Figuras 6, 7 y 8 muestran algunos ejemplos 
representativos.  
 
Figura 6. Redondeamiento celular ejercido por el compuesto 3a. Porcentaje de células 
redondeadas (A). Imágenes representativas obtenidas tras el tratamiento con FAF BSA 
0.1% (B), LPA 1 µM (C), 3a 10 µM (D), 3a 1 µM (E). Escala: 100 µm. 
 
 
Figura 7. Experimento de migración celular para los compuestos 3a y 1c a 10 µM. 
Cuantificación de la migración celular (A). Imágenes representativas obtenidas tras el 
tratamiento con FAF BSA 0.1% (B), LPA 1 µM (C), 3a 10 µM (D), 1c 10 µM (E). Escala: 50 
µm.  
 
C 
D E 
A B 
B C 
D E 
A 
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Figura 8. Internalización del receptor LPA1 tras el tratamiento con 3a 1 µM (A) o LPA 1 µM 
(B). Las células se tiñeron con DAPI y faloidina para observar su morfología y se 
visualizaron con un microscopio confocal Zeiss (escala 10 µm).  
 
5.4 Conclusiones 
En el presente trabajo de investigación se han identificado nuevos agonistas 
con actividad en el receptor LPA1. A partir de las dos series propuestas para 
mimetizar el grupo ácido y la cadena hidrofóbica del ligando endógeno LPA se han 
obtenido nuevos esqueletos capaces de activar el receptor. En cuanto a la 
combinación de subestructuras, la identificación del compuesto 4c, con buenos 
valores de actividad, es un punto de partida para continuar con el proceso de 
optimización.  
De entre todos los compuestos sintetizados, el derivado 3a destaca como el 
primer agonista estructuralmente diferente del ligando endógeno con una 
excelente capacidad para activar el receptor en sistemas celulares.  
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 SUMMARY 
6.1 Background and aims 
Lysophospholipids are lipid molecules that are receiving growing attention 
because, in addition to their structural function in the cell membrane, they are now 
regarded as important regulators for diverse biological functions through activation 
of specific receptors.4 These receptors have been characterized during the last two 
decades as G protein-coupled receptors (GPCRs) and, among them, two families 
stand out: lysophosphatidic acid (LPA1-6) and sphingosine 1-phoshate (S1P1-5) 
receptors. Despite their interest, the high structural similarity between them has 
restrained the development of selective and high affinity ligands and therefore the 
elucidation of the role of these receptors in the central nervous system (CNS). This 
work will focus on the LPA receptors and, in particular, on the LPA1 subtype, 
considering its prominent expression in the CNS34 and the lack of potent and 
selective agonists and antagonists that allow for the elucidation of its 
(patho)physiological roles.  
6.2 Results and discussion 
6.2.1 Synthesis of new ligands for the LPA1 receptor 
At the moment of starting this project, little information about this novel 
signalling system was available. No receptor 3D structures had been elucidated 
and, although several structure-activity relationship (SAR) studies had been carried 
out,40 no potent ligands for the LPA1 receptor had been described, especially in the 
agonist field. In this context, we focused our efforts on finding molecular entities 
with activity at this receptor, using as starting point the structure of the endogenous 
ligand, LPA. Initially, two series of compounds were designed: series I, which 
comprised changes in the acid group, and series II, which included modifications in 
the hydrophobic unit.  
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Figure 31. Design of new LPA1 ligands. 
It has been shown that changes in the polar head of LPA are poorly tolerated 
which is confirmed by the few potent agonists described for this receptor despite 
the variety of phosphate replacements tried. Thus, phosphorous-free isosters, 
specifically carboxylic and boronic acids were chosen as acidic replacements.96 
Compounds belonging to series I were synthesized according to Scheme 1. It must 
be noted that the reaction conditions employed for the obtention of these 
derivatives led to the formation of lactones 1b and 1c instead of the expected 
malonic acids. 
 
Scheme 1 
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In order to determine the agonist capacity of the synthesized compounds, 
calcium mobilization assays in RH7777 cells stably transfected with LPA1R were 
carried out. Activation of LPA1R induces a transient increase in the intracellular 
Ca2+ levels which was detected by fluorescence. Parallel experiments using vector-
transfected cells were carried out in order to rule out non-LPA1R mediated effects. 
From this initial set of compounds only compound 1c activated the receptor, 
with an Emax of 33% and an EC50 value of 1.7 µM. Accordingly, it was necessary 
to confirm if the non-cyclic malonic derivatives originally proposed, with two free 
carboxylic acids, would exhibit better activities at LPA1 receptor. In order to avoid 
cyclization, compounds 1e-g were prepared (Scheme 2). Among them, 
compound 1g stands out, with an EC50 value of 6 µM.  
 
Scheme 2 
Regarding series II, several studies show that modifications on this part of the 
molecule are less critical for activity at LPA1 receptor, probably because its flexible 
disposition facilitates its fitting into the LPA1 receptor pocket. Thus, a 
comprehensive study of the influence of the hydrophobic moeity was carried out, 
including modifications on the overall length of the fatty acid chain as well as the 
incorporation of aromatic rings (Scheme 3).  
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Scheme 3 
Compounds 2a-m and the unexpectedly obtained 3a were tested for their 
agonist activity at the LPA1 receptor. The most remarkable conclusion that can be 
drawn from the obtained data is the great influence on activity exerted by the 
length of the hydrophobic chain. From all the compounds tested, derivatives 2i (X = 
H, m = 9) and 3a, with Emax > 100% and EC50 values of 0.5 and 0.24 µM 
respectively, stand out. Considering the excellent activity of compound 3a, 
additional structural exploration was extended around this scaffold (Scheme 4). 
The obtained results showed that only 3d was able to activate the receptor (Emax = 
39%, EC50 = 3.2 µM), although it did not reach neither LPA nor 3a values.  
 
Scheme 4 
The next step was the combination of some of the hydrophobic moieties 
present in these compounds with the polar heads that seem to be able to mimic the 
LPA phosphate group, leading to products 4a-c (Figure 2) which were synthesized 
and tested as agonists of the LPA1 receptor.  
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Figure 2 
The results obtained for compounds 4a, b showed that replacement of the 
oleic acid chain by 10-phenyldecanoic acid is detrimental for activity. Instead, 
derivative 4c, bearing a palmitoleic acid chain and malonic acid as polar head was 
able to activate LPA1 receptor (Emax = 43%, EC50 = 1.4 µM). 
6.2.2 Additional biological characterization 
All the synthesized compounds which were inactive as agonists at the LPA1 
receptor were screened for their antagonist capacity but none of the compounds 
tested presented significant antagonist activity.  
In order to test the selectivity of all the synthesized compounds, cell lines 
stably overexpressing each of the five LPA receptor subtypes were generated 
during a predoctoral stay at Prof. Jerold Chun Lab, at The Scripps Research 
Institute (La Jolla, California). Up to this moment, the screening of all the 
synthesized compounds at the LPA2 receptor has been completed, being the 
characterization at the rest of the receptors currently under way in our laboratory. 
From the results obtained for this receptor, it must be highlighted that compound 
3a does not present activity at LPA2 receptor.  
Finally, to verify whether compound 3a, which has been identified as a good 
LPA1 agonist by calcium mobilization assay, and which is selective over LPA2 
receptor, is really acting at the LPA1 receptor, a set of additional cellular 
experiments was carried out. The existence of a correlation between the results 
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from these independent in vitro data is the first and necessary step towards a 
complete biological characterization that would continue with diverse in vivo 
studies in the drug discovery process. As expected for an agonist, compound 3a 
induces neurite retraction,17 cellular migration106 and internalization of the LPA1 
receptor (Figures 3-5) in B103 cells stably transfected with LPA1.  
 
Figure 3. Neurite retraction induced by 3a and 1c. Percentage of retracted neurites at 10, 5 
or 1 µM for compound 3a (A). Visualization of neurite retraction: control 0.1% FAF BSA (B), 
1 µM LPA (C), 10 µM 3a (D), 3a 1 µM (E). Samples were imaged under the same conditions 
by using a Zeiss fluorescence microscope (bars 100 µm). 
 
 
Figure 4. Migration experiment for compound 3a at 1 µM. Number of migrated cells (A). 
Visualization of migrated cells (B-D): 0.1% FAF BSA (B), 1 µM LPA (C), 1 µM 3a (D). 
Samples were imaged under the same conditions by using a Zeiss microscope (bars 50 
µm). Cells were stained with 0.1% crystal violet solution. 
 
C 
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Figure 5. Visualization of receptor internalization. Compound 3a, 1 µM (A). LPA, 1 µM (B). 
Cells were stained with DAPI and phalloydin for cell morphology. Samples were imaged 
under the same conditions by using a Zeiss fluorescence confocal microscope (bars 10 µm).  
6.3 Conclusions 
In summary, up to this moment we have successfully identified novel agonists 
with activity at LPA1 receptor. The two series proposed for mimicking the polar 
head and the hydrophobic chain of the endogenous ligand LPA have yielded new 
scaffolds capable to activate the receptor. Regarding the combination of the 
optimal moieties, the identification of compound 4c, with good activity values, 
paves the way for further optimization processes.  
From all the compounds synthesized so far, derivative 3a stands out as the 
first agonist structurally different from the endogenous ligand LPA, with excellent 
capacity to activate the LPA1 receptor in cellular systems.  
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